{
  "name" : "_cyber.sci-hub.se_MTAuMTAyMS9hY3MuY2hlbXJldi42YjAwMDcz_smith2017.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Nanomaterials for In Vivo Imaging",
    "authors" : [ "Bryan Ronain Smith", "Sanjiv Sam Gambhir", "James H. Clark" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "CONTENTS"
    }, {
      "heading" : "1. Introduction A",
      "text" : "1.1. Background B\n1.1.1. Passive Targeting of Nanomaterials D 1.1.2. Active Targeting of Nanomaterials E 1.2. Why Nanomaterials In Vivo? E"
    }, {
      "heading" : "2. Imageable Nanomaterials F",
      "text" : "2.1. Key Nanomaterial Properties F 2.2. Nanomaterial Limitations H 2.3. Magnetic Nanomaterials H\n2.3.1. Magnetic Resonance Imaging I 2.3.2. Magnetic Particle Imaging P 2.3.3. Magneto-motive Imaging S 2.3.4. Electrical Impedance Imaging V 2.4. Optical Nanomaterials W 2.4.1. Luminescence W 2.4.2. Resonance Energy Transfer AE 2.4.3. Raman AH 2.4.4. Optical Coherence Tomography AI 2.4.5. Photoacoustics AK 2.5. Acoustic Nanomaterials AO 2.6. Nuclear Nanomaterials AP\n2.6.1. Radioactive Nanomaterials AP 2.6.2. Nanomaterials for Computed Tomogra-\nphy AV 2.7. Adaptable Nanomaterials AX\n2.7.1. Lipid Nanomaterials AX 2.7.2. Polymeric Nanomaterials AZ 2.7.3. Silicon-Based Nanomaterials BE 2.7.4. Natural Nanomaterials BF\n3. Multifunctional Nanomaterials BH\n3.1. Multimodality Nanomaterials BI 3.2. Theranostic Nanomaterials BJ\n3.2.1. Smart Theranostic Nanomaterials BL"
    }, {
      "heading" : "4. Clinical Nanomaterials BM",
      "text" : ""
    }, {
      "heading" : "5. Conclusions and Outlook BP Associated Content BQ",
      "text" : "Special Issue Paper BQ Author Information BQ\nCorresponding Authors BQ Notes BQ Biographies BQ Acknowledgments BQ References BR"
    }, {
      "heading" : "1. INTRODUCTION",
      "text" : "The explosive growth in novel in vivo imaging modalities has led to a dizzying array of new nanomaterials over the past 5−10 years. These nanomaterials are spurring completely new imaging applications in living subjects, such as exploiting the ability of nanoscale metallic particles to scatter light for added contrast in optical coherence tomography (OCT) applications. Chemists working closely with imaging scientists have played a key role in the development of these novel materials to tackle some of the critical issues confronting diagnostic imaging. At minimum, imaging with nanomaterials rather than conventional approaches can afford intelligent control over delivery and greatly increased diagnostic sensitivity and specificity not\nReceived: January 28, 2016\n© XXXX American Chemical Society A DOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\notherwise possible; in other cases, the use of nanomaterials actually enables the use of contrast agents for imaging modalities that historically did not have contrast agents available, making nanomaterials a driver for molecular imaging capabilities for imaging modalities in which no other contrast agents are yet possible. In even other cases, nanomaterials are required simply to make imaging possiblefor example, magnetic particle imaging (MPI) and magneto-motive imaging require magnetization to image that cannot be found in small molecules but rather require nanoscale magnetic nanomaterials such as superparamagnetic iron oxide nanoparticles for them to produce images. Recent reviews have discussed the advantages of nanomaterials for applications using more than one imaging modality at a time (i.e., multimodal imaging),1,2 while other reviews have focused on subcategories such as disease-specific applications (e.g., cancer diagnostic imaging), modality-specific applications (e.g., optical imaging), cell-specific applications (e.g., macrophage imaging), or nanomaterial-specific applications (e.g., quantum dots).3−6 In our Review, we (i) focus on nanomaterials for in vivo imaging (see Figure 1); (ii) describe how specific chemical and physical properties of nanomaterials drive in vivo imaging applications and potential diagnostic value; and (iii) review only nanomaterials that have actually been used for in vivo imaging (i.e., have actually been injected into living subjects), even though many novel nanomaterials are currently being developed with the eventual intention to be injected in vivo.7−9\nWe define nanomaterials as materials that are specifically engineered and between 1 and 100 nm in at least one dimension that is critical to its application.10,11 Our Review focuses on the recent literature (past 5 years) involving nanomaterials that have been used to enhance image contrast and their roles in diagnostic imaging in living subjects including humans. We review nanomaterials for in vivo imaging without special regard to the particular disease process for which they are being used to provide contrast, but instead focus on the connection between the nanomaterial and its relevance for in vivo imaging. Most of all, we aim to describe the key underlying chemical and physical properties that will likely enable\nnanomaterials to contribute centrally to the future of imaging in living subjects. While nanomaterials reviews have typically divided their sections based on the nanomaterial type (e.g., nanotubes, quantum dots, liposomes, etc.), in this Review we instead divide the information with respect to the particular physicochemical properties enabling the nanomaterial to be advantageous for a relevant imaging modality. Thus, some nanomaterials will be in multiple sections because their fundamental properties lend themselves to detection with multiple imaging modalities, and they are self-contained within each section. For instance, carbon nanotubes are included in both the optical nanomaterials sections (e.g., fluorescence, Raman, and photoacoustic activity) and the acoustic nanomaterials section (ultrasound signal), as their use in each imaging modality arises from disparate properties. This concept-driven approach allows us to organize our Review around the fundamental physicochemical nature of the nanomaterial that results in its ability to provide contrast for a particular imaging modality (see Figure 1 and\nTable 1)."
    }, {
      "heading" : "1.1. Background",
      "text" : "A fundamental goal of contemporary noninvasive imaging is to measure and localize specific molecular targets, pathways, and physiology, often in the context of a disease state. In contrast agent-based imaging, diseases are generally identified by the accumulation of an agent at the disease site. These agents must produce a signal recognized by an imaging modality. Traditionally, the agents are injected systemically and are small molecules or, more recently, may be connected to peptides, proteins, oligonucleotides (aptamers), or antibodies. These small imaging agents are designed to accumulate at disease sites on the basis of a difference in the fundamental biology of the disease in contrast to the biology of normal tissues, e.g., a distinctive physiological/biochemical hallmark. For instance, positron emission tomography (PET) can be performed to locate many cancers because cells in those cancers proliferate so rapidly that they require and metabolize sugars such as glucose more than cells in most other human tissues. Small-molecule\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nB\nT ab le 1. Fe at ur es\nof Im\nag in g M od\nal it ie s D es cr ib ed\nin T hi s R ev ie w ; N ot e: So m e Fe at ur es\nD es cr ib ed\nA re\nO nl y A va ila bl e fo r Sp ec ifi c, C us to m iz ed\nE qu\nip m en t; A bb\nre vi at io ns : $,\nIn ex pe ns iv e;\n$$ , M od\ner at el y P ri ce d;\n$$ $,\nE xp en si ve ; np\ns, N an op\nar ti cl es\nim ag in g m od al ity\nin pu t si gn al ty pe\nsp at ia l re so lu tio\nn te m po ra l re so lu tio\nn pe ne tr at io n de pt h\nse ns iti vi ty\nex am\npl e pr ob es\nco st\nM ag ne ti c na no\nm at er ia ls\nm ag ne tic\nre so na nc e im ag in g\nra di o fr eq ue nc y\n25 − 10 0 μm\n(p re cl in ic al ), ∼ 1 m m (c lin ic al )\nm in − h\nun lim\nite d\n10 − 3 − 10\n− 5 M\nG dba se d np s; iro\nn ox id es ; Fe C o\nnp s\n$$ $\nm ag ne tic\npa rt ic le im ag in g\nra di o fr eq ue nc y\n∼ 50 0 μm\nm s\nun lim\nite d\n10 − 6 M\niro n ox id e np s $$ m ag ne to -m ot iv e ap pr oa ch es m ag ne tic pu ls e <1 m m 10 0 m s de pe nd en t on ou tp ut m od al ity 10 − 6 M iro n ox id e np s $$ O pt ic al na no m at er ia ls fl uo re sc en ce (m ac ro sc op ic ) ul tr av io le t to ne ar - in fr ar ed lig ht 2− 3 m m s− m in <2 cm 10 9 − 10 − 12 M qu an tu m do ts ; C do ts ; la nt ha ni de np s $ in tr av ita l m ic ro sc op y ul tr av io le t to ne ar - in fr ar ed lig ht 10 0− 30 0 nm m s− s ∼ 1 m m (m ul tip ho to n) 10 − 15 − 10 − 17 M (t o si ng le np de te ct io n) qu an tu m do ts ;n an ot ub es ;v ira ln ps $ re so na nc e en er gy tr an sf er ul tr av io le t to ne ar - in fr ar ed lig ht 2− 3 m m s <2 cm 10 − 6 − 10 − 10 M B R E T qu an tu m do ts ; ra di oa ct iv e C R E T qd ot s $ R am an lig ht ∼ 10 0 μm − m m s− h <1 0 m m 10 − 12 − 10 − 15 M (S E R S) go ld SE R S np s; na no tu be s $ op tic al co he re nc e to m og ra ph y lig ht 1 μm s ∼ 2− 3 m m 10 − 10 − 10 − 11 M (g ol d na no ro ds ) go ld na no ro ds $ ph ot oa co us tic s lig ht 5 μm − 1 m m (d ep th -d ep en de nt ) s− m in <6 cm 10 − 9 − 10 − 11 M go ld np s; na no tu be s $ A co us ti c na no m at er ia ls ul tr as ou nd so un d w av es 10 − 10 0 μm (a t∼ m m de pt h) ;1 − 2 cm (a t ∼ cm de pt h) s− m in 10 m s 10 − 6 − 10 − 9 M na no bu bb le s; si lic a np s; ca rb on na no tu be s $ N uc le ar na no m at er ia ls γim ag in g ra di on uc lid e (γ -r ay s de te ct ed ) 1− 10 m m m in un lim ite d ∼ 10 − 10 − 10 − 11 M lip os om es $ po si tr on em is si on to m og ra ph y ra di on uc lid e (p os itr on s) <1 m m (p re cl in ic al ), ∼ 5 m m (c lin ic al ) s− m in un lim ite d 10 − 11 − 10 − 12 M 12 4 I -la be le d C do ts $$ $ si ng le ph ot on em is si on co m pu te d to m og ra ph y ra di on uc lid e (γ -r ay s de te ct ed ) 0. 5− 2 m m (p re cl in ic al ), 8− 10 m m (c lin ic al ) m in un lim ite d 10 − 10 − 10 − 11 M 99 m T cla be le d iro n ox id e np s $$ $ co m pu te d to m og ra ph y X -r ay s 25 − 20 0 μm (p re cl in ic al ), 0. 5− 1 m m (c lin ic al ) s− m in un lim ite d ∼ 10 − 3 M io di ne - an d go ld np s; Fe Pt np s; la nt ha ni de np s $$\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nC\nglucose analogues (e.g., [18F]FDG, fluorodeoxyglucose) will then enter the high-metabolic rate cells and are phosphorylated, meaning they cannot leave the cells and thereby accumulate at the cancer site. This is key, because by designing a glucose analogue that is radiolabeled, chemists created an otherwise innocuous molecule that reports the spatial site of the tumor and provides a quantitative measure of its metabolic status using PET. Interdisciplinary teams of chemists, biologists, clinicians, and engineers have been working on many other new molecules to image diseases, and with the advent of nanotechnology, these teams have often turned to nanomaterials for the benefits they can provide over small-molecule, peptide, and protein-based strategies. Although small molecules are able to travel easily within the body and often can enter cells (or can be redesigned to do so), unlike nanomaterials they are not able to deliver a large payload, cannot be easily multiplexed, typically cannot be combined with therapeutics (e.g., theranostic strategies), and cannot be so precisely nor easily engineered. To compete effectively with small-molecule agents, nanomaterials/nanoparticles must pose no increased safety risk (a potentially critical limitation for some nanomaterials12,13) while providing at least one substantial advantage such as increased imaging sensitivity, improved resolution,14 multiplexing capability, etc. In clinical practice, in part because of their long history, it is notable that small molecules are currently far more prevalent for use in imaging procedures than are nanomaterials. This fact serves to remind us that despite the many apparent advantages of nanomaterials observed in vitro and preclinically, there remain substantial challenges in their clinical translation. Nevertheless, the small-molecule prevalence trend is gradually changing as key lessons are learned so that nanomaterials increasingly cross the valley from preclinical tests to clinical practice (see section 4). Very broadly, the use of contrast in imaging science can be split into two overarching themes: (i) Signal in/signal out: An input signal must traverse the body’s tissues to reach the contrast agent to stimulate, or excite, it. A reporting signal must then be generated by the contrast agent that traverses the tissues until it encounters a measuring device that can quantify the signal and spatially localize it to create an image. (ii) Signal out only: This is in fact a subset of the first theme, with no external excitation necessary; only the reporting signal must traverse the tissues to reach the detection device. For nanomaterials to support in vivo imaging, they must not only display the key properties that all nanomaterials must possess to be used in vivo but their physicochemical properties must be optimized for the chosen specific imaging modality in order to maximize the absorption of incoming excitation energy (if applicable) and to maximize generation of the emissive reporter signal. This Review places emphasis upon the physicochemical properties of nanomaterials required to optimize the incoming and emissive signals of the various imaging modalities. The primary imaging modalities used in clinical and emerging preclinical animal studies are listed with some of their key features quantified and examples of nanomaterials used with them in Table 1. 1.1.1. Passive Targeting of Nanomaterials. Nanomaterial physicochemical properties dictate not only their signaling characteristics but also their transport and biodistribution properties in vivo. In most applications, delivery is systemic (i.e., intravenous injection), so that the agents can ideally access the same set of cells in the body as nutrients and oxygen via the\nvasculature. An increase in vascular permeability to macromolecules often accompanies disease sites in which new blood vessels begin to form such as cancer and atherosclerosis.15,16 Termed the enhanced permeation and retention (EPR) effect, this process represents a premier mechanism by which nanomaterials and macromolecules passively, yet preferentially, accumulate at a target site. This permeation is due to rapidly, dysfunctionally grown blood vessels that can contain gaps (often called pores) between endothelial cells to permit transfer of nanomaterials or macromolecules into the tissue interstitium.15,17,18 An often-overlooked component of the EPR effect is the retention19the propensity of an agent to be retained at the appropriate site for a suitable amount of time. This arises primarily due to diminished lymphatic clearance from the disease site. Nanomaterials are advantageous in this regard, as they are often sufficiently small to enter the tumor but sufficiently large to remain at the disease site for imaging for relatively long time periods. The EPR effect is particularly critical for in vivo imaging of cancer and atherosclerosis,17,20 diseases in which neovasculature is prominent, and is by far the most popular mechanism by which to target nanomaterials. When it works, the EPR effect is a powerful mechanism for efficient deliveryhighlighted by the fact that even the infectious disease field seeks to exploit it.21 However, the EPR effect is highly heterogeneous and unpredictable in preclinical animal models,18−20 and there remain large gaps in our knowledge of whether and how well EPR may function in human patients.17 Interestingly, the apparent differences between animal models and humans have not slowed the nanomedicine community from exploiting the EPR effect in preclinical nanomaterial imaging and drug delivery studies, perhaps due in part to misinterpretation of the EPR effect mechanism by segments of the research community.25 Instead, we suggest that the issue of nanomaterial delivery and the potential need to pursue alternative delivery strategies for clinical translation should always be considered not only in the planning of preclinical experiments but even earlier, in the design of the nanomaterials themselvesfor example, we suggest new alternative delivery mechanisms to EPR in sections 2.4 and 2.4.1.4 including harnessing of the immune system. The EPR effect is highly sensitive to the size, geometry, and charge of the injected macromolecule or nanomaterial22,23,26,27 and to the disease microenvironment and resulting neovascular parameters (e.g., vascular pore size, charge, and configuration);22,27 therefore, because highly predictive computational models do not yet exist, the behavior of EPR currently still needs to be tested for each different combination of nanomaterial type and microenvironmental condition. While size-based studies are fairly straightforward in that it has generally been shown that smaller nanomaterials extravasate better than larger nanomaterials, issues of shape and charge are much more complex. Studies on the geometry of nanomaterials for extravasation suggest that no “one shape fits all” argument exists as it does for size.22,28 This is because the effects of diffusion versus convection of nanomaterials across heterogeneously shaped vascular pores are not well understood, leading to nonintuitive behavior in extravasation across differently shaped nanomaterials for a series of tumor types.22 Nevertheless, when successful, many advantages exist for EPR. EPR can be used as a biological filter that naturally provides specificity in targeting, because normal tissue vasculatures restrict entry to nanomaterial-sized entities but those in diseased tissues do not; it is not possible to use EPR for\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nD\nagents on the scale of small molecules and peptides because normal tissues often allow entry to molecules of that size range, precluding specific targeting with EPR.22,29 Because of the heterogeneity of the EPR effect in humans, a very important application of in vivo nanomaterial imaging has emerged to stratify patients for therapy: the concept is that a physician will not know a priori whether a therapeutic nanomedicine will undergo EPR and thereby whether the patient’s treatment can be successfully delivered, so imaging nanomaterials of the same physical properties (size, shape, etc.) as the therapeutic nanomaterial could be injected into patients to visualize (e.g., using PET or MRI) and establish whether the EPR effect is functioning prior to initiating a treatment that would fail in its absence. Small-molecule imaging agents, including small-molecule PET tracers (e.g., 18[F]FDG-PET) and gadolinium chelates for magnetic resonance imaging (MRI), are technologies that help illuminate disease sites and have become part of common clinical practice.30−32 While their size advantageously enables small molecules to access nearly any site in the body, this promiscuous nature is also one of their greatest weaknesses as it results in high nonspecific uptake. Other drawbacks of small molecules compared with nanomaterials include the increased time and expense of discovering and synthesizing the agents, the complexity of incorporating a signaling moiety without completely changing the pharmacokinetics and in vivo behavior of the parent molecule,33 the low payload, the minimal circulation half-life, and the decreased avidity (because at most one binding site is typically available for targeting purposes; see section on Active Targeting of Nanomaterials). Each of these may be important, depending on the specific application. 1.1.2. Active Targeting of Nanomaterials. In contrast to passive targeting, peptides and other biomolecules can be used as active targeting agents because the concentration of certain proteins expressed in the body can be used as a proxy or biomarker of tissue and cell function to indicate the presence of pathological conditions. The actively targeted agent is thus bound or sequestered on account of its specific biological activity. This is often limited when using small molecules because they typically have one binding site, leading to decreased avidity compared to nanomaterials that have the potential to display numerous targeting molecules for high avidity binding. Cyclic 68Ga-RGD dimers (RGD = arginineglycine-aspartic acid), one of the relatively rare multimeric small molecule/peptide agents, are radiolabeled peptide agents developed for targeting cancer-related integrin protein overexpression for PET imaging. They have a short circulation halflife on the order of minutes, a single radioactive atom per agent, and 50−100 nM IC50 binding affinity (i.e., binding inhibition concentration),34 compared with, for example, an RGD- and radiolabeled silica nanoparticle with a circulation half-life of ∼6 h, multimodal capabilities (multiple PET- and fluorescent tags per nanoparticle), and an IC50 of 1.2 nM with 6−7 RGD molecules per nanoparticle.35 In this comparison, the avidity enhancement was ∼1−2 orders of magnitude, expressible in the IC50 as a multifold multivalent enhancement factor (increased avidity due to more RGD peptides on the larger nanomaterial surface). However, other studies show that multivalent enhancement factors can be much greater and support the increased enhancement as a critical parameter in improved targeting: for example, the Kd (dissociation constant) between folic acid and folate-binding protein showed nanomaterial-\ndriven multivalent enhancements of ∼4−5 orders of magnitude over single-molecule binding.36 These sorts of significant improvements in binding and circulation half-life often lead to increased accumulation, specificity, and retention of nanomaterials at their target site, which result in increased image contrast or reduced total nanomaterials injected, or both. In these instances of RGD targeting, the central question imagers seek to answer is what, where, and how much are αvβ3 integrins expressed on cell surfaces? The presence of this integrin is characteristic of new blood vessels and certain tumor cells and has been used as a potential marker for cancer detection.37,38 However, this marker may more likely be used, at least early on, to help stratify patients (with known cancers) who would benefit from antiangiogenic therapies and to monitor the therapeutic success of those therapies for patients receiving them.39 Many other molecules than peptides can also be used to target these cell surface protein “beacons of disease”, including antibodies, aptamers, and synthetic agents like molecularly imprinted polymers and synthetic antibody mimics.40,41\nTargeting ligands are now commonly used in (preclinical) nanomedicine and nanomolecular imaging to increase accumulation of nanomaterials into disease sites. The first cancertargeted nanoparticles to reach clinical trials are now in Phase II for targeting polymeric nanomaterials to prostate and non-small cell lung cancer.42 Such ligands are typically chosen to bind to specific molecules overexpressed on the surface of disease cells or other cells anticipated to be at the disease site. Yet the advantages of nanoparticle targeting ligands are not completely clear. While many studies have shown that targeting ligands increase the total accumulation of nanoparticles at the tumor,43,44 a number of other studies have shown that targeting does not increase total accumulation but only increases the number of nanoparticles taken up by tumor cells.45,46 To resolve this outstanding question, our group applied intravital microscopy (see section 2.4.1.4) to dynamically image the influx of targeted nanoparticles into tumors in mice and followed their nanoscale interactions within the tumor over a period of weeks.19 It was shown that the ligand-targeting dichotomy was primarily an issue of time-dependence. In particular, the EPR effect resulted in similar uptake between ligand-targeted and nonligand-targeted nanomaterials immediately following injection, leading to apparent high nonspecific uptake. However, as untargeted nanomaterials cleared, specific ligand-targeted accumulation in the tumor was resolved. Ligands therefore both increase nanomaterial accumulation in tumors (at later time points) and help nanomaterials bind to individual tumor cells once the nanoparticles are in the interstitium (even for several weeks) in a sort of equilibrium process. Thus, the time at which one images after injection is a critical parameter in whether specific accumulation is observed.19 This work provided unique insights into the mechanisms and temporal framework of nanomaterial dynamics in tumors, yet delivery is one of many issues to consider when selecting an agent for imaging."
    }, {
      "heading" : "1.2. Why Nanomaterials In Vivo?",
      "text" : "Neither all small-molecule nor all nanomaterial contrast agents are necessarily advantageous for in vivo imaging. An analysis of the desired outcome integrated with specific risks must precede their selection and application. Nevertheless, many nanomaterials are appealing candidates for in vivo imaging for a number of reasons: (i) their small dimensions (1−100 nm by our\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nE\ndefinition), (ii) their potentially high avidity in target binding, (iii) their highly controllable and modular physicochemical properties including size, shape, material, density, and surface charge, (iv) their high payload delivery, (v) their capacity for multiplexing for imaging with multiple imaging modalities, and (vi) the potential for payload combination with therapeutics, e.g., theranostic agents. A nanomaterial’s size is advantageous in in vivo imaging as it is sufficiently large to carry much more contrast than a small molecule, while retaining the ability to travel through the body systemically (through the bloodstream) unlike much larger structures.47 Furthermore, they offer the ability to selectively enter into desired sites like tumors more specifically than molecularly sized agents and than larger agents because of the EPR effect.17,22,26 Indeed, EPR can provide nanomaterials access to a disease site, which can then allow (active) targeted binding to diseased (e.g., cancer) cells. For in vivo imaging, their chemical and physical tailorability make nanomaterials highly flexible agents with the potential for customization not possible with small-molecule contrast agents. The ability to easily customize is important as the size, shape, and surface charge of a nanoparticle govern its biodistribution and its ability to enter disease sites in vivo,22,28,48 allowing unique design of a nanomaterial to best target the pathophysiology of each disease type. Perhaps more importantly, the size, shape, and chemical structure of nanomaterials can often dictate their utility as in vivo contrast agents such as in the case of quantum dots and metallic nanoparticles, where the physical properties prescribe absorption, emission, and light-scattering properties that are critical to their efficacy as imaging agents.49 These properties can be tuned to produce nanoparticles with the ability to be imaged at greater depths by red-shifting the emissive wavelength,33,49 or to increase the Raman signal sufficiently to be useful in Raman imaging in vivo33,50 (see section 2.4.3). The large surface areato-volume ratio of nanomaterials enables them to present numerous targeting ligands for binding to target cells for highly avid binding10,11,51 as discussed in the previous section, making targeting more likely and more stable. By virtue of the size of nanomaterials, being considerably larger than molecular carriers, they can pack many more contrast and therapeutic molecules into a single structure that can be delivered to disease sites and improve detection sensitivity. Moreover, as has become ever more important in the era of multimodality molecular imaging,2,33 nanoparticles lend themselves easily to multiplexing with contrast for multiple imaging modalities on each particle (e.g., multiple contrast types such as MRI, fluorescence, and Raman contrast all on one nanoparticle). This potent combination of capabilities is a key reason why nanomaterials are deemed to have the potential to lead a revolution in in vivo imaging, in part because it enables chemists and materials scientists to (i) design new in vivo imaging assays that substantially improve site-specific delivery and signal strength compared to small-molecule probes52 and (ii) improve the clinical workflownanomaterials that are designed to be amenable to imaging by multiple modalities as part of the physician’s standard workflow (e.g., MRI to localize a disease site and then Raman imaging for image-guided identification and resection of disease sites with highlighted margins) could streamline and improve the standard-of-care."
    }, {
      "heading" : "2. IMAGEABLE NANOMATERIALS",
      "text" : "Imaging supports the ability to peer into the body and uncover anatomical, physiological, and functional phenomena dynam-\nically. Anatomical and functional imaging are frequently complementarywhile anatomic imaging enables visualization of the physical structures of the body, functional imaging reveals physiological and biochemical activity. Physicians have long used imaging to understand the presence, location, and size of pathologies in patients. More recently, however, molecular imaging has highlighted the many benefits of functional imaging to understand physiological changes that can indicate the severity, molecular phenotype, and early presence of diseases such as cancer, heart disease, and many others.33,53 A major problem faced in the clinic is how best to visualize these phenomena, and then how the data is interpreted to enable physicians to make the proper choice of treatment plan and even whether or not to continue upon a particular course of treatment (e.g., by visualizing the therapeutic response54). To provide contrast, particularly to interrogate functional phenomena (e.g., the presence or overexpression of a particular receptor, enzyme, or other protein or nucleic acid), nanomaterials have frequently arisen as an optimal preclinical (and increasingly clinical; see section 4) choice for the reasons described in section 1.2 and as will become clear in the many examples described below."
    }, {
      "heading" : "2.1. Key Nanomaterial Properties",
      "text" : "Nanomaterials designed for in vivo imaging require a suitable reporter structure for the intended imaging application and a biocompatible coating that serves not only to control the toxicological and pharmacological parameters of the nanomaterial but also often as the functional linkage between the reporter and other molecules (e.g., targeting ligands, other imaging agents (e.g., multimodality), and therapeutics). While the coating is quite important, there are many excellent reviews describing nanomaterial coatings in medicine,55,56 so we confine our focus in this Review to the nanomaterial itself and not the chemistry of the coating except as it concerns the imaging. Imageable nanomaterials usually display several key features, which are dependent on their physicochemical properties. For nanomaterials intended for clinical imaging diagnostics, a lack of toxicity is particularly important. This is even more important for diagnostic nanomaterials than for therapeutic nanomaterials because the nanomaterial contrast agent will typically be injected into completely healthy populations for disease screeningthus, no adverse effects are acceptable. This is, for instance, why Gd3+ (gadolinium, and Gd3+-based nanomaterials) has caused some tumult within parts of the MRI communityunder very particular conditions (i.e., patients with advanced kidney disease57), Gd3+ has the potential to cause nephrogenic systemic fibrosis (NSF), which can be fatal under some circumstances. Even though this adverse effect is in a very small portion of the population for whom Gd3+ is now contraindicated, some stigma surrounding Gd3+ still remainspossibly in part because it is an imaging agent and thus must maintain a higher bar of safety than typical therapeutics. Additionally, nanomaterials must provide a high likelihood of targeting the appropriate site in the appropriate time framein the case of cancer, this conventionally requires certain size and shape restrictions so they will be likely to extravasate via the EPR effect15,17,19,22,28,58 (see section 1.1). For blood pool agents designed to map blood vessels, this typically means the nanomaterials should continually circulate for a given number of hours (e.g., for some prolonged imaging scans; for other scans, there is concern\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nF\nfor example about missing the bolus injection).59,60 Typically nanomaterials must be fairly stable (i.e., continue to provide signal) in vivo to allow dynamic imaging (although they must still be ultimately cleared from the tissue and body). An exception is for nanomaterials meant for one-time imaging, where a huge burst of signal is desired, after which the contrast is destroyed and no longer imageable. For example, a nanodroplet vaporization approach allows photoacoustic imaging to detect the contrast agent in vivo with very high signal, but one can image the nanomaterial contrast only once61 (see section 2.4.5 for details). Many other characteristics of nanomaterials help govern their behavior in vivo and can affect their imaging properties such as signal strength. One such feature is polydispersity, a general attribute of nanomaterials that is related to aggregation (aggregation affects polydispersity) but is broader in scope in that it represents the full distribution of size in a nanomaterial formulation. Polydispersity is controlled by the fabrication mechanism and conditions as well as by nanomaterial properties such as surface charge, shape, coating, and solvent. Intriguingly, nanomaterial aggregation can have either positive or negative effects on the imaging behavior depending on the context. For example, on the positive side, aggregation of quantum dots was unexpectedly shown to improve in vivo nanomaterial targeting and circulation behavior, enabling aggregated nanomaterials to target blood vessels significantly better than the individual nanoparticles.22 Aggregation can also be applied positively to boost imaging signal; for example, Raman-active nanomaterials that aggregate can produce tiny “hot spots” at interfaces due to plasmon resonance coupling that markedly amplify Raman output.62 On the other hand, aggregation can disturb the desired pharmacokinetic biodistribution of nanomaterials, causing them to increase their effective hydrodynamic diameter and thereby wreak unexpected havoc with circulation half-life, tissue distribution, capillary blockage (i.e., if they aggregate enough they can even be mechanically retained), and phagocytosis by cells in the blood or the mononuclear phagocyte system (MPS).63 Aggregation tends to increase MPS uptake, leading to decreased availability of nanomaterials to target the tissue of interest.63 Likewise, imaging signal can markedly diminish when nanomaterials aggregate in association with some imaging platforms, such as in the case of iron oxide nanomaterial aggregation when using magnetic particle imaging (MPI).64 In this case, the aggregation leads to variation in the magnetic behavior of the iron oxides due to dipole−dipole interactions, which adversely impacts MPI signal because MPI detects the nanoparticle magnetic moments. Recent studies demonstrate a relationship between nanomaterial polydispersity/aggregation and the protein corona.65,66 The protein corona, defined as the protein cloud that adsorbs to a nanomaterial surface upon exposure to in vivo fluids such as blood, turns out to substantially influence nanomaterial trafficking and biodistribution in the body65,67some studies suggest the protein corona is the most predictive single feature of in vivo nanomaterial behavior.67 A protein corona study used the same base polystyrene nanomaterials with varied surface functionalizations, showing that the protein corona influences aggregation as a function of surface chemistry (e.g., charge). Such aggregation influenced the biodistribution: while all the nanomaterials were rapidly taken up into the liver upon intravenous injection, their tissue distributions otherwise depended on the protein corona formedfor example, some\nnanomaterials entered the lungs early, others did not, and some showed uptake into the skin.65 However, not only does the protein corona impact polydispersity (e.g., driving aggregation) but also the effects are bidirectional66,68polydispersity also affects the protein corona, making its study particularly complex. Traditional characterization of nanomaterials includes quantitation of ζ potential, solubility, particle size and distribution, hydrodynamic size, shape analysis, adsorption potential, serum stability, material analysis, and wettability. Evaluations are typically made primarily with electron microscopy and dynamic light scattering, as well as atomic force microscopy (AFM), X-ray photoelectron spectroscopy (XPS), Fourier transform infrared spectroscopy (FTIR), nanoparticle tracking analysis for Brownian motion, inductively coupled plasma-mass spectrometry (ICP-MS), and nuclear magnetic resonance (NMR), among others. The linkages between nanomaterial properties and their (i) in vivo behavior and (ii) imaging properties are burgeoning subdisciplines, yet the contrast in progress between the two links is stark. Extensive characterization of nanomaterials is beginning to enable predictive insights into their imaging properties based on our physical understanding and mathematical models.69−71 In contrast, even with advanced methods and mathematical models, the complexity and heterogeneity of biomedicine thus far preclude making accurate predictions of in vivo nanomaterial behavior as a function of nanomaterial physical properties. The emergence of structure−activity relationships to help predict biological nanomaterial behavior on the cell scale72 might eventually, once fully validated and greatly extended, be applied to predict in vivo nanomaterial behavior from firstprinciples and physical measurements.67 Yet currently, empirical nanomaterial testing in living subjects remains the only dependable strategy. Nevertheless, once in vivo data is attained, mathematical methods to organize and extract distribution details such as pharmacokinetic and similar models are producing important insights.67,73\nWhen it comes to optimization of a nanomaterial for in vivo imaging, notably the two general nanomaterial behaviors with which we are concernedin vivo behavior and imaging propertiesmay conflict with one another. In vivo imaging nanomaterials must therefore sometimes compromise on one or the other of these behaviors, but successful in vivo imaging nanomaterials will typically either align them or optimize the trade-offs for the intended application if necessary. An instance of alignment is the design of CdSe quantum dot (qdot) nanomaterials of less than ∼5.5 nm in diameter for optimal renal clearance, which simultaneously enables efficient fluorescence emission in the green owing to qdots’ size-based emission.74 Fortunately, many physical parameters are important for only one of the two behaviors: for example, while the surface charge of the qdots was optimally neutral or zwitterionic for renal clearance, the charge was inconsequential for fluorescence emission.74\nOn the other hand, due to the echogenic mechanism of ultrasound contrast, larger materials are much better signal producers. Thus, in an example of optimizing the trade-offs, ultrasonic cancer imaging nanomaterials can be designed to be simultaneously capable of extravasating into tumor tissue via the EPR effect in vivo (requiring smaller size) and to be sufficiently large to be detectable via ultrasound.75 Because the two needs run opposed, compromise is reached on an appropriate size to use that satisfies (yet diminishes efficacy\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nG\nfor) both, although different groups may often reach different conclusions on the optimal size based on the heterogeneity across different tumor models, variation in ultrasonic equipment, etc. The initiative for the emergence of nanomaterials for imaging originally arose in parallel with the need to enhance contrast for MRI in vivo. This turned out to be a natural fit because iron oxide nanoparticles had been used in clinical medicine since the 1960s for anemia treatment.76 As it became recognized that the high magnetic moment of iron oxides exerted effects on nearby water molecules, i.e., to shorten their relaxation times,76,77 it became clear that the use of iron oxides in clinical MRI had much promise. In fact, the work of Ohgushi and colleagues in 1978 first directly portended MR image contrast applications for iron oxides when they found that a simple mixture of dextran and tri-iron tetroxide created a stable suspension of MR contrast particles.78 The controllable properties of these ironbased agents, once fabrication techniques emerged to make them highly monodisperse and coated in biocompatible polymers that enable longer circulation times, were thereafter emulated across a broad spectrum of nanoparticulate imaging agents. These key breakthroughs paved the way for the broad assortment of nanoparticles available today preclinically and some even clinically for a variety of imaging purposes, such as contrast-enhancing nanomaterials developed for computed tomography (CT) to image the blood pool, liver, and spleen in the early 1990s,79,80 optical nanomaterials for use in cancer diagnostics and cell tracking,81,82 sentinel lymph node imaging during surgery,83,84 and many more diseases (e.g., heart disease) and imaging modalities (e.g., PET, single-photon emission computed tomography (SPECT), and ultrasound) as detailed in this Review."
    }, {
      "heading" : "2.2. Nanomaterial Limitations",
      "text" : "For all their advantages, many nanomaterials have certain limitations. Indeed, some advantages can also double as limitations: the size of nanomaterials can sometimes be too large to enter into desired tissues;10,15,17,22 they may also be too large (and/or display incompatible surface charge) to diffuse through interstitial space and be easily taken up into cells.85 However, engineering of nanomaterials to optimize parameters such as charge and functionalization can improve some of these properties. Nanomaterials also must clear from the body after use. While small molecules are typically metabolized or can otherwise clear renally, nanomaterials must often biodegrade to their fundamental constituents in order to be cleared. In some cases, the material from which the nanoparticle itself is comprised can be useful to the bodyas mentioned above, for instance, iron oxide (magnetic) nanomaterials are useful for several types of imaging and also degrade (e.g., for anemic patients) to increase the body’s iron stores for incorporation into proteins like ferritin and hemoglobin.76 However, in other cases, the fundamental constituents may themselves be toxic: for instance, quantum dots based on heavy metals such as cadmium, selenium, and arsenic are not likely to be translated to clinical use because their degradation products are toxic; nevertheless, if they could be designed to be quickly cleared renally or via hepatobiliary excretion and not permitted to degrade in the body, translation for certain low-dose applications might remain possible.86,87"
    }, {
      "heading" : "2.3. Magnetic Nanomaterials",
      "text" : "The vast majority of magnetic nanomaterials have been ironbased. Iron is considered safe, has a long history of use in\nhumans, and many methods have been developed to create a rich variety of sizes, shapes, and combinations with other materials.88−90 Although iron oxide is the most common of the iron-based imaging compounds, recent nanochemistries have extensively expanded the state space of iron and indeed all magnetic nanomaterials.89,91 These new materials have higher magnetic moments, saturation magnetizations, and coercivity and thus lead to improved contrast agents for magnetically actuated imaging modalities. From doped iron oxides (e.g., Zn and Co92,93) and iron cobalt (FeCo)94,95 to amorphous iron96 and iron carbides (Fe5C2), 97 newly engineered magnetic nanomaterials are beginning to transform preclinical magnetic imaging by substantially increasing image contrast and decreasing the masses necessary for injection. Yet not only have new chemistries led to new magnetic materials, but they have also substantially improved the properties of standard iron oxides by redesigning the fabrication chemistries. Recent iron oxide nanochemistry efforts have imparted particularly precise control of their uniformity, crystallinity, size, and surface properties,98 leading to improved in vivo behavior and imaging characteristics. For instance, Bawendi and colleagues developed 10 nm zwitterionic iron oxides to significantly decrease nonspecific serum binding and show excellent stability across a wide range of pH, salinity, and time,99 while Ling et al. demonstrated that their 22 nm, uniformly sized iron oxide nanocubes were able to reach their maximum theoretically predicted relaxivity value (r2 = 761 mM\n−1 s−1)100 for optimized MRI signal. Imaging of magnetic nanomaterials has traditionally been the domain of MRI, which remains highly prevalent and by far the principal magnetic imaging modality. However, recently, several other imaging strategies have arisen that can exploit magnetic nanomaterials. While they are still in their nascent stages, with only a handful of groups having demonstrated in vivo imaging thus far, they are highly promising: these include magnetic particle imaging (MPI) and magneto-motive approaches (e.g., magneto-motive ultrasound (MMUS), magneto-motive photoacoustics (MMPA), and magneto-motive optical coherence tomography (MMOCT)). In fact, these novel magnetically focused modalities do not simply use magnetic nanomaterials for contrast, but their use is required for them to create images. Therefore, unlike MRI, which can and does function without contrast injections, these other modalities are intimately tied to the properties of magnetic nanomaterials. Hence, the nanomaterials’ magnetic properties must be aligned and optimized for the particular physics of the underlying imaging mechanism. A magnetic moment is generally an essential characteristic of magnetic nanoparticles; for some imaging applications, these moments must interact with the molecules in the local environment (MRI), whereas for others they must interact directly with the applied magnetic fields (magnetic particle imaging, magneto-motive imaging). Indeed, the physics of MPI is quite different from that of MRI, although in addition to use of magnetic contrast it employs similar concepts of magnetic excitation, detection, and relaxation as well as pulse sequences (section 2.3.2).101 It allows precise quantitative mapping of the 3D spatial distributions of magnetic nanomaterials without interference from background because there are no endogenous materials in the body that can produce signal, unlike MRI.102 In magneto-motive approaches, a pulsed magnetic field is directed to magnetic particles within a sample, and the motions induced by the field (i.e., displacements) are monitored (section 2.3.3). This is the “engine” driving magneto-motive approaches, and\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nH\nseveral strategies have been developed to monitor the particle displacement in tissues. These strategies are linked to other imaging modalities, such as ultrasound (MMUS), photoacoustics (MMPA), and OCT (MMOCT). MMUS, for example, has the potential to greatly expand the utility of ultrasound, as it allows the use of ultrasmall nanomaterial contrast agents in ultrasonic imaging, in place of the much larger agents (100s of nm and more) to which ultrasound is typically restricted (see section 2.5). Importantly, this allows ultrasound imaging to be performed within tissues (e.g., via the EPR effect in cancer or via draining into lymph nodes), whereas previously the vast majority of agents were too large to enter tissues and thus contrast-based approaches were predominantly limited to vascular or site-injected imaging. For instance, MMUS made ultrasound a possible sentinel lymph node imaging agent: 37 nm diameter iron oxide nanoparticles were site-injected and imaged by MMUS in sentinel lymph nodes.103 These nanomaterials were well within the size range for optimal uptake by sentinel lymph nodes (preferably 5−50 nm),104 unlike typical ultrasound contrast agents of ∼200 nm−4 μm in diameter. 2.3.1. Magnetic Resonance Imaging. Magnetic resonance imaging (MRI) is a noninvasive, nonionizing modality offering anatomical, physiological, and even molecular information within the bodies of living subjects. With penetration depths sufficient to image throughout the entire body of humans and with spatial resolutions down to 10 μm depending on the magnetic field strength (clinical magnets typically go to ∼1 mm resolution), MRI provides information not possible to access with other imaging modalities. However, while MRI is often performed for anatomical reasons without contrast, if one desires molecular information contrast agents such as nanomaterials must usually be used in part as a result of its low sensitivity. The low sensitivity of standard MRI is related to the mechanism of signal detection, which typically measures the relaxation rates of water protons (it can also detect other nuclei with nonzero spins, but by far the most common use is with protons). In general, contrast agents including nanomaterials are used to modify the water proton relaxation rates and can do so typically when present in micromolar concentrations, although recent advances can produce nanomolar detection levels.105\nSeveral classes of MR contrast agents exist, which can primarily be divided into four types on the basis of the physical MR mechanism that enables them to generate signal: T1, T2 (including T2*), PARACEST (paramagnetic chemical exchange saturation transfer), and hyperpolarization. Intuitively, T1 and T2 contrast can be understood in the context of relaxation processes of hydrogen protons. A small percentage of protons are aligned (∼1 in 106 in a 1.5T field, accounting for the low sensitivity) by an external magnetic field (B0) in the B0 direction. The reason that MRI can still produce nice images even with such low sensitivity is the fact that the molecule that one imagesthe water protonis in such high concentration in the body that sufficient molecules can be detected for an image to still be formed. Additionally, increased field strength can improve sensitivity somewhat; for instance, modern 7T scanners can improve the sensitivity nearly an order of magnitude over conventional 1.5T magnets and increase the resolution.106 Radiofrequency (RF) energy is applied perpendicular to B0 in the form of a second magnetic field so that RF can be absorbed by protons to result in a flip (i.e., excite) of its net magnetic precession. When the RF is removed, the net\nmagnetic moment relaxes and realigns to the B0 direction, releasing the absorbed energy. The rates of relaxation are highly sensitive to the immediate microenvironments of the protons and thus provide information about the microenvironment, which is why relaxation rates provide a powerful imaging opportunity. In fact, T1 and T2 are defined by these rates: T1 is the longitudinal relaxation (longitudinal recovery signal) and T2 is the transverse relaxation (dephasing of transverse magnetization). T2* is governed by the extrinsic magnetic field B0.\n107 Thus, T1 and T2 contrast are not observed directly, but their effects may be observed. Water molecules chemically interact with paramagnetic molecules such as Gd3+ or manganese (Mn2+) to give rise to T1-weighted signal. Unpaired electrons from contrast molecules (e.g., 7 unpaired electrons for Gd and 5 for Mn) produce strong magnetic fields that affect water protons when they are in very close proximity by modulating their relaxation times along the longitudinal axis. In T2-weighted imaging, contrast agents such as iron oxide nanomaterials work by creating magnetic field inhomogeneities that affect the proton relaxation rates. Notably, the same materials can be used for either T1 or T2 imaging, depending on nanomaterial physical properties such as size107 (see section 2.3.1.2). PARACEST exploits other aspects of MR physics, becoming a viable substitute for relaxivity-based MR contrast such as T1 and T2. PARACEST contrast agents produce a signal via protons that are exchangeable between bound water and bulk water and that resonate at a distinct chemical shift that is differentiable from bulk water due to the agent’s paramagnetism.108 Typically the contrast agent involves a paramagnetic lanthanide ion in a nanomaterial that enables selective detection by modulating the MR frequency of the exchangeable proton to values distinct from other, bulk protons.108 CEST (chemical exchange saturation transfer) and PARACEST notably allow one to acquire molecular information without contrast using MRI, although contrast can greatly increase their utility. The key advantage of hyperpolarization, the fourth MR technique, is that it eliminates perhaps the principle disadvantage of MRIi.e., its low sensitivity. It can increase the sensitivity 10 000-fold or more by using one of several technologies to greatly increase the percentage of nuclei that are aligned by the external magnetic field. One chief disadvantage is that typically imaging can often last only a short period of time, e.g., when dynamic nuclear polarization is used.109\nIn large part due to its extensive use in human and preclinical animal imaging, MRI physics and its multitudinous sequences have been comprehensively reviewed elsewhere.110−112 We thus restrict our attention in this Review to newly engineered magnetic nanomaterials whose physical properties have been chemically designed to optimize MR signal and have benefits as shown in the imaging of animal models.\n2.3.1.1. T1-Weighted MRI. T1 is a positive contrast mechanism, with contrast agents producing a brightening on T1-weighted MR images. Gd3+ is the conventional extrinsic contrast agent that generates T1 MR contrast, with many formulations having been clinically approved.107,113 The reason Gd3+ is an excellent T1 agent is because it has seven unpaired electrons, which are effective in decreasing T1 values and result in long electronic relaxation times, thereby producing signal for longer times.107 In particular, T1 contrast emerges from the magnetically disordered spin layers that occur at the surfaces of magnetic nanomaterials.91 At these surfaces, metal ions retain various numbers of unpaired electrons (for instance, Fe3+ has 5\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nI\nunpaired electrons) that help accelerate T1 relaxation.91 Most Gd3+ agents are small-molecule chelates, although many Gd3+linked nanomaterials have recently been developed. These are typically multimodal agents (preclinically) and fall under the “multimodal” or “adaptable” nanomaterial labels that we review in sections 2.7 and 3. A key advantage of the use of nanomaterials as opposed to small-molecule approaches is that, while Gd3+ chelates may leach the potentially toxic heavy metal (only leached Gd3+ can be toxic), nanomaterials that incorporate Gd3+ display much lower leaching.107,114 Gadolinium oxides (Gd2O3),\n115 gadolinium phosphates (GdPO4), and GdF3:CeFn3\n116 nanomaterials have all been developed for improved in vivo behavior in MR imaging. GdPO4 nanoparticles of 23 nm diameter were synthesized using a hydrothermal method and injected intravenously into a rabbit tumor model.117 The nanobased GdPO4 strategy was able to reduce the quantity of Gd injected by 10-fold compared to clinically used Gd-based contrast agent Magnevist (gadopentetate dimeglumine, a complex of chelated Gd) largely because of its substantially improved accumulation and retention within the tumor. Gd3+ ions on the nanomaterial surface significantly contribute to the longitudinal relaxation of water protons.107 Finally, some groups are developing paramagnetic nanophosphors with large magnetizations that typically incorporate Gd3+ (or Mn2+) into the particle matrix or in the shell in a core/shell construction.118 These nanomaterials are intrinsically multimodal (see section 3.1), with upconversion optical properties as well as very good magnetic properties; we describe further details of their construction in section 2.4.1. On the MRI side, Hyeon and colleagues developed 20−40 nm diameter NaYF4:Yb,Er/NaGdF4 core/shell nanomaterials, with Gd3+ cleverly positioned only on the outer shell where it could interact with water protons and help form T1-weighted images. Thus, when they i.v.-injected their nanomaterials into mice\nbearing xenograft tumors, the small nanoparticles extravasated and were detectable 1.5 h after injection using a 3T MRI scanner.118 Notably, Mn2+ ions can also serve as the dopant or matrix component in upconversion nanomaterials rather than Gd3+, providing T1 contrast (see section 2.4.1 for upconversion nanomaterials).91\nSome groups have shifted to other types of materials in order to completely avoid gadolinium and its possible toxicity, as Gd3+ is known to be toxic to patients with severe kidney disease as mentioned (leading to the devastating disorder NSF),119 some patients may be allergic,120 and there is evidence that Gd3+ could cause brain hypersensitivity and neuronal cell death.121 Most of these other T1 imaging agents are nanomaterials. For instance, Mn2+ does not display renal toxicity in kidney failure patients as does Gd3+, so many MnO and other nanomaterials have been developed as preclinical in vivo T1 agents.122,123 While spherical MnO nanomaterials were initially used in vivo,124 it turns out that the relaxivity of MnO nanomaterials depends strongly on their geometry and morphology as their interfaces with water critically influence their contrast effects107,122many recent MnO nanomaterials are thus more sophisticated in their geometrical design. MnO are considered good T1 agents because they overcome issues of toxicity, short circulation time, and low efficiency of cellular accumulation that have plagued other T1 contrast agents. Hollow MnO nanomaterials were developed recently to exploit their large water-accessible surface areas while decreasing the amount of metal Mn2+ ion injected (while more biocompatible than Gd3+, it is still a heavy metal and thus its injected mass should be minimized) and simultaneously allowing space for another imaging reporter agent (multimodal imaging) or therapeutic agent (theranostic).123,125 The nanomaterial was optimally constructed because the metal ions with unpaired electrons were positioned at the surface where they\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nJ\ncould best influence T1 relaxation.91 These hollow mesoporous silica MnO nanomaterials (HMnO@mSiO2) were created for tracking of intracranial stem cell implants over time.123 Monodisperse 15 nm MnO nanoparticle cores were synthesized by thermal decomposition of Mn-oleate salt, after which mesoporous silica was deposited onto the surface using a sol gel tetraethyl orthosilicate (TEOS) reaction with oleic-acidstabilized MnO nanoparticles. The hollow core was created by acid etching at pH ≈ 2.4 and refluxing in ethanol. The authors showed that the mesoporous coating of the nanomaterial (∼65 nm) optimally permits entry of water molecules to the surface of the magnetic core (∼15 nm) based on pulsedfield gradient diffusion NMR studies and the fact that the relaxation values are considerably better than those for similar nanomaterials lacking the mesoporous layer such as MnO@ dSiO2, MnO@PEG-phospholipid (PEG = poly(ethylene) glycol), and MnO@mSiO2.\n123 Thus, the mesoporous structure permitted an excellent longitudinal relaxation enhancement of water protons (0.99 (mM−1 s−1) at 11.7T). After electroporating mesenchymal stem cells to enable insertion of hollow MnO nanomaterials, the cells were implanted into the brains of mice in a cell tracking study in which T1-weighted images from a 9.4T MRI machine showed they could be observed intracranially for at least 2 weeks postimplantation (see Figure 2).123\nUltrasmall T1 Nanomaterials. Rather than modifying nanomaterial morphology and coating, Hyeon and colleagues varied the MnO nanomaterial shape to optimize relaxivity. They fabricated thin (1 nm) lamellar MnO nanoplates reminiscent of the graphene structure.126 Because of the ultrahigh surface-to-volume ratio and thus the exposure of a high concentration of Mn2+ ions at the surface, the nanoplates demonstrated very high longitudinal relaxivity values of 5.5 mM−1 s−1 at 1.5T. To achieve this, the authors applied surfactants as a structure-directing agent by which to effectively confine the MnO crystal growth to two dimensions. In particular, the 2D MnO nanoplates were formed by thermally decomposing manganese(II) acetylacetonate in the presence of 2,3-dihydroxynaphthalene (2,3-DHN). This supported 2- dimensional growth by functioning as both a strongly binding surfactant (wherein the bidentate enediol ligand of 2,3-DHN binds to surfaces) and as a structure-directing agent (via π−π interactions that help direct the self-assembly of naphthalene rings).126 MnO nanoplates were PEGylated for biocompatibility and were shown to display almost no leaching of Mn2+ ion over 7 days, implying minimal toxicity. After i.v. injection of the MnO nanoplates into mice, liver, spleen, and kidney uptake was observed on T1-weighted images on a 1.5T clinical MR scanner using a human wrist coil. While Mn-based nanomaterials are typically used in T1 scans, notably they also can be used for T2-weighted imaging, particularly when the size and properties are tuned appropriately.126,127 For example, 5 nm Mn-based nanomaterials yield high T1 contrast (and no T2 contrast), while 12 nm Mn-based nanomaterials displayed the inverse (high T2 contrast and no T1 contrast).127 Seven nm Mn-based nanomaterials are a good compromise if dual-mode T1/T2MR agents are desired, even though both the T1 and T2 signal decrease from their respective maxima. This dual-mode effect applies to typical T2 agents, as well: for example, iron oxide nanomaterials, which are typically used as T2 agents as described in the following section, can also be applied as T1 agents. In recent work, iron oxide nanomaterials were linked to Gd to generate synergistically increased T1 MR enhancement\nin vitro and in vivo.128 Iron oxides (3.1 nm) were linked to the small-molecule neurotransmitter dopamine (DOPA), which was linked to a chelator, diethylenetriaminepentaacetic acid dianhydride (DTPA), via a condensation reaction in organic solvent. Gd(III) (as Gd(NO3)3·6H2O) was then complexed to the Fe3O4-DOPA-DTPA nanomaterials, yielding 3.4 nm Gdchelated iron oxide nanomaterials. In vitro in HeLa cells, the Gd-Fe3O4 nanomaterials displayed ∼3-fold improved T1 contrast compared with control Fe3O4-DOPA + Gd-DTPA added independently and incubated. Injected i.v. into mice, T1weighted MRI at 3T enabled easy visualization of vessels, and due to the very small size of the nanomaterials, they are envisioned as a strong T1 MR contrast agent (also with T2 potential due to their iron character) to leak across blood vessels into tumors.128\nGd2O3 nanomaterials were prepared specifically to improve MR contrast. Fabricated by reducing Gd3+ ion precursors refluxed with air, they were stabilized with D-glucuronic acid.115 The resulting ultrasmall (1−2.5 nm diameter) nanomaterials displayed large longitudinal relaxivity r1 of 9.9 s\n−1 mM−1, higher than Gd3+ chelates and dependent on the nanomaterial core diameter. This conforms with theoretical work that suggests that robust T1 contrast effects can be attained when the sizes of the magnetic nanomaterials are below ∼10 nm.91 These effects likely can be ascribed to the nanoparticles’ high surface-tovolume ratio as well as the cooperative induction of proton relaxation on the nanomaterial surface.107 When injected i.v. into rats with brain tumors, the accumulation of Gd2O3 nanomaterials at the cancer site was obvious within just minutes and remained until at least 2 h postinjection (p.i.). The small size of the nanomaterial likely made it more feasible for the nanoparticles to extravasate through the tumor vascular pores in the brain,115 which are often even smaller than other sites in the body due to the blood−brain barrier. Furthermore, unlike larger nanomaterials, these ultrasmall nanoparticles cleared renally, decreasing exposure of heavy metal Gd3+ ion to the animal.\n2.3.1.2. T2-Weighted MRI. The T2 mechanism gives negative contrast, in which contrast agents produce darkening on T2-weighted MR images. Radiologists and scientists can confuse this signal with other anatomic or pathogenic conditions as it is often more difficult to accurately visualize than positive contrast agents (e.g., T1 agents),129 so in some cases T1 agents are chosen solely for this reason. By far the most commonly used material for T2 contrast has historically been iron oxide, as these nanomaterials display a high magnetization that can induce magnetic inhomogeneities that influence T2 relaxation107 (and as implied earlier, there are some sequences that can produce positive contrast using iron oxideswhich have been used clinically on patientsyet these are not common as the T2 effects are considerably stronger130,131). In particular, iron oxide nanomaterials serve as MR T2 contrast as a function of the local magnetic field gradients they produce for their dipoles (generated by the spins of some of their electrons) to interact with water protonsthe dipolar interaction between the water proton spins and iron oxide magnetic moment increases the rate at which protons are driven out of phase with one another after the radiofrequency pulse is discontinued, which decreases T2 relaxation times.132 Shorter T2 relaxation decreases signal intensity, which leads to the negative image contrast or darkening for which T2 is known. Iron oxides have been used for MR detection of cancer, atherosclerosis, imaging of lymphoid tissues and circulating\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nK\ncells, and tracking cells including stem cells and immune cells throughout the body.132−136 While the vast majority of studies simply exploit the fact that iron oxides darken contrast at their location to provide contrast, in recent developments activatable or “smart” iron oxide nanomaterials have been created that take advantage of the fact that water molecules must be in the immediate proximity for iron oxides to function as a T2 contrast agent. These materials rely on molecules that may be present or overexpressed only at the intended imaging site to “activate” contrast enhancement predominantly at the disease site and provide minimal contrast elsewhere. For instance, iron oxide nanomaterials (∼6 nm diameter Fe3O4) were recently constructed to be activated via copper-free click chemistry when exposed to matrix metalloproteases (MMPs) overexpressed in the tumor microenvironment.137 Once exposed to MMPs (2 and 9), the iron oxide nanomaterials self-assemble into larger superparamagnetic nanoclusters that boost T2 signal contrast by increasing the local magnetic susceptibility. The nanomaterial system was set up elegantly by fabricating two different sets of iron oxide nanoparticles designed to link together in a chain upon activation. One set contains an azide and the other an alkyne, which both are shielded by PEG chains on the nanoparticle surface. These PEG chains are linked to the iron oxide surface by MMP-cleavable peptides. Upon cleavage, the azide and alkyne no longer experience steric hindrance and can thus link together in a bioorthogonal strategy (see Figure 3), thereby generating ∼800 nm nanoclusters. The two sets of iron oxide nanomaterials were injected intravenously (7.5 mg of Fe/kg of animal total per animal) into mice, leading to a 14%\ndecrease in T2 signal in the tumor 4 h after injection, compared with negligible T2 change in controls.137 Interestingly, the authors also injected the two sets of nanomaterials intratumorally, enabling them to establish an upper limit of ∼25% T2 contrast enhancement at the iron concentrations injected.137 This concept allows MRI to readily sense and localize the presence of enzymes via cleverly designed activatable iron-based nanomaterials. Preclinically, this is an elegant and effective system. However, one might question the viability of such an approach to be clinically translated. While it involves little-to-no materials toxicity, there are two hurdles to overcome beyond those typically experienced by nanomaterials on the path to translation: (i) There are two different nanomaterials injected, so it is likely that each would require approval. This may be costly and time-consuming. (ii) It is likely that the biodegradation kinetic time scale of a large in vivo nanocluster would be significantly longer than that of smaller particles. Similarly, the in vivo growth of a nanocluster is a potentially chilling concept unless the particle can be chemically designed to have a guaranteed safe upper size limit; otherwise, the formation of large, rigid particles in circulation or tissues could have undesired effects. In the current regulatory climate, the strategy may thus jeopardize its likelihood for regulatory approval due to possible chronic safety concerns in diverse in vivo environments as well as costs.\nIron Oxide and Iron Alloy-Based Nanomaterials. Iron oxide nanomaterials mainly comprise magnetite (Fe3O4), maghemite (γ-Fe2O3), and hematite (α-Fe2O3). For T2 relaxivity, three properties are criticalsize, geometry, and\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nL\ncompositionthus, T2 is governed by the nanochemistry of construction. In fact, all three iron oxide types display sizedependent properties, which are typically roughly classified as monocrystalline iron oxide nanoparticles (MIONs), superparamagnetic iron oxides (SPIOs), and ultrasmall superparamagnetic iron oxides (USPIOs). These correspond to different size ranges, yet also show a strong dependence on composition and shape. Because of this, definitions often vary across the literaturein one convention, nanoparticles <50 nm in diameter are USPIOs, those from 50 to 300 nm are SPIOs, and MIONs are a subcategory of USPIOs of ∼10−30 nm.133,138 In the theoretical magnetic nanomaterial literature, the different regimes include the motional average regime (short diffusion times), the static dephasing regime, and the echo-limiting regimethese and their underlying equations comprise chemical exchange models that have been built to predict the entire range of diffusion times (and thus T2 relaxation) for spherical particles with various properties.139 Size particularly plays a major role in the utility of these nanomaterials for MRIthe nanomaterial saturation magnetization increases proportionally to the size of the nanomaterials.91 Moreover, they display a transition from superparamagnetic to paramagnetic behavior as nanomaterial size decreases, transforming a T2 contrast agent into a T1 agent.107 The sizedependence is a consequence of the fact that the accompanying decrease in saturation magnetization reduces the T2 effect (thereby simultaneously enhancing T1 contrast) and vice versa;127 therefore, one can easily, for example, increase T2 effects by increasing nanomaterial size. The composition of the magnetic nanomaterials is also a key contributor to MRI contrast effects, with much opportunity for increasing efficiency. The magnetism of the nanomaterials can be tuned easily, for instance, by incorporating transition metal dopants. For example, cobalt (Co), gold (Au@Fe), and platinum (Pt@Fe) are excellent dopants to modulate the imaging properties. As nanomaterials comprising these materials have much higher saturation magnetization values than that of iron oxides of similar size and shape, they have considerably larger effects on proton relaxation and, thus, image contrast.140 While one must be cautious about possible toxicity with new dopants, the aforementioned metals thus far appear to be biocompatible at the low levels at which they are injected.140 Not only the material composition but also examined recently is how the size and geometry of magnetic nanomaterials can have substantial effects on MRI relaxivities. Both saturation magnetization and nanomaterial size (radius) affect T2 relaxation. Because the radius is a function of the shape, one can modulate T2 accordingly: for example, while displaying a relatively moderate saturation magnetization of 71 emu/g, starshaped “octopods” with edge length 30 nm displayed enormous r2 relaxivity of 679 mM\n−1 s−1 due to the increased effective radius imparted by its unusual geometry.141 A volume-matched spherical iron oxide displayed ∼5.4-fold lower relaxivity at approximately the same saturation magnetization (126 mM−1 s−1). Thus, by finely tuning the size, morphology, and composition of magnetic nanomaterials, optimized T2 (and T1) relaxivities are possible that can significantly increase MR sensitivity and/or reduce the mass of material needed for in vivo imaging. The relationships are more clearly observed in the equation relating T2 to the saturation magnetization of the nanomaterial (ms), the nanomaterial volume fraction (V), the radius of the magnetic nanomaterial (r), the thickness of the nanomaterial\nsurface coating (L), the diffusion coefficient of the water molecules (D), and the proton gyromagnetic ratio (γ):91\nπ γ= × +( ) m V r D 1 T2 256 405 1 L\nr\n2 2\ns 2\n2\nThus, with a strong inverse dependence on physical properties such as size, ms, and V, the enormous value that chemists can bring with precise tuning of nanomaterial properties becomes clear in their profound effects on improving signal contrast. Iron oxide nanomaterials have a long history, leading to a great diversity of fabrication approaches. Broadly, they can be categorized into physical methods (e.g., gas-phase deposition), wet chemical preparation methods (e.g., flow injection and chemical coprecipitation), and microbial methods.142 From commonly used chemical coprecipitation and sol−gel strategies to hydrothermal and electrochemical approaches and many more, each method has its advantages and disadvantages. For instance, while the physical methods are generally unable to control particle size down to the nanoscale, wet chemical and microbial approaches often offer appreciable control over the particle size, sometimes the geometry, and importantly increased capacity for scale-upa major concern once clinical applications are sought. These iron oxide nanomaterial construction chemistries have recently been excellently reviewed in a number of publications.89,142,143 The common methods, such as chemical coprecipitation and thermal decomposition, tend to be most often used by scientists because they are simple and efficient, and many surface chemistries have been concurrently developed in order to make them biocompatible and amenable to applications in living subjects. A representative chemical coprecipitation, which typically generates iron oxides of <50 nm (USPIOs), might involve ferrous and ferric salts added to an alkaline solution such as NaOH or NH4OH.\n89 While such approaches can produce a large nanoparticle size distribution and poor crystallinity (affecting their magnetic and thus imaging properties), these issues are often resolvable by inclusion of surfactants (e.g., the oft-used but toxic cetyltrimethylammonium bromide (CTAB), sodium cholate, or polyvinylpyrrolidone (PVP), which can improve nanomaterial monodispersity, aggregation, crystallinity, etc. by helping to control available surface energy of particles) into the reaction chemistry.89 By tuning experimental physical conditions, such as pH, stoichiometry, and ionic strength, nanomaterial size and shape can be manipulated as desired.144\nAside from pure iron oxide nanomaterials, many iron alloys are now produced to provide enhanced T2 signal. These include FeCo, CoFe2O4, NiFe2O4, MnFe2O4, FePt, and others.145 FeCo, which is produced with a biocompatible graphitic carbon (GC) shell, is a particularly interesting material with excellent physical properties for an MR imaging agent given its high per-metal-atom relaxivity, which is among the best of all MR contrast materialsits saturation magnetization is about 3 times that of iron oxide.146 With a blood half-life of ∼4 h and low toxicity, branched PEG FeCo/GC nanomaterials (7 nm core, 23 nm hydrodynamically) allowed visualization of very small vascular structures in living rabbits down to 100 μm with ultrahigh contrast on a 1.5T scanner. The FeCo nanoparticles were compared to the iron oxide formulation Combidex (ferumoxtran-10), which is clinically approved and had been commercially available (currently off the market due to its inability to outperform alternative clinical lymph node\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nM\ndiagnostic procedures147). At the same metal concentration, the FeCo nanomaterials displayed substantially improved signal enhancement factors (3.8 for Combidex vs an exceptional 9.5 for FeCo). The authors also showed that the Gd-based commercially available agent Magnevist would require at least a 10-fold increased metal concentration to match the signal enhancement of the FeCo nanoparticles (and only for very short times because the circulation half-life of Magnevist is short). Such results at high resolution led to exceptional MRI visualization of small microvessel growth in rabbit hindlimb ischemia and aortic stenosis models, including tortuous angiogenic vascular growth,146 which could lead to earlier detection and improved diagnostic accuracy. These FeCo nanomaterials notably display satisfactory T1 relaxivities that make them also amenable to T1 imaging.129 If proven safe, the critical test for FeCo nanomaterials will not be whether they improve upon Combidex but rather if they can outperform nodal diagnostic procedures in patients. In an intriguing method for eliminating artifacts from MRI scans, clever, simultaneous use of both T1 and T2 properties was made possible by development of a new nanomaterial. Cheon and colleagues engineered dual-mode T1/T2 nanomaterials comprising T1- and T2-active constituents separated by a nonmagnetic silica layer.148 This nanomaterial provides both T1 and T2 contrast, which satisfies logical AND gate criteria, i.e., high T1 and T2 signal contrast change must both be\nexhibited to produce a true signal. The nanomaterial may comprise a hybrid of an outer lining of paramagnetic material (including Gd or other lanthanide-based dopant materials such as Eu and Dy) and a superparamagnetic inner core containing iron-based materials such as iron oxide (Fe3O4) and other bimetal oxides of iron (e.g., CoFe2O4, MnFe2O4, and ZnFe2O4), with a 16 nm layer of silica separating them. This structure allows the paramagnetic material to directly interact with water protons (see Figure 4a−d) for a T1 effect because proximity is so critical in T1, while the superparamagnetic core is able to generate a sufficient magnetic field on the external water protons to accelerate T2 relaxation and produce high contrast.148 These nanomaterials are fabricated by starting with the superparamagnetic core synthesized using a one-pot thermal decomposition process. A base is then used to catalyze the silica shell grown using a sol−gel procedure. The silica is used as a spacer layer to separate the two different magnetic materials so that simultaneously high T1 and T2 signals could be achieved. The authors showed in vitro that they could exploit the high T1/T2 signal of the dual magnetic nanomaterial by passing obtained MR images of nanomaterial patterns through a logical AND gate to filter out artifactual MR signal (see Figure 4e, f). As expected, unimode particles, like clinically approved Magnevist (T1) and Feridex (T2), could not produce such filtering (notably, Feridex is no longer marketed due to lack of clinical demand).147 Moreover, Cheon and colleagues’\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nN\ndual-mode nanomaterials displayed 2-fold higher T1 and T2 relaxivity coefficients compared to the maximum relaxivities of the clinically approved agents. Human neural stem cells were then loaded with the dual-mode nanomaterial. Typically, artifacts mar the ability to clearly track cells in MR cell tracking, leading to confusion between true contrast and extraneous signal, and thus obscuring the location and quantification of cells. To show the ability to remove these uncertainties using their system, the authors injected the nanomaterial-loaded stem cells into a rat model of stroke in the brain. On day 14 of tracking in rats, MR images displaying T1 and T2 signal were obtained and processed with the AND gate to produce a brain map of sites where only the nanomaterials were located, which served as a proxy for the stem cell location (see Figure 4g).148 This clever use of nanomaterials chemistry to not only produce high contrast in in vivo imaging but also remove MR artifacts and clean up images to more accurately diagnose and assess disease provides an excellent illustration of one of the many ways in which nanomaterials are beginning to transform in vivo imaging. Iron Oxides in the Clinic. While the clinical application of iron oxide nanomaterials had typically been perceived as successful, the evolving narrative turns out to be considerably more complex. A considerable number of iron oxide nanomaterial formulations have been clinically approved or are in clinical trials, including Ferucarbotran (Resovist or SHU 555 A, Bayer Schering; also SHU 555 C (Supravist), Bayer Schering), Ferumoxtran-10 (AMI-227 or Code-7227, Combidex, AMAG Pharma; in Europe Sinerem, Guerbet), Ferumoxides (Feridex IV, Berlex Laboratories; in Europe Endorem, Guerbet), VSOPC184 (Ferropharm), Ferumoxytol (Feraheme, AMAG Pharma), and NC100150 (Clariscan, Nycomed). However, many of these nanomaterials are no longer on the market or their development has been halted, primarily due to poor clinical adoption/market uptake and a relative lack of sensitivity and specificity (for example, a 24% false positive rate (see section 2.6.1 in the Imaging Screens subsection) when using Combidex to identify lymph node metastasis, which led to unnecessary surgeries).147,149 Resovist is still being used in some countries, and Ferumoxytol, which was clinically approved for treatment of anemia, is now being used by several groups for disease imaging off-label owing to the tendency of macrophages to phagocytose iron oxide nanoparticles.134 While safety concerns for iron oxides are fairly minimal, some of the agents, such as Feridex, have contributed to hypotension and lumbar/leg pain in 2−10% of patients;149 iron oxide formulations may also carry warnings for anaphylactic reactions, which are exceedingly rare (between 21 and 82 reactions per 100 000 persons, depending on the iron oxide coating; dextran-based coatings put patients at significantly higher risk than nondextran coatings150 notably, these findings strongly suggest that the reactions are more to the coating than to the iron oxide material). Applying the lessons learned from earlier generations of iron oxide formulations, it is likely that future generations of iron oxide nanomaterials with clinical efficacy will be relatively straightforward to obtain regulatory approval; however, whether these nanomaterials will ultimately be clinically adopted will depend on their value added (including improved diagnostic accuracy and efficacy, improved coatings for decreased risk of harm, accessibility, decreased costs, etc.) over other diagnostic options for each application. For example, in some cases, iron oxide nanomaterials perform better clinically than alternatives:151−153 iron oxide nanomaterials (Resovist) were compared to Gd\nchelates to characterize focal liver lesions in patients151 (also see section 4). The specificity and positive predictive value were significantly better for the nanomaterials than for Gd, leading the investigators/physicians to strongly recommended iron oxides to characterize liver lesions, particularly when Gd-based images prove indeterminate; however, given that Resovist is only available in a very limited number of countries (e.g., Japan), this is often not possible currently. Ferumoxytol, which is available off label in many countries, has proven superior in diagnostic value to Gd complexes using MRI for diagnosis of myocardial inflammation and much better than noncontrast MRI.152 In other cases, iron oxides probably are not better than other options. For example, in imaging liver blood flow dynamics, innovations in CT and MRI hardware have sufficiently improved small-molecule iodinated (CT) and Gd (MRI) contrast so that in this application iron oxides are less relevant.147 Therefore, while the trail of historical lessons in iron oxide nanomaterials’ past breeds caution for its future, in parallel the wealth of experience attained portends improved agents capable of the diagnostic enhancements (e.g., the utility of immune cell uptake such as macrophages134) that will command the attention of prescribing physicians.\nLanthanide MR Nanomaterials. Just as in T1 contrast, lanthanide-related T2 contrast agents have recently emerged due to their high magnetic moments and brief, sub-ps electronic relaxation times.145 Lanthanides such as Eu, Dy, Ho, Er, and Gd have been developed as MRI agents in their oxide form (Ln2O3, Ln = lanthanide). These nanomaterials exhibit a distinctive 4f electronic structure that endows them with valuable magnetic, optical, and electronic properties, often making them a superior choice for many imaging modalities including MRI, but also optical (luminescence), CT, PET, and SPECT imaging154,155 (as we will cover in later sections). Dysprosium (Dy3+)-based nanomaterials tend to be the most highly studied as they show the highest relaxivity values arising from their high magnetic moments and paramagnetism.156 Moreover, because some magnetic nanomaterials are useful only at smaller magnetic fields (e.g., 1.5−3T) and the use of larger magnets (7T and higher) is growing in both the research and clinical domains, contrast agents amenable to use at high fields are necessary. Dysprosium nanomaterials such as βNaDyF4 can fill this need due to their Curie spin relaxation mechanismthe relaxivity of these nanomaterials was 64-fold improved over typical, clinically approved iron oxide nanomaterials in an ultrahigh field MR scanner (9.4T).157 Ultrasmall 2−3 nm spherical Dy2O3 nanoparticles were developed for in vivo use via a one-pot synthetic method, with Dy3+ precursor in triethylene glycol in the presence of NaOH and then slowly dripped aqueous H2O2. A D-glucuronic acid coating was subsequently added to the surface for water-solubility and biocompatibility. Within 30 min of i.v. injection into mice, the Dy2O3 nanomaterials showed strong T2 contrast in the liver and to a lesser degree in the kidneys. This demonstrated not only that the particles were imageable but also that they were able to be filtered renally. The ultrasmall nature of these nanomaterials may provide them with useful disease-targeting properties (e.g., to extravasate through smaller vascular pores, such as those that may exist in the vasculature of brain diseases such as brain cancer), which will need to be tested in the future.\n2.3.1.3. Paramagnetic Chemical Exchange Saturation Transfer. Paramagnetic chemical exchange saturation transfer (PARACEST) has begun making inroads into the traditionally T1- and T2-dominated fields of MRI with respect to\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nO\nnanomaterial contrast. Paramagnetic nanomaterials are used in this strategy to saturate exchangeable protons via radiofrequency pulses, leading to diminished equilibrium magnetization and thus improving the inherent insensitivity of MRI PARACEST agents. Because of the mechanism, the image contrast can be turned on and off simply via modulation of the radiofrequency. PARACEST nanomaterials generally take the form of adaptable nanomaterials, such as the polymeric, liposomal, and dendrimeric nanoagents described in sections 2.7.1−2.7.2paramagnetic ions such as Eu3+ or Yb3+ are simply chelated to optimally expose them to bulk water protons.105,158 For example, Eu3+ was chelated to generation 5 polyamidoamine (G5 PAMAM) dendrimeric nanoparticles to image brain cancer after i.v. injection into mice.158 The PARACEST detection mechanism involves a functional group (like a hydroxyl) with a labile proton that has an MR radiofrequency shift (i.e., chemical shift) that is typically ∼1−5 ppm different from the shift of water.158 The MR signal from a proton is turned off by applying radiofrequency to selectively saturate the chemical shift of the labile proton. MR signal from water in the sample is thus decreased as the saturation is transferred to water via the proton exchange. Paramagnetic ions such as Eu3+ can enhance the difference in the chemical shift, in some cases by binding noncovalently to the water molecule this is exactly how contrast is formed in the present case of Eu3+-chelated PAMAM dendrimers.158 Glioma imaging showed excellent specificity to tumor and very low signal in the contralateral healthy region, suggesting that, while optimization will be needed, PARACEST is an emerging option for MRI with a great deal of opportunity for developing novel nanomaterial tracers. However, developers of nanomaterials for PARACEST must be cautious, as, for instance, silica nanomaterials were shown to quench PARACEST effects through a condition as seemingly common as excessive positively charged amino groups on the nanomaterial surface.159\n2.3.1.4. Hyperpolarization. Hyperpolarization agents have very high potential as MR contrast because they bridge the gap of MRI’s weakest attributeits sensitivity. While many metabolic agents are beginning to be routinely hyperpolarized for MR-based investigation (e.g., of sites of normal and abnormal metabolism, their biochemical pathways, and their byproducts160), only very few nanomaterials have yet been applied for in vivo hyperpolarization imaging. By temporarily aligning the selected nuclei, hyperpolarization can achieve on the order of 105 better sensitivities than otherwise possible with MRI. The basis for the need for hyperpolarization arises from the fact that, at thermal equilibrium, only slightly more MRactive nuclei are aligned parallel than antiparallel to the magnetic field in which they are placed. This is because of the energetic advantage of the slightly lower energy in parallel alignment compared with antiparallel. Typically the net polarization is on the order of 0.0005%. When the nucleus imaged is the proton, it remains possible to obtain reasonable MR images because the water concentration in tissues is relatively close to its 55 M maximum. Thus, even at low sensitivity, due to the tremendous numbers, the visualization is valuable and reasonably high quality. However, for other appropriate nuclei that can be hyperpolarized such as 13C, 15N, 19F, 29Si, and 31P, the abundance is so low that a boost in sensitivity is required. Hyperpolarization provides just that by improving net polarization from 0.0005% to up to 20−50%.109 Moreover, unlike T2 contrast, hyperpolarization is a positive-\ncontrast imaging strategy that provides nearly background-free visualization for most nuclei.161 This mechanism thus presents great opportunities for imaging other nuclei, as well as improving contrast in proton-based MRI. Dynamic nuclear polarization (DNP) is a standard method to hyperpolarize nuclei. It applies microwave radiation under high magnetic field and low temperature to strongly hyperpolarize a sample by transferring electronic polarization to the nuclei,109 enabling subpicomolar detection sensitivity, a potential game-changer in the field of MR imaging in vivo.162 Core−shell particles containing 29Si nanomaterials were fabricated by Marcus and colleagues for intravascular, tumor perfusion, and gastrointestinal applications.162 These 2 μm microparticles contained many nanocrystalline cores of Si for in vivo visualization using MR hyperpolarization at sensitivity down to 0.42 picomolar. 29Si was used because (i) it enables nearly background-free imaging because Si is naturally rare in the body, (ii) the nuclear magnetic moment of 29Si is similar to more commonly used nuclei such as 13C and 15N so that hyperpolarization parameters did not have to be modified greatly, and (iii) ultralong T1 relaxation times (up to several hours) and T2 coherence times of several seconds due to the physics of spin-1/2 29Si in crystal lattices were achievable.162 DNP hyperpolarization of the nanomaterials immediately preceded introduction of particles into the gastrointestinal (GI) tracts of animals. Detailed images were obtainable within seconds of injection of the hyperpolarized particles into the GI tracts of mice, and because of the ultralong relaxation time they were visible through at least 40 min p.i. This allowed imaging of the complete GI tract, which has been traditionally difficult to do because, for instance, endoscopic interventions are generally inaccessible to the GI and CT and standard proton MRI have had to attempt to overcome major challenges to attain useful images.162 The authors also showed the ability to map the vasculature of prostate cancer in a mouse transgenic model using the 29Si-based particles.162 Because the particles were too large to leak into tumor interstitium, they were amenable to blood pool imaging. This imaging procedure allowed prediction of regions of necrosis within the tumor due to lack of vasculature in certain sites, with postmortem verification. However, these materials are being miniaturized such that current iterations are ∼10 nm and much more likely to be useful for a variety of imaging applications161except for blood pool imaging. The biggest challenge remaining for these sorts of nanomaterials to make a major impact on imaging is likely to be the expense and ultimately prevalence/availability of hyperpolarization for MRI in human medicine. While the detection sensitivity was good (corresponding to 0.007 M 29Si sensitivity), on the order of 10 μg hyperpolarized silicon particles (∼500 000 for 2 μm diameter) were still required per pixel to generate signalthis is significantly better than, for instance, the detection sensitivity for 19F-labeled cells using MRI.163 Yet the sensitivity could be improved considerably if instead of employing the concentration of 29Si at natural abundance levels (only 4.7%), 29Si were enriched. Therefore, with optimization these results are highly encouraging for the future of MRI hyperpolarization using nanomaterials.\n2.3.2. Magnetic Particle Imaging. Magnetic particle imaging (MPI) is a new imaging modality able to employ some of the same familiar magnetic nanomaterials as MRI, such as iron oxides. Yet unlike T2MRI, MPI produces positive contrast from these materials and the MPI mechanism exploits their nonlinear magnetization curve to generate images of\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nP\nnanoparticle localizations with high temporal (ms scale) and spatial (sub-mm) resolutions.164,165 Even early MPI scanners can rapidly (on par with optical and ultrasonic imaging, rather than MRI) image with high sensitivity, resolution, and contrast.101 Its key advantages include that its contrast and sensitivity are already on the order ofand predicted to surpassthose of standard imaging modalities such as X-ray computed tomography (CT), PET, ultrasound, and SPECT. Furthermore, like all these modalities, MPI provides noninvasive body-wide tissue penetration. It is able to achieve such high sensitivity because its signal is generated via the intense electronic magnetic response of the nanomaterial agent, in contrast to the much weaker nuclear magnetic response detected from water in MRI.101 In comparison with the nuclear magnetization of water in a 7T MRI system, MPI’s magnetization is 22 million times more intense. In particular, MPI images are generated by using the magnetic moments of nanoparticles, the signal of which linearly carries information about the concentration, in combination with localization of their spatial position by spatial encoding. The spatial positions of nanoparticle concentrations are mapped in a 3D intensity image.166 Detection of nanoparticle magnetic moments in the samples is performed using a combination of static and time-varying magnetic fields. A static gradient field (also called a selection field and typically ∼2−8 T/m167), which can be generated by a pair of opposing magnets, saturates the nonlinear magnetization of the magnetic nanoparticles in all but a field-free region. Any nanoparticles located in the field-free region (which is often a field-free point) are oriented in random directions and have no net magnetization. The selection field selects the region of interest, enabling spatial encoding of the magnetic nanomaterial signal. The size of this region, and therefore the spatial resolution, is highly dependent on the strength of the applied gradient field. Time-varying drive fields are used to rapidly translate the fieldfree region throughout the imaging field of view. Currently, the drive field typically has a frequency of 25 kHz, although that may change as optimal combinations of physical parameters are better understood,168 with amplitudes usually on the order of hundredths of a Tesla. By scanning the field-free region across the sample, the magnetic moments of the magnetic nanomaterials flip direction, which induces a voltage in the receiver coil. Because this signal is measured at each field-free point scanned across the sample, spatial encoding is accomplished. Each magnetic moment flip additively increases the signal, producing a linear signal that can quantitatively measure the nanomaterial concentration at each voxel. Therefore, one can raster scan the field-free point across the sample to form complete images.91,167 Moreover, since no constituents of the body contain magnetic moments similar to the magnetic nanomaterials used in MPI, only the superparamagnetic nanomaterials are detected, and no background signal arises from the body tissues, which are nearly all diamagnetic. Because the nanomaterials are the sole signal source, they provide essentially near-infinite contrast. Practically, this means that the scans are easy to interpret and that the amounts of optimized nanomaterial necessary to inject tend to be on the order of, or lower than, other modalities (such as MRI and CT) as long as they are efficiently targeted.70,101 Recent improvements to MPI have extended the field-free point to introduce a field-free line approach, which can produce more sensitive scans by an order of magnitude.169\nIron oxide nanomaterials have been nearly the sole contrast agent applied for MPI thus far. This is because the underlying physical MPI mechanism requires its particles to display highly uniform size and surface properties,102 which is now possible with iron oxides because the nanochemistries have been iteratively improved and enhanced by many groups over the decades since they were introduced. The physical properties of the superparamagnetic nanomaterials, including the size distribution, anisotropy of the magnetic core, and surface modification, determine the spatial resolution and sensitivity of MPI imaging.70\nIn addition to increasing magnetic field gradient strength, the spatial resolution of MPI can be enhanced somewhat by decreasing the full width at half-maximum (fwhm) of the fieldderivative of the magnetization of the magnetic nanomaterial,170 which can be done by controlling nanomaterial physical properties through chemistry. Because the fwhm is intrinsically dependent on the nanomaterials’ size distribution and environment, it is important to tailor the chemistry of the nanomaterials used for MPI to yield an ideal size/size distribution to deliver optimal MPI performance. For example, Krishnan and colleagues controlled the synthesis of iron oxide nanoparticles via tight regulation of physical and temporal parameters in the thermal decomposition of iron oleate in the presence of oleic acid.165,171 This allowed fabrication of a monodisperse 19.7 nm diameter iron oxide nanomaterial with a very tight distributiona standard deviation of just 0.27 nm. These distributions are a huge improvement over the bi- and multimodal distributions of typical previously commercially available iron oxide formulations, which decrease MPI efficiency.172 The nanomaterial surface was modified via ligand exchange with carboxylate groups, and PEGs were subsequently linked via amide bonds to increase circulation time (over 3-fold greater than marketed agent Resovist,165 described below). In vivo MPI of the i.v.-injected nanomaterials displayed signal only in the organs of the mononuclear phagocyte system (MPS) such as liver and spleen, with no background signal elsewhere, which was verified via fluorescence imaging of the Cy5.5 labeled nanomaterials.171\nIn a sense, MPI is perhaps the first medical imaging platform to intrinsically exploit nanoscale material properties173 because the images are formed from direct measurements of the magnetic moments of magnetic nanomaterials. Thus, as with nuclear modalities like PET and SPECT, a contrast agent is required to produce MPI contrast with the key difference that in MPI the contrast agent must be nanoscale. Given the importance of optimized nanomaterials to MPI, many groups are now studying the interaction between magnetic nanomaterial physical properties and MPI contrast, sensitivity, and resolution.70,168,174−179\nOptimizing Nanomaterials for MPI. The electromagnetic response of magnetic nanomaterials is dependent on their physical properties, especially their sizefor instance, MPI resolution is theoretically predicted to improve cubically with increasing nanoparticle diameter. However, the possible improvements are restricted on the large end of the range of nanomaterials by their relaxation propertiesBrownian relaxation (described below) begins to dominate at sizes >25 nm and severely degrades spatial resolution. Other physical properties also affect the response; by minimizing the thickness of the surface coating,167 the relaxation properties can be further controlled, yielding a complex interplay between size, surface properties, and sensitivity/resolution in MPI. Unfortu-\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nQ\nnately, because optimization of the nanomaterial properties for sensitivity can conflict with optimization for resolution, one of the two must often be chosen as more important for a particular application. MPI resolution is strongly affected by the two relaxation mechanisms that magnetic nanomaterials undergo, while its sensitivity is marginally affected. When a nanomaterial’s magnetic moment is able to rotate with the magnetic field without the particle structure physically rotating (characterized by materials that undergo Neél relaxation), MPI sensitivity is improved, while optimal MPI resolution typically involves larger nanomaterials (characterized by materials that often undergo magneto-viscous relaxation). The data and theory to date converge to suggest that optimal high-resolution MPI nanomaterials will be large (up to ∼27 nm diameter), highly monodisperse, single-domain structures with thin coatings.167 Monodispersity is important because although coherent, focused MPI images can be produced from broader nanoparticle distributions, the inclusion of smaller diameter nanomaterials in the formulation can decrease resolution and contrast from images by increasing background.167 Interestingly, Langevin theory predicts that, by optimizing nanomaterial design (as well as MPI hardware), nanomolar sensitivity will likely soon be achievable, which is anticipated to drive clinical adoption by making MPI competitive with other imaging modalities such as PET (in terms of approaching the high, near-pM sensitivity of PET) and CT165 (in terms of enabling it to replace CT in certain applications, as discussed in the subsection on in vivo MPI). The MPI discipline is driven in large part by advancements in magnetic nanomaterial chemistries, as well as the quality of the applied magnetic field gradient,167 transmit and detector system electronics, and image reconstruction algorithms. Even though iron oxide nanochemistries have progressed over the past decades, the development of optimized MPI nanomaterials remains in its early stages and has focused chiefly on the effects of nanomaterial size on MPI sensitivity and resolution enhancement. In fact, studies indicate that use of fairly monodisperse 25−27 nm iron oxide nanomaterials can increase the MPI signal by 4−5-fold and the spatial resolution by ∼20% compared with Resovist64,173 (Ferucarbotran), which was previously used as a commercially available and clinically approved iron oxide MR contrast agent for liver imaging. Resovist had been used as it was considered the most accessible iron oxide nanomaterial formulation for MPI,176 yet only ∼3% of the formulation is believed to contribute to the MPI signal.165,172 This is because Resovist falls into a bimodal distribution, one centering around 5 nm and one around 24 nm; the 24 nm fraction likely is responsible for the MPI signal.172\nMPI Applications In Vivo. It is anticipated that MPI will grow rapidly due to its speed, sensitivity, resolution, and lack of natural background. However, because it was so recently invented (ca. 2005164), there are relatively few instances of in vivo imaging as only home-built systems have existed. This is changing rapidly as the first commercial MPI systems are now online. An attractive initial application for MPI is blood pool imaging, with excellent potential for quantitation because MPI signal is linearly dependent on nanoparticle number.180−182 Magnani and colleagues loaded red blood cells with Resovist in order to increase the in vivo circulation time and injected the cells into mice.180,181 The vasculature and the heart were easily visible with minimal background and high temporal resolution using this approach for 24 h after injection (see Figure 5).180\nFor eventual human blood pool imaging applications of MPI using the magnetic nanomaterials available and current MPI hardware, it is estimated that ∼25 mL of blood would need to be nanoparticle-loaded,180 which is already feasible. Another MPI application with high translational potential is the in vivo monitoring of transplanted cells: in a recent study, iron oxideloaded stem cells intravenously injected into mice and rats were dynamically tracked in real time by MPI with CT as an anatomic reference.183 Given that the hardware is not so different from MRI and that MR contrast agents can (albeit nonoptimally) be used, it seems likely that human applications of MPI will emerge fairly rapidly with further optimization of the nanomaterials and shrewd matching of medical needs with MPI advantages. The first clinical use of MPI is likely to be as an alternative to CT for safer angiographic procedures.165 CT angiography employs ionizing radiation, which should be minimized when possible for patient safety. In general, in the clinical diagnostic imaging paradigm, if two different imaging procedures can be ordered, one ionizing and one nonionizing, given similar costs, availability, and medical information gained, then the choice is inevitably the nonionizing modality. In contrast to the radiation of CT, the magnetic field magnitudes used by MPI are below those of MRI and are generally safe. However, it must be noted that, because of MPI’s time-varying magnetic fields, magnetostimulation causing nerve stimulation is a concern and safety parameters to minimize such peripheral nerve stimulation have therefore been set168,184notably, AC magnetic fields of 25 kHz have been proven safe.184 Moreover, CT angiographic procedures use iodinated contrast agents that can be hazardous to certain patients (e.g., those with renal dysfunction), while iron oxide nanomaterials have been proven generally safe.91,98,185 Nevertheless, despite the fact that iron oxide formulations are generally considered safe, as mentioned in the T2-weighted MRI subsection (section 2.3.1.2), it should be noted that some of the first generation formulations that were clinically approved for use in MRI (e.g., Feridex I.V. and Resovist) were discontinued due to insufficient adoption,\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nR\nefficacy, or even safety such as certain rare anaphylactic reactions186reactions that are likely directed toward the coating polymer rather than to the iron oxide material itself.186 Ferumoxytol, a second-generation formulation that was approved for intravenous treatment of iron deficiency, has been used off-label for imaging with MRI and has been proven fairly safe.134,185,187−189\nFuture generations of iron oxide nanomaterials are likely to be split between applications for MPI and MRI. MPI nanomaterials, with highly controlled synthetic conditions to produce nanomaterials with highly characterized, wellcontrolled physical properties, should be expected to be clinically approvable given the history of iron oxides injected into human patients. However, critical to the eventual clinical success of MPI nanomaterials will include (i) selection of applications that display sufficient efficacy (and importance to clinical decision making) over existing diagnostics to drive physicians to use them and (ii) developing particle coatings that further minimize patient side effects such as hypotension, pain, and (already quite rare) anaphylaxis149,150 while simultaneously optimizing MPI signal.70\nMPI is already sufficiently sensitive to use concentrations of clinically approved iron oxide nanomaterials to image at very high temporal resolutions21.5 ms per 3D volume of >4 cm3. This is rapid enough to visualize a beating mouse heart,182 with the potential for much improved resolutions and sensitivity as enhancements to specifically engineered nanomaterials are used to optimize MPI signal. No other technique is capable of such real-time 3D imaging throughout the human bodyfor example, it could image the beating human heart in real time when using optimized contrast.101,176,190 Because of the temporal resolution and contrast, MPI is beginning to be looked upon as the heir-apparent to transform imaging of blood circulation phenomena, such as heart disease, thrombosis, and coronary artery disease. Aside from circulation applications, one could also track and localize the sites of iron-loaded cells (e.g., stem cells) or potentially localize cancer cells when applying MPI-guided sentinel lymph node biopsy.190 It is nevertheless important to point out that MPI is not conceived as a replacement for MRI and other imaging modalities but as a complement. Because MPI is primarily a functional imaging modality that provides no anatomical information, it is very likely that, when MPI is adopted clinically, it will be used in a dual-modality settinglikely in combination with MRI,191 CT, and/or another anatomical imaging modalityto provide complementary information without the need to move the patient.192\nFurther advancing the drive to use MPI in the clinic is its potential to eventually multiplex with multiple colors, the possibility of which is not immediately obvious193,194 and which may make it a more viable alternative to modalities such as PET for certain applications. Multiplexing can be achieved based upon the use of different particle types with different magnetizations; the differences in amplitude (i.e., changes in signal amplitude that occur as a result of differential Brownian relaxation behavior at different excitation amplitudes) and phase distributions over the detected frequency components during the same scanning sessions can be used to reconstruct images with multiple colors (comprising multiple nanomaterials, each with a distinct magnetization).194\n2.3.3. Magneto-motive Imaging. Magneto-motive agents are typically superparamagnetic nanomaterials with high magnetic susceptibility that can be spatially shifted within a\nsample by a time-varying, external high magnetic field gradient. Imaging is performed by instrumentation that is used to detect these minute positional shifts. Dynamic, phase-sensitive quantification and visualization (as contrast) of these movements can be achieved by a number of different imaging modalities, including optical coherence tomography (OCT), ultrasound, and photoacoustic imaging (PAI). Because the magnetic stimulation mechanism is constant across the various magneto-motive modalities, the nanomaterial itself need not changethe same contrast nanomaterial is usable for any of MMOCT, MMPA, and MMUS. The difference lies in how the nanomaterial movements are transduced and interpreted into images. Prudent selection of the proper modality for a particular in vivo imaging application is in part a function of the trade-offs between the depth of penetration and the spatial resolution requiredMMOCT enables high resolution but only up to a couple mm tissue penetration, while MMUS allows very deep imaging similar to ultrasound but with deteriorated resolution (although improved compared to pure ultrasound scanners195). MMPA is restricted by PAI depth and resolution limitations, as it obtains signal from both magneto-motive forces and PAI, placing it midway between MMOCT and MMUS in both parameters. Moreover, similar to how MPI is often paired with MRI in a dual-modality functional/anatomic imaging paradigm, magneto-motive imaging is typically paired with its cognate modality, e.g., MMUS and MMPA with ultrasound and MMOCT with OCT. We provide a brief overview of the magnetic nanomaterials that are used in magneto-motive approaches and how the nanomaterial movements are sensed, and offer examples of state-of-the-art in vivo imaging applications. Note that we separately describe MMOCT in the OCT section (section 2.4.4) in the context of other hybrid OCT-based technologies (e.g., photothermal OCT). High magnetic susceptibility nanomaterials are used for magneto-motive approaches and can be single nanoparticles or, in some cases, may be a sort of tiny “bag” containing many nanoparticles (e.g., a particle of 100s to 1000s of nm containing smaller single-domain nanomaterials) including those of different types. The advantages of the single, dual-modality nanomaterial, which is more common, include a smaller size for better systemic targeting and a more elegant solution to the problemyet they often require novel nanochemistries. On the other hand, larger particles can allow one to simply take advantage of having prefabricated two different nanomaterials, each of which already has the desired properties (e.g., gold and iron oxide) that do not interfere with one another, and packaging them within the same particle for simultaneous injection. Adaptable nanomaterials (see section 2.7) such as liposomes are effective agents for such tasks, particularly for encapsulation of multiple nanomaterial types that can enable magneto-motive or multimodal imaging.196\nIn magneto-motive approaches, actuation of the nanomaterials in the tissue is caused by the gradient force, which spawns local perturbations in the surrounding cells and tissues. Depending on the size of the nanomaterial as well as the magnetic field size and frequency, the displacement of the nanomaterials in the tissues is on the order of 10s to 100s of nm.103 Magneto-motive contrast can be achieved via transverse or axial particle displacement or via rotation of an anisotropic particle.197 The motions of the microenvironment are transduced into images by a mechanism dependent on the modality chosen, whether by varying the light path distance to\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nS\nmodulate the phase of light and thus the tissue-scattering properties (MMOCT), by frequency shifts sampled by Doppler, M-mode, or correlative ultrasound (MMUS), or by applying motion filters to dynamically imaged PAI regions (MMPA). Magneto-motive Ultrasound. In MMUS, the key is that, as\nthe nanomaterials are displaced, they cause the tissue to vibrate along with them.198 These vibrations can be measured by ultrasound. In particular, biological tissues generally remain mute when exposed to an external magnetic field, while the relatively large magnetic susceptibility displayed by magnetic nanomaterials enables them to respond readily to applied fields. Because they are within tissues, the spatial shift experienced by the magnetic nanomaterials produces a tissue resistance force in the opposite direction. The combination of the magnetic and resistance forces generates ultrasonically detectable vibrations.91\nWhile the algorithms for image reconstruction vary, the basis for one MMUS algorithm to specifically detect nanomaterial motion was to match the frequency of induced magnetic nanomaterial displacement by phase gating for ultrasonic detection at the same frequency.103 That way, noise from possible tissue motions (e.g., from breathing, heart beat, or building vibrations, etc.) at other frequencies could be filtered out, and the specific magneto-motive contrast can be superimposed upon standard B-mode ultrasound images. This approach was demonstrated in a sentinel lymph node rat model. Iron oxide nanomaterials (11 nm diameter Fe3O4 cores) were injected into the hind paws of the rats, allowing them to collect in the popliteal lymph nodes. MMUS coupled with the phase-gating algorithm was performed 24 h postinjection. With a magnetic saturation of ∼80 emu/g Fe3O4, the nanomaterials were detectable in the sentinel lymph node with minimal background signal, allowing easy identification of the sentinel\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nT\nlymph node.103 As a cheaper, portable imaging modality, this approach for identifying the sentinel lymph node during intraoperative procedures improves upon other strategies, such as lymphoscintigraphy (the gold standard), which requires use of radioactive materials and also does not provide anatomic reference as the MMUS/ultrasound dual-modal combination does.103 Improved chemistries are now sought to improve the saturation magnetizations of the nanomaterials so that imaging parameters can be improved. In one case, Zn-doping of iron oxide nanomaterials more than doubled the saturation magnetization to 161 emu/g of nanomaterial.93 Such developments could (i) enable imaging at deeper levels of penetration due to increased contrast and sensitivity and/or (ii) halve (or better) the amount of nanomaterial one must inject to attain the same effect, which is generally desirable for in vivo imaging applications. Superparamagnetic Zn0.4Fe2.6O4 nanomaterials (fairly monodisperse at 21.5 nm diameter) were generated in a one-pot thermal decomposition of zinc(II) chloride and iron(III) acetylacetonate in oleic acid, oleyamine, and octyl ester (see Figure 6a−i).93 These hydrophobic nanoparticles were surface-coated and dispersed in aqueous solutions by displacing organic ligands with tetramethylammonium hydroxide and finally coated with carboxymethyl dextran for improved\nbiocompatibility. These nanomaterials were intratumorally injected into mice bearing a human xenograft carcinoma on the flank. The superior magnetic properties allowed extremely clean MMUS imaging of the tumor (see Figure 6d−i), and recent reports suggest that ultrasound sensitivity can also be improved by magnetic nanoparticles.91 Thus, MMUS is highly encouraging for the real-time visualization of cellular and molecular-scale events. However, it is also clear that efficient, systemic tumor targeting of these nanomaterials will need to be resolved for clinical cancer-imaging applications. Traditional tumor-targeting approaches such as EPR (section 1.1) are not likely to be broadly capable of such efficient targeting, although the improvement required depends on the specific application. This is an important general problem in the field that may eventually be solved through novel solutions such as immune cell Trojan Horse approaches199 (sections 2.4 and 2.4.1.4), vascular zip code and transendothelial pumping mechanisms,200 or to-be-developed techniques. Magneto-motive Photoacoustics. MMPA nanomaterials must intrinsically be multimodal agents as they must be optically absorptive (see section 2.4.5) and magnetically sensitive. The key advantage of MMPA compared with PAI alone is that MMPA imaging yields the same sensitivity while\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nU\nconsiderably enhancing the contrast specificity.201 In fact, elimination of extraneous signal is so effective that PAI signal not generated by the magneto-optical nanomaterials could theoretically be filtered down to the level of the imaging system’s electronic noisethis is a major enhancement because PAI contrast can be affected by a variety of endogenous absorbers in tissues, leading to SNR (signal-to-noise ratio) boosts by MMPA of over an order of magnitude.201 However, just as in PAI, a limitation is that one must impedance match the body to the ultrasonic transducer, which can be done with water or a gel (see Figure 7a−f).202 Several studies have exploited the benefits of MMPA in murine xenograft tumor models.196,202 These in vivo studies establish the ability to completely suppress MMPA signal outside tumor tissues (see Figure 8) through use of motion. However, the developed\nnanomaterials were considerably different: Qu et al. developed liposomal particles (∼200 nm) containing citrate-capped Fe3O4 nanoparticles (∼7.5 nm cores) for magneto-motive force and gold nanorods (∼9 nm × ∼30 nm) for PAI signal.196 On the other hand, Li et al. developed single magneto-optical core− shell nanomaterials by locally copolymerizing a polypyrrole shell on the surface of iron oxide nanomaterials.202 Iron oxide precursors were acid-etched to generate an Fe2+/Fe3+ surface, after which a polypyrrole shell was formed using a mix of pyrrole and pyrrole-3-COOH in the presence of the oxidant (NH4)2S2O8 to encourage polymerization, and subsequently PEGylated (see Figure 7g, h). These 51.5 nm diameter dual-\nmodality near-infrared absorbing, magneto-motive nanomaterials displayed high magneto-motive interactions and PAI signal, making them effective MMPA agents (Figure 7). Notably, however, rather than systemic injection, both studies directly injected nanomaterials into the region of interest, whether directly into the tumor196 or attached to tumor cells and injected into the animal202 prior to imaging. Fe3O4 (0.33 mg) was injected directly into the tumor to produce the signal,196 which is several times larger than that necessary for intratumoral injection in MRI,203 suggesting that excessive amounts of iron are required using current technology. However, while MRI cannot quantitatively assess iron oxide nanomaterial content, magneto-motive contrast mechanisms have the potential to be quantitative.103 Thus, while MMPA is highly promising, novel nanomaterial chemistries to increase magnetic saturation will enhance it further, and it will be critical in future studies to demonstrate that systemically injected, highmagnetization nanomaterials can efficiently target disease sites such that sufficient localized signal is produced.\n2.3.4. Electrical Impedance Imaging. The foundation for electrical impedance imaging arises from the fact that electrical parameters of diseased tissues such as tumors are significantly different from normal tissues.204 While these differences can provide rich functional information about tissues that are already used clinically,205,206 they can be meaningfully enhanced using nanomaterial contrast. Instead of exploiting the magnetic behavior of nanomaterials as in the rest of this section, this approach now harvests another related region of the electromagnetic spectrumthe electrical phenomena including conductivity and permittivity associated with conductive nanomaterials such as titania and gold. To image a mouse tumor with electrical impedance, electrodes pierce the outer dermal layers and an AC current is driven across the tissue. In vivo impedance imaging with nanomaterial contrast has only recently been demonstrated and is thus far limited in data. Injected directly into the mouse tumor and measured 30 s p.i., titania nanomaterial sensitizers significantly widened the impedance difference between normal and tumor tissues.204 By increasing the conductivity of the bulk tissue, titania nanoparticles measurably reduced the impedance at 10 kHz to an ∼7.5-fold difference between normal and tumor tissues.204 These very preliminary in vivo measurements advance the idea that nanomaterials could play a major role in future electrical impedance tomography applications as the field’s hardware and reconstruction algorithms improve. However, while it has promise, the impedance approach will need to tackle issues such as operator-dependence, the heterogeneity of normal tissue impedances within and across individuals, and the high concentration of nanomaterials required (400 μg of titania were injected intratumorally204) to become an effective imaging technique. Notably, other adaptations of electrical impedance tomography exist that employ alternative mechanisms of measuring the tissue conductivity and permittivity. These include magnetic resonance electrical impedance tomography (MREIT, which injects currents into the body and measures differential tissue response by evaluating magnetic flux density using MRI).207 While these alternative electrical impedance modalities have not yet been paired with nanomaterial contrast to our knowledge, nanomaterials are likely to eventually play a role in modulating impedance for these emerging modalities as well.\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nV"
    }, {
      "heading" : "2.4. Optical Nanomaterials",
      "text" : "Compared to magnetic and nuclear imaging, optical imaging is typically much more rapid, high-throughput, and inexpensive. While whole animal optical imaging approaches display spatial resolutions and detection limits similar to MRI or slightly inferior,208 optical microscopy approaches can achieve astounding spatial resolutions, the highest attainable in all of in vivo imaging down to a few 10s of nm.209,210 In comparison, with the aid of contrast, the best other modalities such as ultrasound, photoacoustic imaging, and CT have achieved is on the order of several μm. Thereforeeven though the field-of-view is restrictedto observe single-molecule processes or detailed features of physiologic structures such as dendritic spines in living subjects, optical super-resolution microscopy is currently the only choice. Because optical microscopy including superresolution approaches are the only options available to observe phenomena on the same scale as nanomaterials, optical strategies are actively being exploited to image and understand the behavior of nanomaterials of all varieties in living subjects.15,22,24,26,27,199,211,212 For example, the resolution of optical microscopy allowed unprecedented observations on nanoparticle interactions with immune cells in the blood vessels of live animals.199 The discovery opens up new avenues in immune cell targeting by nanomaterials and presents possibilities to, for instance, control trafficking and immune cell fates for immunoimaging purposes. Microscopic optical techniques were also applied to directly observe how variation in the size26,82,213 and shape15,28 of nanomaterials impacts their ability to target disease. These effects can be observed in nanomaterial transport properties within blood vessels, as well as in their differential diffusion and convection from the vasculature into disease sites. In an interesting contrast, while microscopic optical techniques are often very time-consuming particularly for super-resolution (on the order of 1 mouse every several hours in order to image fairly small total volumes relative to mouse size across all data acquired in an imaging session), macroscopic whole-animal optical imaging (e.g., fluorescence or bioluminescence imaging) allows imaging of 10−20 or more mice per hour. Macroscale and microscale optical strategies each have their trade-offs, encapsulated by a commercially available instrument that has been constructed that can perform macroscopic imaging but can also zoom in to do microscopic imaging (i.e., the fluorescence Olympus instrument, OV100).214\nOptical imaging is the most intuitive imaging modality: optical approaches generally allow us to detect photons with familiar parallels to our eyesight. Optical approaches allow spatial and temporal resolutions unachievable otherwise. However, while photons are detected in both, sophisticated technology has enabled us to observe optical phenomena far beyond the power of human sight: from (i) increasing spatial resolution several orders of magnitude (from μm down to nm using super-resolution technologies) and (ii) increasing photon sensitivity to (iii) using special properties of light to extend penetration depths of photon detection down to cm (e.g., optical coherence tomography), (iv) discriminating and observing extremely rare but highly specific events (e.g., inelastically scattered photons in Raman imaging), and (v) extending detection of photons to an extremely broad range of wavelengths compared to the very narrow band to which human vision is sensitive. These advances have brought physicians from simple superficial visual inspection of external (e.g., skin) surfaces all the way to the ability to sensitively probe\nfor molecular abnormalities deep below the surface. Alongside the technological improvements in optical imaging hardware that are allowing us to exploit our improved physical understanding of optical phenomena, newly engineered nanomaterials are being developed to manipulate and greatly amplify these optical signals. Many of these nanomaterials offer improvements in sensitivity and, as the chemistries improve, allow increasingly tiny amounts of material to be injected to achieve the same imaging results. For example, the plasmonic effects of surface-enhanced Raman spectroscopy (SERS) can be exploited by encapsulating Raman dyes close to the surface of certain metallic nanomaterials, which can improve detection sensitivity by 6−10 orders of magnitude compared to Raman dyes alone.215\nA diversity of in vivo optical imaging techniques has been developed in the last few decades. A key to imaging living subjects using optics is to maximize penetration depth (which comes at the price of decreasing spatial resolution) and minimize background signal while retaining resolution and signal intensity. As we will describe, this can be accomplished using a variety of very clever strategies that include varying the light’s wavelength, coherence, polarization, exploiting some of its rarer scattering properties, and more. One of the key limitations throughout optical approaches, particularly for larger animals (including humans), is the limited penetration depth. However, by applying new sophisticated optical approaches (e.g., optical coherence tomography and photoacoustics) whose properties are enhanced further by nanomaterial contrast (e.g., gold nanorods) and shrewdly choosing the appropriate mechanism to excite/collect signal (e.g., endoscopes for internal structures near luminal sites), imaging scientists and chemists are developing an incredible array of strategies to interrogate the molecular properties of tissues all over the body that is likely to revolutionize preclinical and especially clinical diagnostic imaging.\n2.4.1. Luminescence. Luminescent materials have broad applications, including optical devices such as photovoltaics, security (e.g., anticounterfeiting), lighting, lasers, diagnostic sensing, color display, and, recently, in vivo imaging approaches. Luminescence is an umbrella term for entities that emit light upon energetic excitation without heating. It includes photoluminescence (such as fluorescence), bioluminescence, chemiluminescence, phosphorescence, mechanoluminescence, etc.\n2.4.1.1. Fluorescent Nanomaterials. Quantum dots (qdots) have been perhaps the foremost nanomaterial in fluorescent nanomaterial imaging since their introduction into small animals for fluorescence imaging over a decade ago.216,217 Many reviews have covered the chemistry of qdots218,219 especially due to their varied applications in visual displays220 as well as biosensing and in vitro assays,221 so we focus on the key qdot features for animal imaging. Broadly, although qdots have conventionally been semiconductors in composition, the “quantum dot” moniker is applicable to any nanoscale object in which the excitons are confined in all three spatial dimensions, i.e., there is a quantum size effect.222 Qdot nanocrystals have fascinated the field of (preclinical) nanomedicine due to their ability to target disease with a high extinction coefficient, quantum yield, intensity of emission, and photostability, as well as their broad absorption/excellent emission characteristics and potential for multiplexing. Qdots also have the unique feature that, for any particular material structure, their precise size dictates their photon emission\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nW\nwavelength. This intriguing physicochemical characteristic has been exploited in the case of CdSe core/ZnS shell qdots injected into mice to establish the renal filtration cutoff.86,223 This cutoff is a key parameter for in vivo imaging, because if one designs a nanomaterial for systemic injection, there must be a mechanism of clearance whether degradation, uptake into other organs, etc. Kidney uptake indicates that clearance/ excretion likely occurs through urine, minimizing the body’s exposure to the nanomaterial. Precisely engineered qdots were constructed of 5 different diameters from 4.4 to 8.7 nm. In this case, qdots were used as a model nanoparticle with an extremely tight size distribution to interrogate this cutoff, so when only qdots 5.5 nm and less were found to be filtered by the kidneys, the finding had implications not only for qdots but for all of nanomedicinein particular, with respect to design considerations for nanomaterial biodistribution.86,223\nKey issues in fluorescence imaging include autofluorescence, quenching/photobleaching, and depth of penetration. qdots are highly photostable and help resolve photobleaching issues, while red-shifted near-infrared emitting qdots substantially improve penetration issues at least for small-animal imaging.219 However, autofluorescence and especially penetration depth help prevent fluorescence from being more useful in human imaging, except in certain very specific applications such as fluorescence-guided surgery224,225 and endoscopy.226,227 However, when considering clinical applications, one must carefully consider the nanomaterial composition. While qdots have traditionally been inorganic semiconductor nanocrystals, material toxicity worries have led to novel syntheses of more biocompatible structures, including silver and even carbonbased qdots.228−230 Recent iterations of these biocompatible qdots do not require conceding major losses in key parameters\nsuch as photonic efficiency and intensity.228,230 Biocompatible peptide-coated (RGD) silver qdots directed to cancer provided excellent signal, displaying an outstanding 9:1 tumor-to-muscle ratio228 compared to, for example, a ∼5.5:1 ratio for the (radiolabeled) peptide alone.231 This is a striking example of the fact that, after much tuning and optimization, including surface engineering for minimization of opsonization, nanomaterials can exhibit comparable and often even better uptake than small molecule and peptide/protein-based agents. This is in stark contrast to older studies suggesting that nanomaterials typically displayed considerably worse targeting ratios than small-molecule agents. The silver qdots were highly engineered, from the light-emitting core to the coating: the size of silver sulfide (Ag2S) qdots was easily tuned simply by modulating the reaction time and solvents. This allowed construction of qdots with a 1.1 eV bulk bandgap (compared with a 1.74 eV bandgap for the most common inorganic qdots, CdSe). Due to quantum confinement effects, they were tunable to emit between 500 and 1200 nm; two different reaction conditions were necessary depending on the emission wavelength: for 840−1200 nm emissions, organic, viscous reaction conditions were necessary to synthesize the qdots from silver diethyldithiocarbamate, while aqueous conditions were applied otherwise with silver nitrate.228 The near-infrared-shifted qdots were slightly larger and required a thin silica coating to solubilize them in aqueous solutions, make them biocompatible, and provide a surface by which to conjugate the targeting peptide RGD. After tail-vein injection of these qdots into tumor-bearing mice, the tumor signal clearly outlined the tumors with very strong signal at 24 h postinjection (p.i.) with minimal background signal elsewhere (see Figure 9). Intriguingly, Ag2S qdots are one of the few nanomaterials that have been imaged in the second near-\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nX\ninfrared window (∼1100−1400 nm) in vivo (semiconductor qdots and carbon nanotubes, for instance, also have been imaged in this optical range232,233), which requires use of special cameras but is worthwhile due to tissue penetrations much deeper than possible even with conventional nearinfrared fluorophores.234 By systemically injecting these Ag2S probes, deep imaging of tumors in living mice was feasible,234 potentially penetrating nearly 5 cm of tissue.232\n2.4.1.2. Carbon Nanomaterials. Carbon qdots, in contrast to Ag2S and semiconductor qdots, lack a classical bandgap structure. They can be constructed, however, to achieve semiconductor bandgap-like fluorescence via surface passivation-created defects.235 The trapping of excited-state energy likely occurs between the defects responsible for absorption and defects responsible for emission, as opposed to the classical paradigm of trapping between the excitonic state and the emissive state.236 Thus, the function of surface passivation in\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nY\nfluorescence is that it likely stabilizes surface sites, supporting more effective radiative recombinations.235 Because of the dependence of wavelength and quantum yield on surface passivation, as our understanding of passivation chemistry has grown, so too have the efficiency (quantum yields up to 60− 78%) and emissive wavelength tunability of carbon qdots and therefore our use of them for in vivo imaging.236 This has led to carbon qdots emitting throughout the visible and near-infrared regions and displaying a strong two-photon cross section that can be orders of magnitude larger than organic dyes.235 Surface passivation such as ZnS doping has increased the quantum yield of carbon qdots by ∼50%, making them a strong competitor to commercial semiconductor CdSe/ZnS qdots in terms of their photon efficiency and imaging utility.237 Ko et al. worked out a chemical treatment to transform tire soot into near-infrared emitting carbon qdots that could efficiently target and fluorescently image a xenograft tumor in mice.238 Soot collected from tires was refluxed for 12 h of a thermal oxidation treatment in 5 M nitric acid, yielding a majority sp2 (graphitic) carbon (based on X-ray photoelectron spectroscopy\n(XPS)) as ∼8−15 nm carbon qdots after a purification procedure consisting of centrifugation and dialysis. These qdots emit in a broad spectrum up to 800 nm. It is not clear if the photonic emission in this case could be due to surface passivation, but the authors speculate that it might arise from photoemissive bandgaps in the sp2 carbon core.238 Carbon qdots are exciting as they are effective imaging agents while displaying little to no toxicity as organic nanomaterials, are environmentally friendly, lower cost, and follow simpler syntheses in general.230 Furthermore, carbon qdots do not blink, are comparable in size to conventional qdots, and can be even >2-fold brighter than classical CdSe/ZnS qdots.236\nMany other carbon-based nanomaterials also exhibit exceptional optical properties, particularly for imaging in the nearinfrared region, allowing optimal tissue penetration. These include single-walled carbon nanotubes (SWNTs), graphene, and nanodiamonds. As much or perhaps even more than silver nanoparticles and conventional qdots, SWNTs have shown extremely high potential for in vivo imaging in the second nearinfrared window. Their emission is due to their unique\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nZ\nstructure, made up of a single sheet of graphite (i.e., graphene) rolled up into a quasi-one-dimensional cylinder.239 Because sidewall defects in the SWNT reduce the radiative lifetime of an exciton and decrease their quantum efficiency, it is important to prepare SWNTs for imaging in the second near-infrared window carefully, e.g., via sonication with sodium cholate and subsequent surfactant exchange, rather than directly by sonicating with phospholipid-PEG (which tends to induce defects).240 SWNTs, and their multiwalled cousins, display two key features that make their use in optical imaging important: high fluorescence yield and excitation/emission properties in the second windowwhich is nearly biologically transparent and allow astounding imaging depths for an optical technique at high spatial resolution. Using intravenously injected SWNTs, Dai and co-workers stunningly illuminated the internal organs of live mice including deep tissues and color-coded them using principal component analysis (Figure 10a).241 Using the same technology, the Dai group was able to produce high-resolution fluorescence images (sub-10 μm) of SWNTs flowing through brain microcapillaries across the skulls of living mice nearly 3 mm deep (see Figure 10b−j). Importantly, this novel imaging technique using SWNT contrast was able to reveal strokerelated vascular abnormalities without even cutting the mouse’s skin, much less the skull.233 The second near-infrared window thus portends many possibilities for preclinical imaging and analysis of mouse models of brain disease without the need for surgery using simple optical imaging approaches. While it is unlikely that such approaches are translatable to human head applications, because the human skull is considerably thicker, deeper optical penetration depths enabled by imaging of nanomaterial contrast in the second window could be extremely helpful for clinical endoscopic, dermal, and surgical guidance applications. Like SWNTs, graphene has enthralled a number of scientific communities, including those in mechanics, optics, and chemistry; the excitement has now extended into in vivo imaging and medicine.242 For instance, upon i.v. injection graphene shows extraordinarily high uptake into tumors in mouse models.243,244 A single planar layer of graphite, graphene is sometimes converted to graphene oxide when used in practice.222 This has ramifications on its optical properties, in particular on the energy of the photons graphene qdots emit. Furthermore, the oxidation state of graphene likely has implications on its toxicity in vivo, as one study showed essentially no toxicity for graphene qdots injected into mice, yet graphene oxide does display high toxicity apparently as a result of aggregation.245 It is likely, however, that improved surface passivation or reduced oxidation of graphene oxide would minimize these observed toxic effects.246 Graphene’s excitons have an infinite Bohr diameter, meaning that, unlike most qdots, graphene-based qdots of any size will display quantum confinement and a nonzero bandgap222 (although most graphene qdots in practice tend to be in the 1−20 nm range). This is the source of fluorescence excitation/emission in graphene qdots. Indeed, the synthetic route of graphene production, including the starting materials and the method of fabrication (whether hydrothermal, electrochemical, acidic oxidation, and so forth), is responsible for the size, functional groups, and defects found on grapheme.247 These parameters, particularly graphene size and surface chemistry, modulate its bandgap, which in turn directly regulates the fluorescence properties (e.g., emissive wavelength).247 Several examples of chemical modifications to graphene are displayed in Table 2.\nHowever, although relatively little is known about the electronic properties of graphene qdots, fluorescence quantum yields of >30% have been observed.8 In the context of in vivo imaging, these graphene qdots are typically passivated with PEG and even glutathione, which significantly increases the fluorescence quantum yield.8,222 Even newer in vivo imaging applications likely await graphene qdots as they appear to be one of the only materials other than lanthanides that also can be used in upconversion in vivo imaging strategies (see below).222 Although the upconversion mechanism is not yet fully known, one possibility is that electrons in the π-orbital are excited, transition to the lowest unoccupied molecular orbital, then relax back to a lower energy statethe decreased wavelength photoluminescence emission would thus occur when the electrons relax to the σ-orbital.248\nDespite their common carbon makeup, nanodiamonds are rather distinct from carbon and graphene qdots in their electronic and crystal structure,250 although similar in their low cytotoxicity.251 A distinctive characteristic in the chemical structure of these sp3-hybridized nanodiamonds differentiates them from their carbon-based cousins and fortunately allows extrinsic modulation of their optical properties. The nitrogen vacancy center (NVC), a type of point defect in which a substituted nitrogen and lattice vacancy form a nearestneighbor pair,252−254 is a key route by which nanodiamond fluorescence arises. The NVC electron spins can be externally modulated by various forms of radiation (e.g., magnetic, electric, microwave, or optical). For example, NVCs have a spin ground state of S = 1, which makes it useful as it can be spin-polarized via optical pumping and regulated by electron paramagnetic resonance.251 Shirakawa and colleagues exploited the fact that 2.87 GHz microwaves modulate the fluorescence intensity of NVCs/nanodiamonds but not fluorescence from other sources (e.g., autofluorescence), thereby minimizing autofluorescence via their selective imaging protocol.253 Suppression of background autofluorescence is a highly sought property throughout imaging in order to increase signal-tonoise ratios (SNRs), and this approach is an elegant demonstration of such suppression,253 as is the use of the fact that nanodiamonds have fluorescence lifetimes at least 3- fold longer than autofluorescent materials.252,255 This allows one to easily separate the signals by time-gating. In a recent study of NVC-containing nanodiamonds injected into the footpads of mice to image lymph nodes, magnetic modulation of the NVCs gave rise to SNRs that were enhanced up to 100- fold by removing the background.254 In addition to the excellent SNR, NVC-containing nanodiamonds display indefinite photostability and excitation/emission spectra extending from the visible to the near-infrared,254 both key features for dynamic imaging intended for eventual clinical use. It should be noted that the origin of some nanodiamond fluorescence remains a point of contention in the literature and is likely multifaceted. Aside from NVC-related mechanisms, observations suggest that fluorescence also arises from particular functional groups (e.g., hydroxyl as well as ketone and ester CO groups) that can be modulated on the surface to engineer desired fluorescence, and potentially also from silicon vacancy defects acting as “color centers” that are sufficiently thermodynamically stable (even in nanodiamonds as small as 1 nm) to display quantum confinement and to fluoresce.250,256 With relatively few in vivo imaging studies of nanodiamonds to date, there is clearly much to build on for this apparently highly biocompatible optical platform.\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAA\n2.4.1.3. Upconversion and Persistent Luminescent Nanomaterials. Upconversion nanomaterials transduce two or more lower-energy photons into a higher-energy photon. The lowerenergy (higher-wavelength) photons are absorbed by a (typically) rare-earth ion that nonradiatively transfers the energy to an emitter ion within the same lattice, which then emits a higher-energy (blue-shifted) photon. The absorptive rare-earth ions and emitter ions are doped into a nanoscale crystal lattice during synthesis, typically a thermal decomposition of their corresponding salts.257 For in vivo imaging, upconversion nanomaterials typically have the Yb3+ ion as the lanthanide donor, while Er3+ is the typical acceptor ion (which generates upconverted visible green or red wavelengths when excited at 980 nm). Although broadly similar to multiphoton imaging (described in section 2.4.1.4), the physical principle underlying upconversion differs, and the stimulating photon intensity required to generate upconverted photons is orders of magnitude lower than two-photon imaging (<0.1−1000 W/cm2 versus 106−109 W/cm2, respectively258,259). Another key advantage of this low-to-high energy photonic conversion effect is that autofluorescence, the bane of imagers using traditional fluorescent approaches,260−262 is decreased to nearly nothing. Recent interest in upconversion nanomaterials has been spurred by the fact that they are much less toxic than traditional qdots, decrease photodamage to tissues, display minimal autofluorescence, have a long fluorescence lifetime, are less costly to synthesize, show highly efficient excitation in the\ntissue-penetrative near-infrared region, and their fluorescent output is up to 7 orders of magnitude higher than that of qdots.260 Due to the low background, individual cells can easily be visualized as deeply as 1.3 mm263 and more macroscopic imaging can go as far as nearly 2 cm deep depending on the precise material and stimulation photon intensity.257,264 This is because of (i) their ability to efficiently absorb near-infrared stimulation light deep in tissues, (ii) minimization of autofluorescence due to the anti-Stokes nature of upconversion and thus essentially no autofluorescence (for instance, although hair is intensely autofluorescent and absorptive, in upconversion strategies the autofluorescence is so low that it is typically unnecessary even to shave imaged mice prior to imaging265), and (iii) their capabilities to be used as antennae to convert near-infrared light into an activation signal for photosensitive tissue nanosensors such as hypoxia sensors266 or for photosensitive therapeutics.267 Just as with the other fluorescent nanomaterials covered, upconversion nanomaterials have been exploited in cancer imaging.268−270 Intravenously injected nanomaterials have been targeted to tumor via either RGD or the high-affinity neurotoxin, chlorotoxin (which can bind cancer cells via interaction with matrix metalloprotease 2 (MMP-2) endopeptidase) (see Figure 11).268,269 The striking feature in Figure 11 is that the signal in the mouse body is essentially completely derived only from upconversion nanomaterials emissions, with no autofluorescence. Upconversion nanomaterials are typically ∼20−40 nm in hydrodynamic\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAB\ndiameter271 and thus relatively likely to passively target tumors via the EPR effect prior to binding.15,19 Once targeted and unbound nanoparticles are cleared, the tumors are clearly delineated via fluorescence imaging (Figure 11). In a side-byside competition performed to understand the advantages of upconversion nanomaterials compared with conventional semiconductor qdots, the upconversion strategy was over an order of magnitude more sensitive than 545 and 625 nm emitting qdots.272 Notably, the qdot sensitivity could likely be improved by use of near-infrared emitting qdots, but perhaps not enough to make a substantial difference. On the other hand, one of the issues with upconversion nanomaterialsthe fact that they typically emit in the visible range, which leads to problems in detecting emitted photons from deep in absorptive tissueshas been rectified by the generation of upconversion nanomaterials that can now absorb at 980 nm and also emit in the near-infrared (831 nm), further increasing their depth of penetration for in vivo imaging. Chemists have spent years engineering upconversion-based nanosensors, integrating them into powerful, unified systems. For instance, an upconversion core/hollow mesoporous silica shell nanomaterial with a ruthenium-based oxygen indicator molecule (tris(4,7-diphenyl-1,10-phenanthroline) ruthenium(II) dichloride) for in vivo imaging266 was just developed. The system permits highly sensitive real-time dissolved oxygen sensing and is reversible, meaning the same probe can continually read out different measures of oxygen dynamically. The probe detected cerebral anoxia in zebrafish when cardiac contractions were chemically ceased temporarily and showed restoration when contractions continued. Hypoxia measurements, particularly in relatively deep tissues where upconversion nanomaterials excel, have great potential in cancer imaging and therapy. Hypoxia plays a critical role in inducing cancer cell quiescence, which factors into many of the features of cancer that drive morbidity and mortality such as recurrent tumors and metastasis.273,274 Upconversion technology could thus be useful, for example, for radiotherapy in which radiation oncologists can direct therapy with very high precision. If they can localize regions of hypoxia using imaging, this could allow them to adjust the dose with high spatial accuracy to regions that most require it (i.e., dose painting275−277) or modulate the cellular biochemistry.278 Indeed, localizing regions of hypoxia has become a highly researched, major subdiscipline within cancer imaging.262,279 One key point, however, is that hypoxic regions also happen to be the very sites to which it is extraordinarily difficult to deliver even small molecules (e.g., drugs) and nanomaterials due to physical biobarriers such as oxygen and nutrient diffusion gradient barriers and cell-packing density.280,281 Thus, the delivery issue remains to be solved in order to practically apply some of these nanomaterial-based solutions in such cancer applications. In another type of luminescence, that emitted by persistent nanophosphors, the materials have the ability to store energy and gradually release it. Unlike upconversion, persistent luminescence requires no input energy during in vivo imaging so that the emission is steady for minutes, hours, or even days. This results in an absence of autofluorescence similar to upconversion nanomaterials so that the background is zero. This also means that, after it has been initially excited, the signal typically only has to travel in one directionfrom inside the body to an external detector. From the perspective of optical methods, in which tissues absorb and scatter photons near the visible region greatly, this can lead to improved depth of\npenetration as in bioluminescence imaging (persistent luminescence is often captured in the bioluminescence mode of instrumentation) compared with signal in/signal out approaches. However, as in essentially all optical methods, greater depths lead to degraded spatial resolution. Microemulsion and solvothermal/hydrothermal synthesis routes are often employed to generate these nanoparticles, with fairly high control over the size and shape of the product.282,283 These nanomaterials can be excited by a range of wavelengths across the electromagnetic spectrum, including X-ray, ultraviolet, visible, and near-infrared.282 Moreover, their excitation is renewable (i.e., can be re-excited whether in situ or in vivo), making longer term experiments achievable.282−284 The advantage of no autofluorescence can lead to very high SNR. Wu et al., for example, embedded persistent nanophosphors into stem cells for tracking using TAT peptides attached to the particles.282 The group’s hydrothermally grown and sintered Zn1.1Ga1.8Ge0.1O4:Cr\n3+,Eu3+ nanomaterials (∼37 nm diameter) were excited by a UV lamp for 5 min prior to in vivo injection of the nanomaterial-loaded stem cells. The persistent luminescence emitted by these nanomaterials at 694 nm is almost exclusively due to the 2E → 4A2 transition of distorted Cr3+ ions in gallogermanate.282 Luminescence could be boosted by in vivo exposure to red LED light for 1 min prior to luminescence imaging. All the photons could be collected, i.e., no filters were necessary when counting emissions because of the lack of autofluorescence and lack of multiplexing. The nanophosphor-loaded stem cells were tracked under several in vivo conditions: injected subcutaneously into the backs of mice; in a wound-healing mouse model; and in a murine tumor model because mesenchymal stem cells can target tumors. Large SNRs as high as 172.8 were observed when nanoparticles alone were injected; nanomaterial-loaded subcutaneous stem cell injection led to an SNR of 46.2. For comparison, when qdot-loaded and dye-loaded stem cells were tested within the same study from the same imaging angle, the qdot signal was challenging to distinguish over background autofluorescence a stark difference from the high nanophosphor SNR. While no acute and medium-term cytotoxicity has been observed with these nanomaterials, chronic toxicity and long-term leaching studies would need to be performed in order for these structures to advance toward the clinic. Moreover, despite their depth advantages over many other optical nanomaterial strategies, these nanophosphors would remain restricted to superficial (e.g., skin) or other optically accessible (e.g., colon and esophagus) sites for clinical use. Notably, these materials can be configured to display multimodal properties that can alleviate optical accessibility concerns through use of other imaging modalities, such as CT-imageable tantalum oxidecoated nanophosphors.284 Despite their promise with no autofluorecence, good depth penetration, and large SNR, specific clinical applications for these nanomaterials are likely to compete with whole-body approaches such as MRI (with iron oxides) and CT. To proceed clinically, they will need to exhibit key benefit(s) beyond those offered elsewhere, such as efficacy and price. Many other nanomaterials have been applied in fluorescent/ luminescent in vivo imaging, yet the vast majority are made fluorescent by incorporating organic fluorescent dyes either covalently linked to the surface or incorporated in a surface coating such as silica, often via a Stöber-based process.211,261 These adaptable nanomaterials, such as polymers, silicon- and lipid-based materials, and many others, have high modular\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAC\npotential to be tailored for imaging by one or more of the imaging modalities described later in this review (see section 2.7). The fundamental limitations of fluorescence imaging, including of fluorescent nanomaterials, are primarily light scattering; autofluorescence; absorption by surrounding tissues, water, and lipids; and relatively low penetration depth. As discussed, working in the near-infrared regime helps to curtail some of these issues, as does use of newer optical approaches such as diffuse optical tomography, optical coherence tomography (OCT), and bioluminescence by minimizing one or more of the key limitations. However, for many applications, the advantages of fluorescence imaging of nanomaterials such as being noninvasive, cost-effective, nonionizing, and fairly sensitive, as well as displaying real-time imaging capability, outweigh the limitations. 2.4.1.4. Intravital Microscopy. In the context of nanomaterials, intravital microscopy (IVM) has primarily been exploited to track and deconvolute their behavior and targeting in vivo.15,22,26,27,199,212,285,286 IVM is the only modality capable of illuminating what is actually happening to nanomaterials in living subjects, including their interactions with the internal biology in real-time, on their own scale; this makes it highly complementary to every nanomaterial-based imaging strategy described in this Review. Indeed, IVM can provide visualization with lateral spatial resolutions down to 100s of nm and even down to 10s of nm under special conditions,287 providing unparalleled insights. IVM has provided insights into how variations in the size and shape of nanomaterials dictate their delivery to disease sites15,24,26,28 and can even help identify and quantify how each uptake mechanism is responsible for a nanoparticle’s macroscopic imaging signal.19 Typically using fluorescent molecules, proteins, and nanomaterials to visualize nano- to microscale biological phenomena in vivo, IVM has become a go-to tool for evaluating everything from immune cell biology, tumor dynamics, successful gene knockdown or editing, and cell−cell interplay to angiogenesis and nanoparticle behavior.280,285,288−292 Prudent use of IVM can dynamically discriminate differences between specific and nonspecific targeting (e.g., elucidating the effects of targeting ligands) and provide invaluable insights to chemists creating nanomaterials in terms of how specific parameters must be improved or modified in order to support translation of nanomaterials into patients15,199,288,293,294 (generally for use with other imaging modalities)for example, whether and how the nanomaterials are reaching targeted tumor cells, whether they enter the cells, and how long they are retained there. Unexpected behaviors of nanomaterials in vivo can also be explored with IVM, behaviors that could not be discovered using any other in vivo imaging modality nor cell culture. For instance, our group examined how SWNTs target cancer as they have displayed among the highest in vivo uptakes into disease sites like cancer.239,295 IVM supported our discovery that not only did peptide-targeted SWNTs home to tumors via expected routes such as binding to new blood vessels and extravasation via the EPR effect but an entirely new mechanism was uncovered in which SWNTs were visualized (at the sub-μm scale) selectively entering immune cells in the blood.19,199 These cells then carry a significant percentage of the SWNTs into the tumor bed. This prompted us to look more deeply into the particular cells that were taking up SWNTs. While the uptake mechanism is not yet established, we found that a particular subtype of monocytes, Ly-6Chi monocyteswhich are heavily implicated in cancer and\natherosclerosisvery selectively took up the SWNTs in blood.199 This and other works3,132 are harbingers for immunoimaging applicationsharnessing the power of the immune system to track and visualize particular immune subsets, niches, and diseasesusing nanomaterials. One could, for instance, now apply these IVM-derived insights to drive novel cancer and atherosclerosis imaging applications using other, more translatable imaging modalities and to study other diseases in which Ly-6Chi monocytes are implicated. In this case, potentially one could visualize disease with Raman, photoacoustics, or near-infrared modalities because SWNTs can easily be detected with any of them (see Figure 12 and\nsections 2.4.3 and 2.4.5). From the imaging perspective, there is a need for additional highly selective nanomaterials to target other immune cell subsets. This would support tracking and studying the spatiotemporal localization of neutrophils, specific lymphocytes, NK cells, and many other types of immune cells that are implicated in various disease states from autoimmune disorders and cancer to sepsis and neurological diseases. IVM has a rich history in revealing many critical facets within immunology, including leukocyte trafficking, in live animals.289,290 When coupled with improved, multiplexable fluorescent nanomaterials (e.g., qdots and upconversion nanomaterials) that can efficiently target particular immune cells,199 IVM has the potential to offer unprecedented insights into immune cell behavior, such as immune cell interactions with one another and their roles in various diseases, within living subjects. With recent discoveries heavily implicating the immune system in cancer (e.g., immunotherapy),296,297 neurological diseases,298,299 and many others, such basic studies will\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAD\ntake on increased clinical importance. New nanomaterials are likely to be a key enabler of such studies by permitting selective, real-time cellular visualization without requiring fluorescent genetic reporters for each cell type of interest. Both one-photon (1P) and multiphoton microscopy are used to image nanomaterials in vivo. Fluorescence microscopy has traditionally been performed using single-photon excitation, meaning that a single photon excites an electron within the fluorophore/fluorescent nanomaterial, which subsequently emits a photon (i.e., fluorescence) as it drops back down to its ground state. However, it was discovered that if two (or more) lower-energy photons (which sum to a total energy approximately equivalent to that required to excite the electron via 1P excitation) are absorbed nearly simultaneously, the system behaves similarly as 1P, emitting a Stokes-shifted photon of the same energy as the 1P emission photon. Multiphoton microscopy lasers are typically tunable to emit photons from ∼680 to 1000 nm, although some systems enable up to 1300 nm and more, depending on the laser type. While single-photon systems (which are generally confocal) are cheaper and can image essentially all fluorescent materials (assuming one has the appropriate excitation lasers and filters installed), multiphoton approaches have other important advantages, including considerably deeper penetration depths (upward of 600 μm, due to the red-shifted excitation) and decreased photobleaching and tissue damage, and they can be endowed with intrinsic imaging capabilities such as second harmonic generation (SHG, which is a nonlinear frequencydoubling effect that can arise when a multiphoton laser is shined on noncentrosymmetric materials, such as biological materials like type I collagen as well as myosin from muscles). Note, however, that the advantages of multiphoton microscopy are not all necessarily automatic and must often be attained via optimization of the instrument, particularly the excitation wavelength for a given system.300 Furthermore, multiphoton microscopy requires larger, more expensive lasers and not all fluorophores and nanomaterials have large multiphoton cross sections that allow straightforward imaging. Because IVM is so complementary to other imaging modalities, its use in combination with imaging of nanomaterials in MRI, PET, SPECT, CT, ultrasound, and macroscopic fluorescence imaging can be powerful. While the nanomaterial distribution in the entire tissue can be quantified with macroscopic imaging modalities, IVM can provide functional information on the subcellular scale: for example, the dynamic effects of therapeutic nanomaterials can be tracked, for instance, by simultaneously probing apoptosis, pH, hypoxia, cell motility, or costaining at the cellular level.301,302 Similarly, one can ensure that the intended cellular target of ligand-coated nanomaterials is in fact its destination, validating that macroscopic images showing uptake are due to the reasons one typically presumes303,304e.g., that a targeting ligand is in fact supporting increased uptake of a nanoparticle to a cancer site by binding to cell targets.19\nIVM is unlikely to be easily or broadly translated into clinical applications in large part due to depth of penetration issues, as depths of even ∼600 μm are usually not highly useful in human medicine. Nevertheless, IVM may be clinically useful to superficially image at epithelial surfaces, such as in endoscopic applications, at dermal surfaces, or intraoperatively.305 For example, qdots were used to tag and analyze cell populations for multiplexed in vivo flow cytometry to quantify specific types of cells moving through the vasculature.306 Such applications\ncan take advantage of the multiplexing capabilities of qdots, which can be excited by a single laser due to their broad absorptions, yet emit in 4 or more different colors (due to narrow emission bands) corresponding to different proteins on the cells. These applications could eventually be applied clinically (although likely not with semiconductor qdots, but with safer luminescent nanomaterials) to superficial blood vessels to quantify rare cell populations including circulating cancer cells or stem cells,306 although improved nanomaterial targeting capabilities may be necessary as accurate in vivo discrimination between a wide variety of cell types is likely to remain challenging in the absence of new technologies.\n2.4.2. Resonance Energy Transfer. There is great utility in the unique features displayed by resonance energy transfer (RET) mechanisms, particularly its strong distance-dependence, which can be applied as a sort of molecular nanosensor to detect disease-relevant biomolecules. The most well-known and widely used form of optical RET (nonradiative transfer of virtual photons from donor to nearby acceptor) in imaging is fluorescence resonance energy transfer (FRET), which has been used, for instance, to monitor enzymatic activity within living subjects.307,308 FRET is governed by long-range dipole− dipole interactions, making it an exquisitely sensitive molecular ruler for distances of the order of ∼1−10 nm. The signal intensity falls off as 1/R6, where R is the distance between donor and acceptor. In all RET mechanisms including FRET, the emission frequency of the donor must be matched to the excitation frequency of the acceptor. While the majority of FRET-based assays are designed for in vitro applications such as ultrasensitive diagnostic assays or to detect toxic molecules in the military, for biological terrorism detection, and the food industry,309,310 FRET also has great potential for in vivo imaging. There are few other approaches able to quantitatively answer questions about enzymatic activity in living subjects. These probes are often known as “smart” or “activatable” nanomaterials because these materials do not simply travel through the body always “on”rather, they are on (producing signal) when one wants, where one wants, and off otherwise; this substantially decreases nonspecific background signal.311 For example, Lee and colleagues prepared a self-assembled activatable polymeric nanomaterial consisting of a dye (Cy5.5) linked to a quencher (BHQ-3) via an enzyme-cleavable peptide with selectivity toward several matrix metalloproteases (MMPs, several of which tend to be overexpressed in cancer and other diseases).311 The quenching mechanism is via FRET between the closely spaced quencher and dye moleculesnanomaterials are generally excellent tools for spatially constraining molecules that must, in order to be effective, cooperate by localizing within a given distance of one another. The nanomaterial precursors were synthesized by generating polymeric amphiphiles via hydrophobic modification (5β-cholanic acid) of glycol chitosan. By sonicating the solution with the activatable peptide, a self-assembled nanomaterial was formed. Intratumoral injection of these effective MMP-nanosensors provides a fluorescent readout of the MMP activity in the imaged region (see Figure 13). This is because the nanomaterial is quenched when unactivated (without the presence of MMPs); however, once cleaved by MMPs, the previously quenched Cy5.5 molecules fluoresce upon illumination. Figure 14 illustrates the generalized scheme of a nanomaterial FRET probe, with FRET occurring when the nanoparticle is locked in proximity to its complementary donor or acceptor molecule.312 Other\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAE\nthan MMPs, typical enzymatic reactions of interest include the activity of caspases and cathepsins.307\nZou et al. exploited FRET to monitor drug release from their copolymer nanoparticles intravenously injected into living mice.313 In their configuration, they encapsulated both the donor dye (e.g., DiD) and acceptor dye (e.g., DiR) into poly(ethylene oxide)-b-polystyrene (PEO−PS) copolymer nanoparticles. The close proximity of these two lipophilic dyes within the nanoparticle gives rise to FRET, but when dyes are released, they diffuse so that the mean inter-dye distance increases sufficiently that minimal FRET occursthis principle is used to quantify release kinetics in vivo. The release kinetics are measurable as a FRET ratio, which evaluates the quantitative ratio between intensities of FRET donors and acceptors: FRET ratio = IFRET/(IFRET + IDiD), where IFRET and IDiD represent the average intensities of nanoparticles using the FRET and DiD filter sets, respectively.313 When only dyes were included in the nanomaterial, the in vivo release half-life was only 9.2 min; however, when the authors coencapsulated oleicacid-coated iron oxide nanoparticles into the PEO−PS copolymer nanoparticles, the release kinetics shifted. Premature\nrelease was prevented and a more desirable release rate with a release half-life of 50.8 min was achieved and measured with FRET. Curves to quantify the release would be difficult to obtain in vivo using other methods. This provides a nice model of release of lipophilic small-molecule drugs. Indeed, it would be possible to perform such a study using not only dyes but additionally with a drug such doxorubicin as one of the lipophilic molecules (which in this case would serve as more than solely a therapeutic, but also as a fluorophore with an excitation ∼480 nm and emission ∼575 nm). One could also imagine a clinical application, optically ensuring that (at least in shallow tissues or during surgery) a fluorescent drug such as doxorubicin is being delivered, and in particular that it is being delivered at an appropriate rate to kill the desired cells. However, while this in vivo assay has potential, it is important to note that, because this is a fluorescence-based assay particularly in the visible range, tissue autofluorescence in living subjects decreases both confidence and the level of quantitative accuracy achievable. FRET requires input stimulation light. However, by intelligently pairing materials together, many groups have optically imaged tumors deep inside living animals without the need for excitation light and the resulting autofluorescence, thereby achieving very high sensitivities.308,314 Through such a strategy, Rao and colleagues developed cancer-targeted selfluminescing polymeric nanomaterials that achieved tumor-tobackground ratios of over 100 in living mice, compared to typical values on the order of 10 or less.308 The mechanism underlying FRET is similar to that in related RET phenomena, such as bioluminescence resonance energy transfer (BRET), luminescence resonance energy transfer (LRET), plasmon resonance energy transfer (PRET),315 and Cerenkov resonance energy transfer (CRET). Physically, these resonance energy transfer (RET) mechanisms are the near-field (nonradiative) parallel to longer-range radiative transfer mechanisms. RET systems tend to make excellent biosensors particularly because of the strong dependence on distance, as described above, but some RET systems offer further advantages. In particular, most optical techniques (including FRET and LRET) require both input light to excite the target and outgoing emission light to be detected. In fluorescence imaging, photons traverse tissues to excite nanomaterials and back out where they are quantified by cameras; photons scatter heavily in both directions, decreasing the total depth of penetration possible and increasing the amount of input light intensity required for detectable signal. Some RET strategies can partially help overcome the penetration limitations of light: i.e., the ability to restrict the required light path to only output light, e.g., for BRET and CRET. While nanomaterials are not required for successful RET strategies, their targeting properties, circulation times, and superior properties for accepting virtual photons (conceptual particles encapsulating the nonradiative energy that is transferred) often make nanomaterials preferred depending on the application. For example, the CRET process takes advantage of the fact that when isotopes emit positrons some of the positrons for a short time travel faster than the speed of light in the medium, generating optical photons as they lose energy in tissues.316,317 This radiation, Cerenkov radiation, consists of photons that can be donated to an acceptor nanoparticle.316,318 Chen and colleagues created self-illuminating 64Cu-gold nanoclusters, in which the 64Cu isotope may emit positrons upon radioactive decay. The gold nanocluster accepts the rapidly generated photons, producing near-infrared fluores-\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAF\ncence that can travel relatively deep through tissues. It can be very sensitively detected as no autofluorescence is generated. This particular approach is an intrinsically multimodal strategy with intrinsic radiolabeling, in which 64Cu is integrated into gold nanoclusters as part of the synthesis (see section 2.6.1 on intrinsic radiolabeling), and both CRET and PET imaging is possible.316 Cerenkov radiation is broadband but weighted toward the ultraviolet and blue end of the spectrum, so it would not be easily detectable in tissues as is; thus, a RET mechanism is indispensable to red-shift the light and make it detectable from deeper tissues. This was verified experimentally by in vivo optical imaging in a direct comparison between Cerenkov radiation and CRET that produced near-infrared radiation. Upon i.v. injection into xenograft tumor-bearing mice, the photon flux from CRET was >4 times that of the Cerenkov radiation through at least ∼10 h postinjection. In this case, the still quite small (∼1−2.5 nm) gold nanoclusters are able to efficiently absorb photons created by the 64Cu-generated positrons. Indeed, because of the larger optical absorption\ncross section of nanomaterials compared to small-molecule dyes, nanomaterials are usually preferable for such tasks. Sometimes multimodal strategies such as CRET and PET can be useful for new clinical paradigms of imaging, but in this case, the approach’s multimodality strategy was particularly useful for internal comparison between the modalities: based on an ROI (region-of-interest) analysis, a linear correlation was demonstrated between PET and CRET across all animals imaged, with R2 = 0.9687. This suggests that the self-illuminated CRET signal can serve as a proxy for PET imaging.316\nIn an amalgam of upconversion nanomaterials and RET, LRET (upconversion luminescence transferred to acceptor dyes) easily permitted multicolor imaging with ultralow autofluorescence background in vivo.319 Upconversion nanomaterials were excited in the near-infrared (980 nm), and the LRET pair for each color consisted additionally of prudent choice of dye to physically adsorb to the upconversion nanomaterial. The images produced displayed very low autofluorescence and high-dimensional color multiplexing in\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAG\nliving subjects (see Figure 15a, b), which are somewhat reminiscent of the features of the Raman imaging capabilities discussed in the following section (Figure 15c).320,321\nFinally, semiconductor polymeric nanomaterials were designed to detect reactive oxygen species (ROS) and reactive nitrogen species (RNS) as a proxy to evaluate drug-induced hepatotoxicity with RET.322 A nanosensor was contrived by connecting FRET (between the fluorescent semiconducting polymer matrix and an oxidation-degradable fluorophore) to a subtype of LRET (i.e., chemiluminescence resonance energy transfer, CRET, arising from a chemiluminescent substrate embedded in the polymer matrix designed to detect levels of H2O2 sans external light excitation). The nanomaterials were systemically administered and targeted to the liver, where they could evaluate ROS (via H2O2, indicative of oxidative cellular processes) and RNS (via peroxynitrite, ONOO−, the nitrosative result of drug-metabolite-induced mitochondrial toxicity). Drug-induced hepatotoxicity in a mouse model was thus detected based on ROS and RNS production by RET imaging of H2O2 and ONOO\n−.322 These sorts of nanomaterials could improve the dynamic study of disease pathophysiology in real time in living subjects. These semiconducting polymers and the ROS detection mechanism in this work are very similar to the semiconducting polymers described in further detail in section 2.4.5 on photoacoustic nanomaterials. 2.4.3. Raman. Raman imaging, with its ultrahigh specificity, relatively high penetration depth, and high-dimensional multiplexing potential, is a viable alternative to fluorescent imaging of nanomaterials.323 Due to its weak signal, however, in vivo Raman imaging in a reasonable time frame is challenging (but possible for small regions324) unless nanomaterials are used for signal amplification in deep tissues. By applying nanomaterialenabled surfaced-enhanced Raman scattering (SERS) imaging (and variants such as SESORS, surface-enhanced spatially offset Raman spectroscopy, which promises to further increase the penetration depth even through bone325,326), researchers have detected nanomaterials up to 1−5 cm deep in tissues at concentrations as low as 1.5 fM.325,327 These features, in addition to the fact that Raman-based imaging nanomaterials are typically nontoxic, suggest high potential for Raman imaging in future clinical applications.323\nThe Raman effect was discovered nearly 90 years ago and is well-known to chemists, who often apply the spectroscopic technique to identify bonds and molecules through their vibrational modes50 by measuring the magnitude of energy loss of inelastically scattered photons. As photons pass through a material, the vast majority scatters elastically (i.e., their energies are conserved), while only 1 in ∼107 photons scatters inelastically. This is why the Raman signal is intrinsically quite weakin fact, Raman cross sections are ∼10−29−10−30 cm2 compared with usual absorption cross sections of fluorophores on the order of ∼10−15−10−16 cm2.328 However, it turns out that some metallic nanomaterials can amplify Raman signal with an enhancement factor on the order of an incredible 1010-fold329,330this is the SERS effectimproving the sensitivity by raising the signal close to the fluorescence range. SERS is the basis for use of most nanomaterials in Raman imaging in vivo. Raman-active dyes, which provide a unique Raman signal due to a distinctive set of bonds and molecular structure, are required for SERS. The SERS effect arises from intense localized fields resulting from surface plasmon resonance in metallic nanomaterials (e.g., Ag, Au, and Cu).323 Large numbers of free electrons in a metal can be\nexcited by the electrical components of incident light to collectively oscillate. The surface plasmons (oscillating electrons) generate a secondary electric field that, when added to the incident electric field, is quite large.331 This has been used for in vivo Raman imaging and multiplexing in mouse livers using spherical gold nanomaterials with high sensitivity (see Figure 15c). In this case, 5−10 different Raman dyes are used, each with the same gold nanomaterial core and silica coating, making the multiplexing process highly modular. While advancing the higher-dimensional multiplexing limits is not a major initiative, perhaps due to lack of sufficient in vivo targets, the sensitivity limits have recently received great attention and are being probed to even greater depths. This is primarily done in two ways: by increasing the dye absorption/ SERS effect via dye molecule chemistry or by engineering the nanomaterial shape to enhance the electric field on the metal surface. For an example of the former, Kircher and co-workers recently developed a new class of Raman dye, 2-thienylsubstituted chalcogenopyrylium, which has the property that the 2-thienyl group can lay coplanar against the gold nanoparticle surface to help minimize the distance between dye and surface.332 Because the SERS effect of a dye molecule is an exponential function of distance from the surface,333 tuning of these chemical properties resulted in new Raman nanomaterials detectable with attomolar-level sensitivity.332\nOn the other hand, due to the physical mechanism of SERS, one can intelligently modulate the nanomaterial shape or surface roughness to significantly increase the electromagnetic field enhancement via localization of optical fields in metallic nanomaterialsthese are commonly known as Raman hot spots. The majority of SERS signal from a nanomaterial sample typically arises from the hot spots, even though they only make up a small fraction of the surface area.62 This is why chemists often now design Raman nanomaterials with sharp features and edges, such as stars, nanoparticle−nanoparticle junctions, and pyramids.327,334 These shapes, configurations, and surface roughnesses can produce hot spots with fields enhanced up to 1015-fold due to the spatial confinement of the surface plasmons, producing a resonance effect on the oscillations in response to a characteristic frequency.331 This leads to highly concentrated local secondary electric fields and results in the large signal produced by hot spots. To fully exploit the hot spots that Raman physicochemistry provides, scientists are carefully studying the dye−surface interactions.62 For instance, optimized Raman dyes332 could be paired with engineered surfaces to ultimately detect ever-smaller disease sites (e.g., tumors) and significantly decrease the total amount of metallic material necessary to inject for clinical applications. In the nearterm, SERS-enhanced gold nanostars and nanospheres are being developed for clinical applications in colon cancer imaging and solid tumor delineation during surgery.327,335 These two approaches are notable as they are intended to lead to clinical utility as quickly as possible. When nanomaterials are injected systemically, they are carried throughout the body and numerous tests must be performed on the biodistribution and various tissues to ensure lack of toxicity for regulatory approvals. However, localized application of the nanomaterials is likely to lead to a lower threshold for regulatory approval, as they are not expected to travel throughout the body.335 In this framework, colon cancer screening could be performed by rinsing Raman-active silica-coated SERS gold nanospheres through the colon for binding to any malignant lesions (including the flat lesions that are difficult for physicians to\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAH\nobserve with standard techniques336,337) and detection with a dedicated, multiplexable Raman-based endoscope.320,321 In a separate application, Raman nanostars were created to display increased signal through engineering of hot spots. These also were endowed with a Raman dye-embedded silica surface coating using a modified Stöber method.327 Contrary to the surface application of gold nanospheres in the colon, the nanostars were i.v.-injected into mice in order to spatially define tumors during surgical resection so that surgeons can be certain they do not leave behind tumor cells. In five different genetically engineered mouse models of cancer, the Raman particles targeted the tumors and clearly defined the tumor margins both at primary tumor sites and critically at sites of metastasis.327 If it can be confirmed that the Raman nanoparticles (which have been shown thus far to be nontoxic327,335) are taken up into clinical tumors, this could support surgical interventions with Raman-assisted guidance to ensure excision of all the regions of disease. However, for translation of the nanostars, instead of i.v. delivery it may be prudent to first direct Raman nanomaterials to the surgical surface (with a washing step) in order to decrease the total amount of nanomaterial introduced and decrease the risk of nanomaterials spreading throughout the body. Although typically not as intense as SERS-based Raman nanomaterials, other nanomaterials intrinsically give off a distinct, strong Raman signal that can be used for in vivo imaging. Because each band within a Raman spectrum corresponds to a particular bond vibrational frequency within a molecule, certain bonds tend to appear highly distinctive.338 In particular, the sp2 C−C bonds in carbon allotropes such as nanotubes and graphene are different from any C−C bonds throughout biological organisms and, thus, can be sensitively detected338 when targeted to tumors in living mice for imaging.339\nWhile Raman instrumentation and software are improving rapidly, extracting useful disease-related information from intrinsic Raman signal remains exceedingly difficult due to the weakness of the signal. Therefore, in addition to developing completely new Raman probes for molecular imaging as discussed above, scientists are working to develop ways to amplify the native signal of disease-specific telltale chemical signatures by adding metallic nanomaterials to the system in attempts to apply the SERS effect to native molecules. These nanomaterials must be sufficiently close to the desired chemical signatures to disturb and localize their electromagnetic fields and amplify them enough to achieve detection, which is strongly distance-dependent. Thus, unless issues of steric hindrance and charge-based repulsion between the nanomaterials and desired chemical groups are overcome, this approach may prove exceedingly difficult. The field of Raman nanomaterials has thus branched into these two broad categories: (1) nanomaterials designed to target disease and provide a specific, unique signal that is completely absent in vivo and (2) nanomaterials designed to amplify intrinsic signal. 2.4.4. Optical Coherence Tomography. Optical coherence tomography (OCT, a 3-dimensional interferometric optical imaging technique) typically derives its distinctive contrast capabilities from the scattering properties of biological tissues such as cells, extracellular matrix, and other stromal and vesicular components. Therefore, fundamentally a critical aspect in the pursuit of appropriate nanomaterials to generate basic OCT contrast is their scattering properties. However, one might ask “is contrast crucial for OCT?” After all, one\nadvantage of OCT touted by its practitioners is that it is label-free and no extrinsic contrast is necessary.340,341 While OCT can indeed easily be and often is performed without extrinsic contrast, just as in clinical MRI, if one requires functional, molecular information, contrast agents often become critical and even indispensable. The best OCT contrast (i.e., best scatterers) are nanomaterialsentities below ∼20 nm usually exhibit negligible scattering, but ∼20−100 nm nanomaterials have great potential in OCT.342 In fact, lightscattering nanomaterials compare well with typical fluorophores; for example, one 80 nm gold nanoparticle displays a light-scattering power equivalent to the signal arising from nearly 106 fluorescein molecules and does not photobleach.343 Gold nanoshells have been developed that allow precise tuning of the resonant wavelength and the scattering and absorption efficiencies based on the size and composition of the shell structure.344 Tuned for near-infrared deep-tissue imaging, gold nanoshells comprising a 16 nm gold shell around a silica core were optimized in part for optical backscattering, which is key to create OCT contrast.345 Mie theory scattering computations can predict the relative contributions of scattering and absorption so that, if an OCT imaging-focused nanomaterial is desired, one can maximize scattering; if, on the other hand, therapeutic heating were desired, one could optimize for maximum absorption. Gold nanomaterials that were used recently to target tumors in living mice were generated using a modified Stöber method to form the silica core. The surface of the core was aminated, and 2−4 nm gold colloids were deposited onto the larger silica core surface to serve as nucleation sites. To form the shell, gold was reduced from chloroauric acid (HAuCl4) to plate the surface and create a continuous gold shell. The time permitted for reduction correlates to the gold thickness, which provides the capacity to tune the scattering properties of the shell in a wavelengthdependent manner for use in OCT. These gold nanoshells were i.v.-injected into tumor-bearing mice, localized to tumor interstitium via the EPR effect, and were detected using OCT.344,345 This has high potential for cancer detection but is limited like most optical modalities due to issues of penetration depth (∼2−3 mm even at near-infrared wavelengths in tissue); thus, only superficial tumors such as dermal or endoscopically reachable regions have clinical potential using this nanomaterial contrast-enhanced OCT strategy. OCT captures images in cross section, collecting line images in the z-plane. The optical parallel of ultrasonic tomography, OCT likewise reconstructs images based on tissue reflectivity by measuring the returning echo time delay to an input pulse or spectral signalbut OCT generates images with backscattered light instead of sound.346 In fact, OCT can achieve much higher spatial resolution than ultrasound, under certain conditions nearing 1 μm, with fairly high penetration depths for an optical modality. Because the speed of light is orders of magnitude higher than that of sound, interferometric technology (i.e., light is split into a reference arm and a sample arm, which is directed into the tissue) can be applied to measure these time delays. Comparison between the back-reflected optical intensities from the two arms ultimately forms images that are reconstructed. By increasing the backscatter through use of nanomaterials (i.e., with a high scattering coefficient), the coherence of the input light beam is diminished and OCT contrast is generated.342 As in the above gold nanomaterial examples, metallic nanomaterials are generally potent light scatterersin fact, many OCT contrast agents are based on gold as well as titanium,347,348 as\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAI\nthese nanomaterials intensely absorb and scatter light at their surface plasmon resonance wavelengths, which are tunable (between the visible and near-infrared) by changing the size, shape, and shell thickness of the nanoparticle. By applying the physics of scattering using scattering theory and experimental measurements, Xi and colleagues fabricated scattering-optimized gold nanomaterials with an excellent scatter-toabsorption ratio of 1.31 by decreasing gold nanocage porosity and marginally increasing their edge length through minor tweaks to the standard nanocage chemistry.349 Thus, they were able to achieve the highest OCT contrast enhancement to date by nanomaterials of similar size/concentration in a living mouse. Injected i.v., the gold nanocages homed to tumors grown in the mouse ear, where OCT was able to detect >3-fold signal enhancement in tumors at depths of ∼100 μm and up to 1.5-fold at 700−800 μm.349 The unique structure of the gold nanocages, which displayed optical cross sections over an order of magnitude better than OCT agents of similar size, resulted in their superior in vivo imaging properties. Dermal nanomaterial applications require two key properties aside from safetycapacity for penetration into the skin and a strong imaging signal. Titanium dioxide nanomaterials, a common ingredient in many cosmetics and particularly for sunscreens as protection against UV photons, have been reintroduced as dermal OCT contrast agents.347,348 With a high backscattering coefficient (signal) and reams of data on titanium dioxide nanomaterial safety in skin, dermal applications of titanium dioxide as an OCT agent seem an obvious match to develop rapidly into clinical applications for dermatological disease. The titanium dioxides used are commercially available and typically fabricated via a sol−gel method by hydrolysis of titanium alcoholates. Applied dropwise in aqueous solution on the skin of rabbit and pig animal models, titanium dioxide nanomaterials have shown strong dermal OCT contrast.347,348\nAn interesting effect of the physics of OCT is that not only does the resonance wavelength depend on the nanomaterial dimensions but the signal is sensitive to the orientation of nonspherical nanomaterials within the tissues.350 One must typically average over all orientations of the nanoparticle to determine its effective backscattering coefficient,349 but the signal so calculated is far from optimal, i.e., if all nanoparticles were oriented for maximal backscatter, the effective signal would increase multifold with no additional contrast material. Therefore, one way to increase the signal would be to work out a way to homogenize the orientation to maximal intensity, for example, by incorporating magnetization into the nanomaterials and using a strong external magnet to align them during OCT. While the OCT penetration is ∼2−3 mm in typical highly scattering tissues, in tissues such as the eye, these depth limits are of course significantly extended due to the low scattering media, enabling imaging of the retina. Because of this, OCT has already become a powerful clinical tool for identifying abnormalities in a wide variety of ophthalmological phenomena (e.g., retinal diseases, glaucoma, wet and dry macular degeneration, etc.). However, like ultrasound, OCT can only observe chiefly structural featuresthe use of nanomaterials in ophthalmological OCT is being driven by the desire for functional, molecular imaging of ocular pathologies. Thus far, there is minimal work in nanomaterials for OCT ocular imaging, but recent results suggest that gold nanorods injected into the anterior chamber or cornea of eyes in living mice can be detected down to concentrations as low as 120 pM.342\nThese nanorods were tuned for plasmonic resonance in the near-infrared region (∼780 and 850 nm absorbance peaks). Given the substantial contrast boost of 50-fold compared with no injected nanorods, there appears to be a promising future for ocular OCT nanomaterials. With low toxicity, gold-based nanomaterials have the potential to fundamentally transform how ophthalmic diseases are diagnosed, particularly if they are endowed with molecular targeting biomolecules to address diseases such as ocular tumors, age-related macular degeneration, diabetic retinopathy, and many other vascular and other abnormalities.342\nHybrid OCT Technologies. Significant efforts have been made over the last 5−10 years to marry OCT with functional molecular imaging technology instrumentation. While we described earlier how conventional OCT is becoming fortified with molecularly targeted nanomaterials, new imaging technologies are being developed that facilitate the use of contrast in OCT and thus the ability to acquire molecular imaging data. Recent innova t ions inc lude phototherma l OCT (PTOCT),351,352 magneto-motive OCT353,354 (MMOCT; see also section 2.3.3), spectroscopic OCT (SOCT),355 and second-harmonic OCT.356 While it is beyond the scope of this Review to describe the details of the instrumentation and signal processing of all these hybrid OCT systems, several reviews examine them in detail.357−359 Here we briefly review several nanomaterials that have been used in conjunction with these novel approaches. For instance, the principle of PTOCT is to heat small regions (using contrast and a separate laser light source) of tissue within the optical path length of the OCT beam. The temperature variation causes changes in the local refractive index, which in turn modulates the optical path length. Such changes in distance can be observed using phasesensitive OCT.357 The technology was recently applied in vivo for the first time using gold nanorods with aspect ratio of 3.5 injected intravenously into tumor-bearing mice. These nanorods accumulated in the tumor and were detected using an amplitude-modulated heating beam that produced oscillations in heat dissipated by the nanorods to cause oscillations in the optical path. These fluctuations were detectable in the phase of the time-dependent OCT interference pattern.360 Because the gold nanorods were efficient at absorbing and releasing the heat, unlike other materials within the tissues, PTOCT resolved the presence and location of the nanorods with no background (see Figure 16). Overlaid with conventional OCT approaches (e.g., OCT for morphological information and speckle-variance OCT to identify blood flow), PTOCT could be highly informative about a tumor and its vascular permeability. In this case, nanorods were not molecularly targeted, but the tumor was identified based on vascular leakiness to the nanorods.360 Other disease sites, such as atherosclerosis, have been identified with PTOCT based on the selective uptake of gold-coated/iron oxide core “nanoroses” by macrophages in atherosclerotic plaques of rabbits.361 In the future, molecular targeting (e.g., using RGD or VEGF receptor ligands) could demonstrate binding to cancer blood vessels44 and to cancer cells,19 or perhaps to identify locations of immune cells199 within the disease site potentially using hybrid OCT approaches. Any highly absorbing nanomaterials are applicable in this scheme, including other gold nanomaterials such as nanoshells and nanospheres, as well as carbon nanotubes and other carbon-based absorbers. Iron oxide nanomaterials are typically not as useful for PTOCT, but these magnetic nanomaterials are central to the use of MMOCT.\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAJ\nMMOCT is another hybrid OCT technology that has great promisein part because one can exploit iron oxides that were previously approved by regulatory agencies, were used in clinical MRI or for anemia treatment, and display sufficient magnetic susceptibility. Because the costs and time associated with MRI are often major limiting factors in its use, technologies such as MMOCT would be much cheaper in eventual clinical use and importantly would be accessible even to patients with implants that preclude use of MRI (e.g., pacemakers). The principle underlying MMOCT is similar to that in PTOCTmodulation of the distance the OCT sample light beam must travel. This is accomplished in MMOCT by inducing minute movements of the magnetic nanomaterials using modulated magnetic fields and then applying phasesensitive OCT to detect the signal in the interferogram as in\nPTOCT.357 Recent advancements show that, using MMOCT, magnetic nanomaterials can be detected at very low concentrations (∼2 nM) with magnetic fields as low as 0.08T (compared with MRI, which typically applies a minimum 1.5T field at considerably higher nanoparticle concentrations, depending strongly on the MR sequence, field strength, and resolution).353 The use of magnetic nanomaterials for MMOCT is burgeoning, with groups using it to detect cancer,353 atherosclerosis,362 and ocular disease363 in living mice. Molecularly targeted iron oxide nanomaterials (∼20 nm diameter), for example, were directed to orthotopic breast cancer in rats using anti-Her2/neu antibodies, which bind the well-known prognostic Her2/neu receptor expressed on cells in ∼30% of breast cancers. MMOCT was highly specific, displaying signal only when the cancer was targeted by iron oxide nanomaterials but not at all in controls.353 MMOCT is thus positioning itself as a promising alternative to MRI when visualization is required on dermal surfaces or in endoscopic or ocular procedures.\nNext-Generation OCT. Second-generation OCT approaches, which operate in the frequency domain (Fourier domain), offer image-acquisition speeds 50−100-fold better than conventional OCT, which operates in the time domain. In a recent study, the increase in speed has helped support use of these optical frequency domain imaging (OFDI) approaches to identify two different nanoparticles in living animals. The approach takes advantage of differential plasmon resonances in two different nanomaterials by combining with spectroscopic OCT to simultaneously image two different nanomaterials and spectrally separate them.364 Kim and colleagues spectrally distinguished gold nanorods and silver nanoplates in the ears of mice that had been intradermally injected. The nanomaterials were specifically designed for resonant scattering at particular wavelengthsgold nanorods of 8 nm diameter and 47 nm length scattered strongly at 1040 nm, while triangular silver nanoplates with edge length 170 and 20 nm thickness scattered broadly at 1300 nm. While future improvements in silver nanoplate fabrication to enhance monodispersity and homogeneity will improve their scattering resonance intensity, the two nanomaterials were still detectable in vivo based on their differential scattering characteristics at the respective wavelengths.364\n2.4.5. Photoacoustics. Photoacoustic imaging (PAI) harvests the advantages of both optical and acoustic imaging by directing (laser) light pulses into a sample and receiving acoustic information in the form of ultrasound to create images. PAI’s key advantage is that the light in/sound out paradigm permits detection up to 5 cm deep into tissues at fairly high spatial resolution. The contrast mechanism is critically dependent on the optical absorption of the sample. Thus, nanomaterials, which can be highly engineered for optimal absorption in the visible or near-infrared with very high cross sections, are favored in PAI applications with sensitivities as low as the picomolar range. Recently, chemists have been drawing on inspiration from nature to generate some of the newest PAI nanomaterials, taking evolutionarily developed light absorbers (dyes) and creating PAI-imageable nanoparticles out of them.365,366 Melanin, an endogenous molecular absorber that gives skin its color, was cleverly packaged together with human serum albumin to construct nanoparticles for PAI via ethanol precipitation. Upon i.v. injection, these biocompatible (and thus likely clinically translatable) melanin nanoparticles\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAK\npassively accumulated in tumor xenografts of mice, leading to a PAI signal 3-fold higher than baseline at 24 h postinjection.365\nThe mechanism by which nanomaterials generate PAI contrast is that they absorb energy from short, energetic input light pulses and thus heat up. The heating causes transient thermal expansion, which results in broadband ultrasonic waves emanating from the local disturbance that can be recorded outside the body by ultrasonic transducers at a variety of frequency ranges. Over the past 5−8 years many groups have been creating PAI molecular imaging agents by choosing nanomaterials with high optical absorption cross sections and targeting them to sites of disease using liganddirected targeting including many nanomaterials that have been previously discussed such as gold-based materials, SWNTs, and graphene.242,342,367\nActivatable PAI Nanomaterials. Some of the latest developments in PAI probes involve smart or activatable nanomaterials that, like the RET activatable probes, are off until they are turned on by molecules of interest within the living animal. These molecules are proteins or other molecules that signal some pathological state. A novel approach to deep-tissue imaging of reactive oxygen species (ROS) in vivo was implemented by appending PAI dyes (a cyanine dye derivative, IR775S) sensitive to ROS-mediated oxidation to strongly PAIactive semiconductor polymer nanomaterials. By quantifying the PAI signal at 700 and 820 nm input laser wavelengths, ratiometric imaging entails computing the PA700/PA820 signal ratio to provide a measure of ROS.368 This configuration can assess ROS levels because, upon oxidation with certain molecules (e.g., ONOO− and ClO−), the dye’s absorption is nearly eliminated at 820 while the 700 nm absorption remains steady due to the nanomaterial presence. Using this approach, the authors were able to clearly detect and localize the ROS formed in response to acute edema in a mouse model, with a signal maximum 2 h after intravenous nanomaterial injection.368 PAI can be done at sufficient tissue depths and will likely be done at sufficiently low costs to make monitoring of ROS in real time a viable application in clinical medicine (note that ROS are implicated in a wide variety of pathologies, including cancer, atherosclerosis, aging, diabetes, obesity, chronic inflammation, and many more369). The semiconductor polymer nanomaterial for ROS detection was made via a polymeric nanoprecipitation procedure. Semiconductor polymers have been exploited in organic electronic devices and sensors, but Rao and colleagues’ work represents its introduction as a new class of photoacoustic nanomaterial. The PAI signal of the new semiconductor polymer nanomaterial proved several fold higher than other excellent nanomaterial optical absorbers that are commonly used such as SWNTs and gold nanorods on the basis of mass.368\nOther nanomaterials have also been developed for detection of enzymatic activity370,371 deep within living subjects for pinpointing abnormal or pathological processes. These strategies typically employ a molecule linked to a PAI-active nanomaterial via an enzymatically cleavable peptide. The molecule is often a quencher370 or a protecting group such that, once cleaved, PAI signal can be detected. In one example of this paradigm, protecting groups are linked to short, linear monomers via enzyme-cleavable peptides.371 Upon cleavage, self-assembly of the raw monomeric material rapidly leads to in vivo formation of nanoparticles, which can produce significant PAI signal. Thus, due to their small physical size, upon i.v. injection these small monomeric molecules are able to easily\ntravel around the body, including to disease sites. Once these small molecules enter a site where the pathological enzyme is expressed and active, the protecting groups are removed, triggering rapid oligomerization leading to polymer nanoparticle formation. The nanoparticle aggregates at the disease site display strong PAI signal (the “on” state), while small molecules in the rest of the body, still enzymatically uncleaved, remain in the “off” state. This modular approach means that one can probe for any enzyme of interest simply by exchanging the short peptide for a sequence cleavable by the desired enzyme. This strategy was implemented in the detection of the protease furin, a key regulator of tumor progression and metastasis, in a mouse model of breast adenocarcinoma. PAI clearly showed that furin-positive xenograft tumors had a significant PAI signal over accumulation into furin-negative tumors (i.e., small-molecule accumulation is expected to be approximately equivalent to that in the furin-positive condition, but no oligomerization occurs, leading to low PAI signal in the control).371\nNanochemistries for Highly Sensitive PAI. The PAI subsection could fit easily within either the optical or acoustic nanomaterials sections. In our framework it fit better in the optical section because the key property that nanomaterials must display to be highly effective PAI contrast agents is that they must be excellent absorbers of light (i.e., have a very high optical absorption cross section). While nanomaterials have been used in PAI for a decade,44,372 recent nanochemistries have led to 100-fold or more improved sensitivities so that PAI can now detect nanomaterial concentrations at picomolar levels.373 Some of these nanomaterials are fairly innovative and distinctive for PAI, for instance, CuS nanoparticles and inorganic graphene analogues such as near-infrared absorbing TiS2 nanosheets.\n374 Others are adaptations of oft-used nanomaterials such as gold nanomaterials (which can be optimized for PAI by geometric modification, including spheres, rods, prisms, bipyramids, shells, stars, cages, and vesicles (see Figure 17)). Still others are combinations of known PAI nanomaterials with PAI-active dyes that together produce much-improved imaging properties.373 Nanosheets composed of TiS2, a member of the transition metal dichalcogenides including MoS2, WS2, WSe2, MoSe2, and Bi2Se3, were fabricated in a bottom-up fashion by Liu and colleagues using solution-phase chemistry via ethanol precipitation.375 These structures, like many other nanomaterials (e.g., nanotubes and graphene), were made biocompatible via PEG functionalization. TiS2 nanosheets (uniform and ∼100 nm laterally) behave optically in line with other intensely nearinfrared absorbing materials such as their dichalcogenide cousins with an extinction coefficient of 26.8 L/g·cm. This promotes strong PAI signal when imaging tumors in vivo. i.v. injection of TiS2−PEG nanosheets into tumor-bearing mice led to a 4.5-fold signal PAI increase by 12 h p.i. Given the recognized biocompatibility of Ti and low cytotoxicity displayed by the TiS2 nanosheets\n375 in combination with their excellent near-infrared absorption, these nanomaterials have a potentially promising theranostic futurein diagnostics with PAI and in therapeutics using thermal ablation due to their strong photonic absorption (see section 3.2). Gold nanomaterials, which have long been used in other modalities including optical and nuclear imaging, are being cleverly designed to absorb light by tuning their inherent and geometrically induced optical absorptions. By modifying the fabrication chemistry of the gold, the absorption can be tuned\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAL\nso that these nanomaterials can be used to perform PAI, leading to, for example, detection of cancer and atherosclerotic plaques, brain function measurements, and image-guided therapy. A great deal of power emerges with a small set of similar protocols as relatively minor modifications give rise to widely varying shapes of gold. This is true partially because of the flexibility of the general mechanism by which gold nanoparticles are grown, as gold seeds/nanorods with ionic character grow via reduction of metal ions onto their surface. This basic protocol allows preferential growth in a crystal facet under certain conditions. Many gold nanoparticle chemistries begin with nucleation using spherical gold seeds, ∼1.5 nm diameter single crystals that are generated via the reduction of chloroauric acid by borohydride with CTAB.376 Gold nanorods, for example, are formed from the seeds in an Au(I) growth solution that includes chloroauric acid mildly reduced by ascorbate in addition to AgNO3 and CTAB. Gold nanorods of various aspect ratios can be obtained from this protocol, ∼10− 20 nm diameter and up to 300 nm in length in fairly high yield; the range of aspect ratios can be generated by varying the amount of AgNO3, the number of gold seeds, or the gold ion concentration. Modifying either the ratio of gold seed to gold salt or the relative concentrations of impurity ions (in the sense that they are nongold ions in the gold nanorod) can be used to regulate crystal growth and the nanorod aspect ratio. Gold seeds nucleate nanorods, and nanorods in turn have been used to nucleate growth of more exotic shapes such as rhombic dodecahedrons, octahedrons, and cubes (see Figure 17).376 Once reactions are set up, the final gold nanomaterial geometry/anisotropy is often determined by the amount of time allowed for a reaction to take place, by mixtures of single crystal or defect seeds, or by the concentration of seeds in the solution,377,378 as well as by the preferred crystallographic growth direction (which can, for instance, be controlled by\npreferential aldehyde/ketone adsorption in the solution phase376,379). Aside from these methods, electrochemical and metal-deposition strategies are also available to construct gold nanomaterials. The latter approaches can be advantageous particularly when one wants to functionalize only a specific region of the nanomaterial, rather than the whole entity, as functionalization can be performed when gold is still on a solid phase prior to release. Engineering the shape of gold nanomaterials is important for PAI because architectures with sharp surface features and strong intraparticle near-field coupling display intense near-infrared absorption (and due to their plasmonic character can also lead to efficient SERS contrast for Raman imaging; see section 2.4.3). Hollow gold nanocrescents and gold nanopyramids are good examples of such sharp-featured constructions.376 Nevertheless, the size of the gold nanomaterial is highly influential on its absorption properties as the optical molar extinction coefficient scales with the cube of its diameter. An interesting mechanism to transiently produce massive PAI signal was reported by Emelianov and colleagues in which they combined the advantages of perfluorocarbon nanobubbles with small gold nanorods61 by loading the nanorods inside the nanobubbles. Instead of the common approach of exploiting solely thermal expansion to generate PAI signal, they created an agent capable of thermal expansion in addition to vaporization to boost the signal substantially. Plasmonic gold nanorods were fabricated by a typical seed-mediated method and functionalized with dodecanethiol (an optical absorption shift verified the organic functionalization as in Figure 18c) to allow suspension in chloroform. After evaporating the solvent, the nanorods were briefly sonicated in the perfluorocarbon, perfluoropentane, and emulsified in bovine serum albumin (BSA). Extrusion of the product through a membrane with a 200 nm pore size resulted in 200 nm BSA-capped perfluorocarbon nanobubbles containing gold nanorods. While they were stable in circulation, the gold nanorod-loaded perfluoropentane nanodroplets superheated upon pulsed irradiation with a fluence of only a few mJ cm−2, triggering a liquid-to-gas phase transition. This led to their vaporization. The gold nanorods (40 nm × 10 nm) serve as the optical trigger to vaporize the perfluorocarbon nanodroplets upon photonic absorption, giving rise to three different contrast mechanisms (i−ii for PAI, iii for ultrasound): (i) liquid-to-gas vaporization transition of the perfluoropentane, (ii) prolonged thermal expansion of the gold nanorods, and (iii) acoustic impedance mismatch between the induced gaseous phase and the liquid microenvironment to create ultrasonic signal. Together, the PAI contrast mechanisms produced enormous contrast when the nanomaterial was injected into the pancreas of living mice. Compared to a contrast increase of ∼50% using gold nanorods alone, nanorod-filled nanodroplets displayed an ∼10-fold signal increase (Figure 18).61 One notable drawback to this approach, however, is that the contrast mechanism is irreversible and cannot continue to be imaged, as the act of imaging destroys the contrast agent. Multispectral optoacoustic tomography (MSOT), a multiwavelength version of PAI in which nanomaterials or chromophores are spectrally identified in tissue over background tissue absorption, can exploit differential absorption properties of nanomaterials.380,381 While MSOT is being used to spectrally distinguish multiple native in vivo absorbers such as hemoglobin and melanin, a potentially exciting subfield involves also discriminating multiple different nanomaterials\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAM\nbased on their differential photonic absorption. In this vein, optimizing MSOT requires use of nanomaterials/labels with steep absorption curves that can be resolved by scanning narrow spectral bands.381 This allows one to multiplex PAI with nanomaterials of varied absorption properties in combination with multiple excitation wavelengths. Precision tuning of differential absorptions via chemistry (e.g., by modifications to nanoparticle geometry) is one key aspect toward enabling multiplexed nanomaterial MSOT. However, while many studies have been performed in vitro and ex vivo, MSOT of nanomaterials in vivo has been hampered by the difficulty of accurately reconstructing multiple absorbers in highly heterogeneous tissues that include the various native absorbers. Chen and colleagues performed such a study with the development of chitosan-capped gold nanorods and gold nanostars, multiplexing them with MSOT by virtue of their differential shapedependent absorption properties.380 The two gold nanoparticles displayed offset MSOT absorptions by ∼70 nm, but their broad, overlapping absorption curves can make reconstruction challenging. Nevertheless, the group was able\nto perform in vivo pharmacokinetic measurements of both nanomaterials, showing and validating that, while the kinetic time-course curves of liver accumulation were similar, the splenic accumulation of gold nanostars was significantly higher, and cleared more rapidly, than for nanorods.380 Next steps may include demonstrating viable disease applications for MSOT, such as the ability to accurately unmix nanomaterials targeted to distinct sets of biomarkers that could be used to help diagnose disease. Still, future work in nanoparticle MSOT is likely to require improved nanochemistries to tune narrower nanomaterial absorptions, in conjunction with enhanced multispectral unmixing algorithms to ensure accurate reconstruction of materials in living tissues, especially at higher dimensions of nanoparticle multiplexing.\nNew Classes of PAI Nanomaterials. Unconventional PAI nanomaterials are beginning to emerge that are designed to make certain intrinsic nanomaterial properties beneficial. For example, one group asked what happens when an upconversion nanomaterial has a high absorption cross section, yet exhibits luminescence quenching at the chosen near-infrared wave-\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAN\nlength. Maji et al. chose to exploit what was considered an existing problemthat the doped lanthanide ion in upconversion nanomaterials can suffer luminescence quenching due to solvent relaxation in aqueous solutions.382 They realized that, rather than attempting to correct the issue and applying it for luminescence, if they instead enhanced the natural quenching, they could apply the material as a heat generator to provide PAI signal. Indeed, a high optical cross section, luminescencequenched nanomaterial can absorb considerable energy and display strong heat-generating capacity. Twenty-four nm diameter NaYF4 (doped with Yb\n3+ or Er3+) upconversion nanomaterials were generated with α-cyclodextrin inclusion complexes and stabilized with oleic acid (for aqueous solubility) in order to enhance the quenching effects and PAI signal. The authors i.v.-injected their doped upconversion nanomaterial, using PAI at a 980 nm excitation wavelength to image the accumulation in the thoracic region of the mouse 35 min p.i. with high contrast.382 Upconversion nanomaterials, traditionally a luminescent agent, thus represent yet another new class of chemically tuned PAI agents. Optical Nanomaterials Conclusion. Optical nanomaterials are playing an expanding role in translational optical imaging. Novel chemistries have increased the biocompatibility of these agents (e.g., generating biocompatible carbon and other qdots after conventional semiconductor qdots displayed toxicity), improved their signal reporter capabilities to substantially boost image contrast, and enhanced nanomaterial reproducibility and in vivo delivery properties. For these reasons, optical nanomaterials are entering clinical trials with increasing frequency. Notably, there are some common threads across the various optical imaging approaches, such as metallic particles including gold nanomaterials. This is because of their multifaceted, tunable interactions with light, allowing them to be highly efficient absorptive, plasmonic, and/or scattering contrast agents for in vivo imaging. This allows their widespread use across imaging and even therapeutic platforms, from optical coherence tomography and plasmonic (e.g., Raman) imaging to photoacoustic imaging and photothermal ablation (i.e., therapy)."
    }, {
      "heading" : "2.5. Acoustic Nanomaterials",
      "text" : "The primary modality applied in the realm of acoustic imaging is ultrasound. Ultrasonic technology has become a major clinical tool for soft-tissue imaging at high penetration depths due to its safety, low cost, and ease of operation. However, in other ways it cannot compete with nuclear and magnetic modalities as it images only a relatively small region of the body and cannot image bone or air-containing organs, necessitating selective use. The ultrasonic sound wave frequencies applied for both wave generation and detection in imaging are typically >20 kHz (>1 MHz for clinical use). Usually physicians apply pediatric ultrasound at ∼2−3 MHz and adults at 5−12 MHz, resulting in frequency-dependent spatial resolutions of ∼0.2−1 mm.105 The images are created based on the pulse-echo principle. Echogenic materials provide contrast in ultrasound by their ability to reflect and refract the sound waves. Extrinsic acoustic contrast has traditionally been the domain of larger microscale structures such as gas-filled microbubbles of ∼1−4 μm.75,383,384 These intravascularly injected structures can easily be directed to vascular targets but are constrained to the vasculature due to size. We refer the reader to recent reviews as their size puts them beyond the scope of this Review.75,383−385 Miniaturization of echogenic materials is being driven by a\ndesire to enhance tissue contrast extravascularly. We provide here an overview on the miniaturization of ultrasonic contrast agents prior to describing the few nanoscale acoustic contrast agents that have been used for in vivo ultrasonic imaging. Nanobubbles, silica nanoparticles, and nanotubes have all been developed recently for ultrasonic imaging. Unfortunately, because contrast interactions with acoustic waves require reflection, acoustic impedance mismatch, refraction, attenuation, or diffraction, nanoscale materials as defined (<100 nm in at least one dimension) are often poor alternatives to their larger relatives with respect to contrast strength. This poses a challenging technical problem in the field, a tightrope-walking maneuver as a palatable compromise is sought between the smaller nanosize regime for favorable in vivo biodistributions and kinetics is balanced by the need for sufficient echogenicity to enhance contrast. In particular, the EPR effect requires smaller nanomaterialsthe smaller the better to increase the likelihood of extravasation in a given tumor.17,386 However, even “nano”bubbles tend to be considerably larger (≥150 nm) than required by the conventional definition of nanomaterials, and thus in some sense perhaps a misnomer. Even scaling down to relatively large nanobubbles of 350 nm has required the development of new chemistries, e.g., a modified doubleemulsification solvent-evaporation procedure, to endow them with sufficient contrast at that size to be useful for in vivo imaging.387 One of the largest challenges is to avoid use of unstable gases, and even gases at all, in nanoscale ultrasonic contrast. Even in cases where very clever chemistries can multiply the number of interfaces available for acoustic interaction (e.g., a “rattle”-type mesoporous SiO2 architecture that provides double scattering/reflection interfaces in a single particle) within the material to substantially increase contrast enhancement,388 the diameter of these materials is still 100s of nm. For silica and similar glass-based nanomaterials, the contrast is produced by a slightly different mechanism than the bubblesthe inhomogeneity in the tissue of interest due to the nanomaterial displays a higher mismatch with the physiological environment than soft-shelled materials.389,390 Due to the mechanism, the vast majority of acoustic silica nanomaterials are also 100s of nm in diameter. Yang and colleagues produced a size series of hollow silica nanospheres from 100 to 400 nm.391 The silica nanomaterials were produced by a hard-template synthesis: polystyrene nanospheres (100−400 nm) were first fabricated via an emulsion polymerization, and then a 25 nm silica shell was grown on top by dropwise addition of tetraethyl orthosilicate (TEOS) under slight heat. The polystyrene was dissolved by soaking in hot tetrahydrofuran (THF) to create the hollow silica nanospheres. While the 100 nm silica nanomaterials produced ultrasonic signal at 6 MHz frequency, on a by-weight basis the 400 nm spheres produced such a sufficiently higher signal that the authors chose to focus on the 400 nm silica nanospheres.391 However, for clinical use in cancer detection, the need for extravasation will likely require smaller materials, whether higher-performance nanoscale silica or other materials to be developed in the future. One strategy to create such nanomaterials would be to provide the raw nanoparticle subunits that home to disease sites due to their very small size and self-assemble into active acoustic agents only after accumulationakin to the approach taken by the Rao group for nanoaggregation and activation of photoacoustic and other nanomaterials.371\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAO\nSmaller nanomaterials are being explored for their echogenicity, and some perhaps will need to be reengineered to achieve sufficient contrast in ultrasound. Surprisingly, a nanomaterial famous for its contrast and applications in many other modalities (e.g., optical, photoacoustic, etc.) was demonstrated to display ultrasonic contrast in vivo. Multiwalled carbon nanotubes (MWNTs), 20−30 nm in diameter and 400 nm in length and thus likely of dimensions able to extravasate from many diseased blood vessels, displayed detectable ultrasonic contrast in living animals such as mice and pigs.392,393 The strength of the signal observed was at the same level as clinically used sulfur hexafluoride microbubbles,393 yet the signal does not degrade, as rapidly occurs with microbubbles. However, it should be noted that very high concentrations of MWNTs were required to generate the high ultrasonic signalthe authors injected at a concentration of ∼1 mg/mL into the animals either directly into the bladder (5 mL, in pigs) or intravenously (300 μL, in mice). i.v. injection of MWNTs (commercially available and chemically functionalized for biocompatibility and targeting, Figure 19) targeted to PSCA\n(prostate stem cell antigen) via monoclonal antibodies led to high ultrasonic contrast in the mouse prostate tumor grown in the abdominal wall (see Figure 19b).392 However, the mechanism by which contrast is generated remains unclear comparing signal from degassed and nondegassed samples eliminated the possibility that the signal was derived from minibubbles liberated from inside the nanotubes. On the other hand, it is possible that the nanotubes may serve as the center of nucleation for air bubbles that generate the echogenic signal,393 rather than originating from the nanomaterial itself; indeed, in the preparation protocol to produce nanotubes, acoustic cavitation bubbles are typically used to help exfoliate MWNTs or SWNTs.394 It is not clear whether diagnostic ultrasonic pulses may have sufficient energy to produce such\nbubbles and whether the bubbles would be sufficient to generate the strong contrast observed. However, once the mechanism is uncovered, it may be possible to design new smaller nanomaterials for ultrasonic contrast or to increase contrast by intelligently reengineering nanotubes and similar nanomaterials. A completely new variety of agent was recently developed for in vivo ultrasound imaging.395 Gas nanovesicles are genetically encoded by certain bacteria to control their buoyancy. Shapiro and colleagues borrowed these gas vesicles by purifying them from bacteria and prepared them for injection into mice for ultrasonic imaging. Many of these protein-shelled (shell thickness of 2 nm) vesicles are in the nanoscale range, at 45−250 nm in width and 100−600 nm in length. However, it is likely that the majority of the ultrasonic signal is derived from the larger end of the vesicle diameter range. The vesicle properties, such as shape and size, are potentially tunable via genetic engineering of their corresponding sequence. While the authors show that these vesicles are imageable with ultrasound upon intravenous injection into mice in vivo and are highly stable unlike many of the nanobubble alternatives,395 a major feature of the advance is the potential for the first genetically encoded ultrasound reporter strategy for mammalian cells. A wholly new ability to image cells with ultrasound could thus result from transducing selected cells with the gene vectors encoding the gas nanovesicles. Expression of these nanovesicles could, for instance, allow easy and cheap clinical tracking of injected stem or other cells to ensure that they are in the appropriate location, are alive, and are at the appropriate quantity in vivo."
    }, {
      "heading" : "2.6. Nuclear Nanomaterials",
      "text" : "Nuclear nanomaterial-based imaging approaches, like those of magnetic nanomaterials, offer the ability to image through the entire depth of the human body. Therefore, they are generally applicable to visualize any site one might wish to image within the body, including bone, soft tissues, and regions containing air such as lungs. Imaging of nuclear nanomaterials is principally performed with γ imaging (a), positron emission tomography (PET) (b), single-photon emission computed tomography (SPECT) (c), and computed tomography (CT) (d) (Figure 20).396−399 Nuclear nanomaterials for imaging are defined as either nanomaterials decorated by radioisotopes that can be detected and imaged based on radioactive decay or those which can attenuate high-energy radiation to help form contrast in an image.\n2.6.1. Radioactive Nanomaterials. Essentially any type of nanoparticle can be labeled with radioisotopes, which can be used to sensitively localize their site(s) of accumulation. Upon accumulation at a target site, radiolabeled nanomaterials produce many radioactive decays that are detectable by γ imaging, PET, or SPECT. A major advantage of radioisotopic nuclear imaging is the ultrahigh sensitivityonly “trace” amounts of materials are required to produce ample signal. Nanoparticle-based assays in vivo can be accompanied by targeting to produce function-specific imaging probes that can quantify the concentration of biomolecules such as proteins. Elevated expression of the protein ICAM-1 (intercellular adhesion molecule-1), for instance, is indicative of inflammation. Therefore, nanoparticles bearing targeting antibodies directed to ICAM-1 can localize at and potentially identify inflamed sites, e.g., an arthritic joint.396 When the radioisotope125I is linked to gold nanorods,396 an easily detectable γ-\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAP\nray emission signal can be imaged via γ imaging. Conceptually perhaps the simplest form of nuclear imaging, γ imaging is fairly similar to optical imaging, with the caveats that (i) γ photons can travel much further distances than visible and near-infrared photons depending on their energy and the density of the material traversed and (ii) γ photons are detectable only by γ cameras. These cameras consist of scintillators that transduce γ photons into a burst of photons detectable by standard photomultiplier tubes and a 2-dimensional image is thereby created similar to standard fluorescence imaging. Thus, a spatial map of photon counts is generated, e.g., Figure 20a, in which the arthritic joint of a rat can be differentiated from nonarthritic joints on the basis of ICAM-1 expression.396 This imaging approach is useful as ICAM-1 is an early molecular indicator of arthritis, potentially allowing early detection of arthritic joints that could lead to preventive treatments and lifestyle changes in patients. The imaging technologies SPECT and PET eventually arose from basic γ imaging via the development of rotation gantries and computational algorithms for image reconstruction. SPECT is essentially the three-dimensional equivalent of γ imaging, detecting single γ photon emissions typically using 1 or more rotating γ cameras to accumulate data for the third\ndimension. However, the most common modality used for imaging nuclear nanomaterials is PET (based upon a PubMed search of relevant terms using search terms such as “X-ray” “computed tomography” (nanoparticles or nanomaterials) and “in vivo” or “living animal” or mouse or mice in relevant combinations, 259 hits for PET-related nanomaterials, 84 for SPECT-related, and 214 for CT-related were identified). This is due to PET’s high sensitivity and precision spatial quantitation capabilities, as well as its major role in diagnosing and monitoring human disease. Notably, primarily due to improved nanochemistries, there has also been much recent activity in CT-directed nanomaterials (described in section 2.6.2). The central tenet of PET is that a radioactive isotope decays via ejection of a high-energy positron, the location of which is detected indirectly by using sophisticated algorithms to localize the two γ photons produced by the annihilation of the positron with a nearby electron.53 The γ photons are emitted ∼180° apart, which can be used not only to help spatially localize events but, with good time resolution, can also validate their authenticity. The source of PET’s sensitivity is that so many of the radioactive decays, each from a single atom, can each lead to a detectable signal. Therefore, a major advantage for PETbased nanomaterials is that they can carry a large payload of isotopes to the proper site, reducing even further the trace amounts of radioactive materials required in PET imaging; moreover, their high surface-to-volume ratio often allows high loading capacities for not only radioisotopes but other diagnostic agents (see Multimodal section, section 3.1), therapeutic agents (see section 3.2 for theranostics), and targeting ligands capable of directing the nanomaterial to a particular site. After the choice of the nanomaterial for PET imaging, which should be dictated by parameters such as toxicity, circulation half-life, and targeting efficiency, the two key design considerations are (i) which radiolabel to use and (ii) how to incorporate the radiolabel into the nanoparticle. The choice of radiolabel is determined by the physical characteristics of the isotope such as the positron energy (which dictates its travel distance in tissue and thus the spatial resolution of the resultant image), the decay half-life, and the efficacy of the radiolabeling approach.400 Nanomaterial radiolabeling strategies, which must optimally be robust, safe, rapid, and efficient, can be classified into four main categories: (a) chelation (radiometal ion complexation reactions with chelators through coordination chemistry); (b) hadronic projectile bombardment of nanoparticles prepared with radioactive atomic precursors; (c) direct synthesis (of natively radioactive nanoparticles using radioactive and nonradioactive materials); and (d) chelator-free postsynthesis radiolabeling (see Figure 21).400\nChelated Nanomaterials. Nanoparticles have traditionally been decorated with radioisotopes through chelation chemistry.400−402 Small-animal PET imaging is often used to evaluate nanomaterials of all varieties (optical, magnetic, etc.) designed for eventual clinical translation. This is because the gold standard approach to dynamically and quantitatively understand nanoparticle biodistributiona key step for eventual regulatory approvalis to radiolabel them and perform PET. Previously, one had to sacrifice mice at each time-point, remove organs, and perform γ-counting, which is expensive, timeconsuming, and wasteful of mice. With PET, we can now derive quantitative understanding of nanoparticle biodistribution over time in the same animals, which makes this strategy also statistically superior. Representative of this paradigm is the\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAQ\nchelation-based radiolabeling of Raman nanoparticles with 64Cu (decay half-life 12.7 h) to track differences in their biodistribution depending on whether they are injected intravenously or intrarectally.403 Because the expected route of administration in eventual human use was intrarectal, it was of critical importance to demonstrate that rectally administered nanoparticles do not emerge from the colon and spread through the body; this was quantitatively demonstrated up to 24 h through dynamic PET imaging.403 An important consideration is that chelators can suffer from issues of radiolabel detachment, which can lead to transchelation of endogenous proteins that may lead to erroneous interpretation of probe localization.404 Indeed, radiolabel stability, i.e., remaining attached to the nanoparticles, is critical for accurate quantification of nanoparticle distribution, because free radiolabel is cleared very quickly and may pool in the thyroid (e.g., iodine) or liver (e.g., Cu) or be excreted via the bladder.405 Varied excretion of free radiolabel and their degradation products thus convolute studies of nanoparticle biodistribution. New methods have thus been developed to improve stability. Louie and colleagues, for instance, developed a bifunctional chelator to label silicon-based quantum dots with 64Cu with ultrahigh stability. A commercially available form of DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), typically used for complexation of the 64Cu ion, displayed steric hindrance leading to unstable radiolabel attachment. Instead, a more flexible bifunctional linker arm was synthesized to replace DOTA, termed DO3A (1,4,7,10-tetraazacyclododecane-1,4,7triacetic acid, which is also clinically approved). The improved sterics facilitated a highly stable complex with minimal-to-no loss of radiolabel upon chelation to silicon quantum dots. Hence, when the authors demonstrated the renal and hepatic clearance of these nanomaterials in vivo via PET (see Figure 22), they were certain that it was in fact the nanoparticles clearing both renally and hepatically and not two different mechanisms corresponding to a combination of radiolabeled nanomaterials and free radiolabel alone.401 Indeed, when choosing nuclear probes, including nanomaterial-based probes to be translated into clinical use, two key parameters in the regulatory approval process are the stability and excretion pathways.406\nFor oncologic applications, Yang and co-workers developed a 64Cu nanoparticle chelate using a smaller relative of DOTA, NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid), and targeted them using cRGD,402 an integrin-binding peptide enabling targeting to the neovasculature and the tumor cells. For cardiology applications, nanomaterials can be targeted to macrophages as a proxy to assess plaque inflammation407,408 or to detect rejection of cardiomyocyte allografts.409 Macrophages and their precursors are heavily implicated in the immune response directed to these clinical conditions, in fact serving as inflammatory harbingers of the underlying pathologies. Thus, by chelating, for instance, 64Cu or 89Zr (using the chelator desferoxamine,407 decay half-life 78.41 h for 89Zr) to the nanomaterial’s polymer coating, and with macrophages likely at the disease site phagocytosing the nanoparticles, one may use PET to evaluate and dynamically track the biological evidence of these cardiac problems. Nuclear nanomaterials can be used not only for monitoring a site of disease but also for cell tracking (e.g., stem cells or immune cells for immunotherapy), i.e., to track the location and quantity of cells injected into the body.410 There is generally little difference in how the nanomaterials are prepared\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAR\nfor cell tracking as compared with injectable systemic applications. For instance, Cooper and colleagues chelated 64Cu via DOTA to gold nanoparticle constructs, which were externally loaded into cells.410 In cell-tracking applications, the nanomaterials must first be easily engulfed by cells in culture for efficient loading of radioactivity. In adoptive T cell therapy, an immunotherapeutic strategy with very high potential, cytotoxic killer T cells engineered with specific tumor-killing abilities are injected into cancer patients.411 However, once these cells are injected, their biodistribution is unknown. PET imaging approaches offer whole-body visualization. In our example, 64Cu-gold nanoparticles report back on the approximate quantity of T cells and their localization within the body.410 This ensures they are in the correct site(s) to perform their intended function at disease (tumor) sites and that they are not deposited at inappropriate sites to minimize off-target effects. Nanomaterials offer several key advantages over the more conventional choice of small molecules for nuclear imaging. For example, building up from molecules to nanomaterials with carefully controlled free radical polymerization chemistries, the Hawker group directly demonstrated the advantages of nanomaterials by comparing the behavior of small-molecule constituents of the nanoparticle with the assembled nanoparticles.412,413 These nanoparticles were constructed from linear copolymers each containing a hydrophilic PEG outer segment, a hydrophilic inner segment containing functional groups, and a hydrophobic gel central core segment. Assembled nanoparticles (star copolymers) were covalently connected in the central core, and the inner segment’s functional groups were used to link PET agents, in this case to chelate 64Cu via DOTA (Figure 23). The nanomaterial size was dependent on PEG length, varying from ∼25 to 70 nm in hydrodynamic diameter. In this study, the nanoparticles significantly outcompeted small molecules on key parameters such as blood circulation half-life (assembled nanoparticles had circulation half-lives approximately an order of magnitude longer than the individual polymer strands, increasing the likelihood of nanomaterial binding to target due to many more passes across target sites). Moreover, precise variation of PEG length and number of linear copolymers per nanoparticle enabled the authors to limit the accumulation in clearance organs such as the spleen and the liver. This highly controllable chemistry illustrates the ability to precisely tune pharmacokinetic profiles and MPS organ uptake based on assembling nanomaterials and engineering the small-molecule constituents. Of course, for some applications such nanomaterials may also have limitations compared with small-molecule agents: for example, if the decay half-life of the radioisotope is very short, one might prefer the very short circulation half-life of small-molecule agents. Intrinsically Labeled Nanomaterials. Intrinsic radioisotopic nanoparticles have recently begun to replace chelation chemistries.404 This transition has arisen because large complexation agents (chelates) can adversely modulate the pharmacokinetics of nanomaterials in vivo, the chemistries can be costly and inefficient, and they can sometimes suffer from poor radiolabel stability. The most straightforward and widely used procedure for creating intrinsically labeled nanomaterials is by adding trace levels of hot (radioactive) precursor material with cold (nonradioactive) material.404 In PET imaging, this sort of intrinsic radiolabeling most commonly incorporates 64Cu. This can take the form, for instance, of a metathetic reaction between a radioactive salt (e.g., 64CuCl2) and a\nnonradioactive salt (e.g., CuCl2) in the presence of Na2S and heat to create [64Cu]CuS nanoparticles that integrate the radioactive isotopes into their core structure.414 Similar reactions can be used to generate [64Cu]Au and 64Cu−Fe3O4 nanoparticles415,416 that are not only useful as nuclear, PETimageable nanomaterials but could potentially be multimodal as they are detectable by plasmonic and magnetic imaging modalities, respectively (as described in multimodal imaging strategies in section 3.1). In the latter case of 64Cu−Fe3O4 nanoparticles, 64Cu (and other radioactive metal ions such as 89Zr and 111In) can be integrated into the nanoparticle structure simply by mixing the radioactive metal salts with native iron oxide nanoparticle cores and heating to produce intrinsically radioactive nanomaterials. The appropriate isotope is typically chosen based on the desired radioactive properties, e.g., a decay half-life from 12.7 h (64Cu) compared with 64.02 days (111In),416 depending on their intended application. Longer half-lives are excellent for imaging longer-circulating nanoparticles and nanoparticles that one expects to image dynamically over the long term in tissues. For nanoparticles with shorter circulation times, 18F (decay half-life of 110 min), for example, can be used as the nanoparticle’s radiolabel as 18F can be “trapped” via an inorganic reaction between lanthanide cations and 18F anions.417 Therefore, one could engineer a short-circulating nanoparticle for short half-life isotopes to try to clear background signal quickly and improve target-tobackground ratios as is typically done for conventional smallmolecule nuclear studies; alternatively, one could engineer medium-to-long nanoparticle circulation half-lives for longerlived isotopes to maximize total specific targeting and be able to\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAS\nscan dynamically the signal localization at relevant time points. For instance, if a target is present in vasculature and on tumor cells, as is the case with some integrins, different time points (and thus different radioisotopes) are pertinent for imaging vasculature versus imaging the tumor cell surface.19\nHadronic Activation of Nanomaterials. Another intrinsic method activates radioactivity in nanomaterials as part of the nanoparticle-synthesis process. In this context, activation means creating a hot (radioactive) nanomaterial from the cold nanomaterial via hadronic bombardment of the nanomaterials. Because the nanoparticles are already fully fabricated, this strategy can be valuable for several reasons: (i) One can generate isotopes with very short half-lives and rapidly image them in the body because no synthetic steps remain. Llop and colleagues demonstrate this elegant paradigm by bombarding Al2O3 nanoparticles with protons.\n418 Thus, they converted many 16O atoms into 13N throughout the crystal lattice of the nanoparticles (a 16O(p,α)13N nuclear reaction). They imaged the tail-vein-injected short-lived 13N isotope-based (9.97 min half-life) nanomaterials in mice using PET. (ii) As long as they are stable in solution, the nanomaterials can be rapidly activated as needed. For instance, a very large batch can be synthesized, and experiments could be performed after irradiating only the amount needed per experiment. (iii) Because the radioactive atoms are embedded within the nanoparticle, the signal they\nproduce is guaranteed to be representative of their location as opposed to other strategies in which the radiolabel can detach. The limitations of this approach, however, suggest that it be applied only on a case-by-case basis because issues such as collision-induced nanoparticle damage or structural/material weakness (due to the fact that the resultant atomic species is often different from the original) can in some cases render the nanoparticles poorly suited for in vivo use.419\nChelator-free Postsynthetic Nanomaterials. In an example of postsynthetic chelator-free labeling, Liu and colleagues recently integrated several self-assembly approaches to create PET-imageable nanomaterials.420 In this case, defect sites in the nanomaterials actually permitted the chemistries necessary for their construction. To create the nanostructure, iron oxide nanoparticles were self-assembled onto MoS2 nanosheets via sulfur defect sites on the MoS2 surface,\n420 which were caused in part by nanosheet exfoliation. The nanosheets were subsequently radiolabeled with 64Cu via adsorption onto the MoS2 surface due to the affinity between Cu2+ ions and S at Mo defect sites. The adsorption-mediated approach was surprisingly radiostable, at ∼80−90% stability after 48 h incubation in serum (see Figure 24a−e)420 in comparison to, e.g., a chelatorbased 64Cu-nanoparticle labeling approach that displayed ∼70− 80% stability under the same conditions (Figure 24g−i).421\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAT\nPET vs SPECT for Nanomaterial Imaging. A number of reviews have covered the differences between the physics and advantages of PET versus SPECT as clinical/preclinical imaging modalities,422,423 but none have specifically examined the differences through the lens of nanomaterial-based approaches. While SPECT detection efficiency and spatial resolution is degraded compared to PET, a major advantage of SPECTthe ability to multiplex for simultaneous detection of multiple different targetshas yet to be exploited using nanomaterials. In the context of nanotechnology, SPECT has typically been used to track the biodistribution of atherosclerosis- and cancerdirected nanomaterials in living subjects,154,424−429 but these studies do not exploit the full potential of SPECT: the ability of SPECT to discriminate which isotope is present based on the characteristic energies of emitted γ photons provides the platform for multiplexing different nanomaterials. For instance, one could differentially radiolabel several different nanomaterial types, each optimized for a different protein target, and inject them together to simultaneously image a multiplexed constellation of disease targets. Alternatively, one could simultaneously track the biodistributions of several types of nanomaterials in the same animals, decreasing the animal numbers needed and allowing direct comparison within each animal. Such multiplexed nanomaterial systems are likely to become increasingly important as physicians seek to minimize false positive and negative disease diagnoses and improve accuracy by concurrently identifying and quantifying key sets of multiple biomarkers. Imaging Screens: False Positives/False Negatives. One of the primary reasons that imaging scans are developed is for disease screening. However, these scans are not foolproof due in part to biological and interindividual heterogeneity. The errors involved in screening are typically quantified as false positives and false negatives. When one is diagnosed with a disease (positive) but does not actually have it (false), the false positive error occurs. In the field of nanomaterial-enhanced in vivo imaging, a false positive can be caused by nonspecific uptake of a nanomaterial contrast agent. Such uptake could be due to unexpected trapping of the agent, nonspecific sticking to a site, or even to molecular activity (meant to be detected by\nthe agent) present in the body that resembles, but is not representative of, that of the disease. Patients in certain circumstances may exhibit elevated false positive rates: for example, once therapy has begun, treatment-related effects such as infection or thymic hyperplasia can lead to false positives as may occur in PET/CT imaging.430 False positives in clinical imaging can have grave effectsthey lead directly to overdiagnosis and an accompanying host of problems. For instance, if the imaging results are used to diagnose disease or plan treatment, these errors can lead to superfluous biopsies and in some cases even (toxic) therapy on healthy individuals. Not only do unneeded biopsies and therapies exert great human costs, triggering morbidity and toxicity in healthy populations (as well as the psychological trauma and anxiety of believing one has a disease that one does not have), but they also result in high unnecessary financial costs. False negatives, on the other hand, are the inversea patient has the disease but tests negative for it. These errors lead to underdiagnosis and come with their own set of challenges, including the elimination of the ability to treat the disease at an earlier stage when it is more likely (in many cases) to be more amenable to treatment and survival rates are much better.431\nClearly, false positives/false negatives must be minimized. However, even once false positives/false negatives are reduced to acceptable levels, an imaging/screening test must pass another hurdle to be considered clinically useful. It must not only reliably detect the disease but also must improve patient mortality (for example, in cancer, a screen might determine that an ambiguous lesion is malignant rather than benign; that diagnosis must then be actionablesuch as with surgery or chemotherapywith an intervention that significantly improves the patient’s lifespan).432−434 Therefore, even if the screen is scientifically valid and successful, if it is not actionable and does not decrease patient mortality, it will not be perceived as clinically successful. Notably, the screen’s status can change as treatment landscapes transform.\nRadiolabeled Nanomaterials in the Clinic. C dots, a silicabased nanomaterial intended for optical and nuclear detection in human applications, have recently been radiolabeled and injected into patients, marking the first time humans have been\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAU\ninjected with radiolabeled nanomaterials.435 The uptake was specific and promising in the small, unblinded cohort of N = 5 metastatic melanoma patients with poor prognosis that have thus far received the nanomaterials. These nanoparticles were generated using the well-known Stöber silica condensation process436 and targeted to cancer using a cyclic RGDY peptide (Arg-Ala-Asp-Tyr) sequence that is linked to the nanoparticles via PEG.35 The nanoparticles are not themselves directly radiolabeled, but rather the cRGDY sequence is radiolabeled with 124I in an electrophilic substitution to a side-chain hydroxyl in the tyrosine residue using the iodogen (1,3,4,6-tetrachloro3α-6α-diphenylglucoluril) oxidizing agent.35 The C dot radiolabels were fairly stable, with only 2.5% of total activity coming from free 124I at 24 h postinjection.435 However, it is likely that the radiostability could be improved significantly in the future if an intrinsic radiolabel mechanism were used, because the nanomaterials themselves proved extremely stable to degradation over 2 years in water. For instance, one could choose any of a number of oxophilic radioisotopes to intrinsically label silica nanomaterials with isotopes of the appropriate half-life.437 Use of 124I (decay half-life 4.2 days) in the C dots allowed detection of the signal for several days (at least 72 h in this prePhase I study) after administration, which permitted time for clearance of nonspecific nanoparticles to remove background activity and more accurately image specific accumulation19,35,435 as illustrated in the human images of nanomaterial PET-CT imaging in Figure 25. While injection of 2 × 1015 silica nanoparticles into the 5 patients showed successful PET imaging of the metastatic tumors, unfortunately efficient targeting of the nanomaterial remains a concern. The cRGDY peptide targeting led to 1.78 × 1011 of the silica nanoparticles localizing in the tumor site, ∼0.01% of the injected dose.435 While this may be sufficient for clinical imaging in many patients, improved targeting ligands or more efficient mechanisms to transport the nanomaterials into the tumor may ultimately be required to optimize imaging for all patients. Ongoing clinical trials for this probe will help determine whether it is sufficient (currently recruiting patients, identifier NCT01266096). Recently, a new polymeric nanomaterial that relies on controlled self-assembly of functional polymers was approved to begin clinical trials for detection of heart disease.438 The simplicity and safety profile of the comblike polymer nanoparticle led to a fast track toward clinical applications. Detailed design of the functional components enables the coordinated interplay between hydrophilic and hydrophobic components, resulting in assembly in aqueous solutions. The nanomaterial, which uses a specific peptide to target chemokine receptor 5 (CCR5) overexpressed in late-stage atherogenesis,438 has been slated to be injected into patients in clinical trial NCT02498379. The particles are formed by blending the radioisotope-containing hydrophobic segment (poly(methyl methacrylate) (PMMA)) conjugated to the DOTA chelator with the hydrophilic segment (a poly(ethylene glycol) containing the targeting peptide). The hydrophilic PEG and hydrophobic methacrylate were joined, after which the comblike nanoparticles were polymerized and the nanoparticles were permitted to self-assemble (see Figure 26). To perform PET imaging, 64Cu was chelated to the DOTA prior to imaging. Inflammation caused CCR5 overexpression in the plaques, which resulted in specific plaque accumulation of the CCR5-targeted comb nanoparticles 2−4-fold higher than to various controls depending on time pointlater time points\nallowed nonspecific nanoparticle clearance, so that the final 48 h time point displayed the highest plaque-to-control intensity ratio.\n2.6.2. Nanomaterials for Computed Tomography. Xray computed tomography (CT) is an imaging technology that can image nanomaterials that attenuate high-energy radiation.154,439,440 While conventional X-ray scanners are 2- dimensional, CT applies computational algorithms to transform the absorption of X-rays passing through many angles of a body into high-resolution, three-dimensional images of the internal structures. CT has long been a common technique in clinical imaging, used traditionally for bone imaging due to the high contrast between bone and soft tissues. This is because CT easily distinguishes between electron-dense structures (high-Z materials, e.g., bone) and relatively electron-poor entities (e.g., soft tissues). However, its soft-tissue contrast is quite poor; therefore, to generate soft-tissue contrast, extrinsic contrast agents are required. These agents can be chosen intelligently based on the physics of an X-ray passing through a certain medium, which is described by the Beer−Lambert Law:\n= χ−I I e k0 where I0 and I are the intensities of the input and outgoing Xrays, respectively. k represents the absorption coefficient, and χ is the length of the medium through which the X-rays pass.399 Thus, denser materials (e.g., gold over iodine) with higher absorption coefficients make better nanomaterial contrast structures. Contrast can be derived from differences in material atomic number; the dominant factor for the mass attenuation coefficient is the photoelectric effect, which is approximately proportional to the fourth power of the Z (atomic number) of the material. Thus, for nanomaterial imaging, by far the simplest way to increase contrast/signal is to increase nanomaterial Z. However, it is possible to increase contrast further by tuning the energy of the X-ray photons applied for a particular material to match the minimum energy necessary to ionize the outer K shell electrons, creating a resonance absorption. This increases the effective absorption coefficient of the material. Therefore, understanding the physicochemistry\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAV\nof the nanomaterial matched to the X-ray energy allows optimization of the contrast regimen to minimize the nanomaterial amount injected and/or the total incident X-ray energy to the imaged body. For the sake of patient safety, minimizing radiation exposure is one of the goals of both improving CT efficiency and the use of nanomaterials. Taking gold as an example, the minimum energy of ionization is 80.7 keV. Thus, due to the K-edge absorption of gold, X-rays of energy greater than 80.7 keV are considerably more efficient for generating image contrast than those of lower energy.441\nApplications for CT Nanomaterials. Nanomaterials can make compelling CT contrast agents because they can carry a high-contrast payload (necessary for CT compared with the more sensitive PET/SPECT nuclear imaging modalities that require only trace amounts of material), circulate for long periods of time, and can easily be fabricated with the requisite electron-dense contrast materials. Due to the long circulation times of nanomaterials, delineation of soft tissues such as the vasculaturei.e., blood pool agentshas become a major application of CT. Such sharp demarcation of the vasculature throughout the entire depth of the body can facilitate early detection of structural and functional vascular abnormalities.439 Nanomaterials make optimal blood pool agents in part because they provide improved sensitivity and specificity compared with small molecules, but particularly because they can be chemically tailored for circulation times as long as a few days. For example, Yin and colleagues use a simple polyaddition chemistry to generate an iodine-based nanomaterial that yields much longer circulation times (see Figure 27b), increased tumor retention time, and 36-fold higher contrast at the tumor site (Figure 27c, at 4 h p.i.). These enhanced circulation times and contrast allow both improved diagnostic accuracy and imaging of the blood pool over multiple days without multiple contrast administrations. By cross-linking iohexol with hexamethylene diisocyanate and then nanoprecipitating with mPEG (Figure 27a), the authors were able to help minimize issues such as low loading efficiency typical of small-molecule grafts complexed to nanoparticles442 and undesirable burst release kinetics characteristic of solid polymeric nanoparticles (Figure 27). Thus, using the same source materials, the team was able to demonstrate much longer circulation times for nanoparticles compared with the small-molecule form. Nanomaterials are therefore a more optimal choice when designing blood pool agents as their size and tunable surface chemistry enables them to extend circulation times from minutes for conventional agents to tens of hours or even days.439 Not only do size and surface chemistry play a role in avoiding MPS uptake but perhaps surprisingly nanomaterial anisotropywhich has not yet been extensively studiedappears to also increase the circulation time.443,444\nMany nanomaterials are naturally taken up by macrophages, meaning they tend to accumulate in the liver,442 spleen,445,446 and lymph nodes.447 Thus, macrophage targeting of CTimageable nanomaterials facilitates imaging of these organs.439 Targeting of macrophages and their precursors can also be used to target diseases, such as atherosclerosis and cancer.3,199 This is because the response of the body to such diseases is to become inflamed, driving many monocytes/macrophages to the site as part of the immune response. The high local macrophage density is ideal to allow targeting of these diseases. While PET and MRI have been used to image atherosclerosis with nanoparticle contrast, the scan times can be very long, which presents problems due to chest movement from breathing. CT\nis advantageous as complete heart scans can be performed within seconds. Thus, plaques, particularly vulnerable plaques (i.e., vulnerable to rupture and catastrophic occlusive thrombosis) rich in macrophage content, can be imaged by macrophage-targeted CT nanomaterial agents.3,448 In cancer, on the other hand, contrast nanomaterials are typically directed to cancer cells rather than macrophages simply because there are generally many more cancer cells than macrophages present at the disease site.3,449 Reuveni and colleagues, for example, targeted 30 nm gold nanoparticles to squamous cell carcinoma cells using antibodies to epidermal growth factor receptor\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAW\n(EGFR) overexpressed on the tumor cells.450 While the tumor was completely undetectable sans contrast, at 6 h postinjection of the targeted gold nanoparticles the tumor was easily identifiable via CT imaging (Figure 28). However, because\nthe molecular signature on the surface of cancer cells is highly heterogeneous especially across individuals, the more homogeneous markers on myeloid-derived cells such as macrophages (both within individuals and across the populations of each species, including humans) may ultimately prove more optimal for efficient cancer uptake unless the patient population can be prestratified on the basis of their cancers’ molecular markers.3,199\nInterestingly, although several gold nanomaterials have been introduced into humans, e.g., Aurimmune and Auroshell451,452 as therapeutic agents, none have thus far been directed to CT imagingthough not owing to lack of effort.439 The critical issue in nanomaterial CT is a lack of sensitivity. The minimum detectable concentration difference between target and background is on the order of mMestimated to be 5.9 mM for gold.453 Thus, the key bottleneck aside from safety/toxicity is the total accumulation of nanomaterials into the target site, making agent delivery perhaps the most important factor driving the viability of CT nanomaterials as clinical diagnostic agents. Nanomaterials for Multiplexing CT. Other high-Z nanomaterials apart from gold also make potent CT agents, including lanthanides (e.g., Gd, Eu, and Yb) and heavy metalbased agents such as Ta (Tantalum) oxides and Bi (Bismuth) sulfides.454 A major use for these other agents involves some of the latest CT imaging advances, particularly spectral CT. Traditionally in CT one can visualize up to one parameter at a time with a contrast agent. Spectral CT opens new avenues in molecular imaging, for example, by distinguishing materials based on their K-edge electron characteristics.455 However,\nbecause of the mechanism underlying spectral CT, nanoparticles must be loaded with huge metal content. In particular, each X-ray must typically be detectable by dedicated detectors that then stratify their energies into different energy bins. In this fashion, one can simultaneously multiplex two or more different metals by identifying and quantitatively imaging each metal (sans background signal) by exclusive identification of their K-edge (i.e., the binding discontinuity in the attenuation cross sections456). Thus, not only can spectral CT allow discrimination between natural high-Z materials such as bone or teeth and nanomaterial contrast (e.g., Yb) in living subjects,456 but critically it also has the potential to multiplex different nanoparticles in the living body to potentially observe diverse functional characteristics such as the expression of different proteins within the same scan."
    }, {
      "heading" : "2.7. Adaptable Nanomaterials",
      "text" : "While we have touched on adaptable nanomaterials in previous sections, we define and describe their general use here. In particular, while a feature of many nanomaterials is their flexibility and modularity in chemical design, a defining characteristic of adaptable nanomaterials is that they are essentially imaging modality (and/or therapy) agnostic. This does not preclude the fact that some adaptable nanomaterials may display intrinsic imaging potential (e.g., luminescence from porous silicon; see section 2.7.3). One may carve out an adaptable nanomaterial’s utility for a particular imaging modality by incorporating smaller, intrinsically imageable nanomaterials or molecules (e.g., fluorophores, dyes, Gd, nuclear isotopes, iron oxides, etc.) within them; adaptable nanomaterials are carriers that can be loaded with one or more of nearly any diagnostic/therapeutic material. Examples of common adaptable nanomaterials include lipidic (liposomes, micelles, etc.), polymeric, silicate, and natural nanomaterials, and while we have already mentioned some of them briefly, we explore here their latest developments for in vivo imaging.\n2.7.1. Lipid Nanomaterials. The literature surrounding lipidic nanomaterials is vast, in part because they have been studied since their discovery in the mid-1960s. The most commons forms of this nanomaterial class include liposomes, micelles, solid lipid nanoparticles (SLNs), nonlamellar lipid liquid crystalline interfaces, and nanostructured lipid carriers (NLCs).457,458 While much of the characterization and literature in the lipidic nanomaterials field is directed to drug delivery due to their high drug-loading capacity and their lipophilicity to more easily interact with and enter cells, these characteristics often also prove rather useful in imaging particularly for multimodal imaging (acquiring image information from multiple different imaging modalities, potentially requiring multimodal nanomaterials; see section 3.1) and theranostics (combining drug delivery with imaging diagnostics; see section 3.2). Lipidic nanomaterials characteristically display a hydrophilic surface for ease of interaction within the body and a hydrophobic shell or core. The hydrophobic/ hydrophilic regions within the same nanomaterial support loading of both hydrophobic and hydrophilic contrast agents for delivery to disease sites. The dual nature of the nanomaterials thus easily supports multimodality imaging, which has been exploited by many groups.2,459−461 However, with many recent reviews on lipidic nanomaterials available,462−464 we highlight here only key recent advancements. While the route of administration may vary broadly, including topical, pulmonary, ocular, intranasal, vaginal, and oral delivery\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAX\nfor therapeutic applications,465 the primary route of administration for imaging remains systemic injection. Liposomal Nanomaterials. Liposomes are vesicles consisting of one or more lipid bilayers (∼5−6 nm thick) arranged concentrically around a typically aqueous core and often synthesized via mechanical or solvent dispersion, emulsion, or detergent solubilization methods.2 While a wide range of liposome sizes exists, from 10s to 10 000s of nm, nanoscale liposomes (≤100 nm) are typically small unilamellar (singlebilayer) vesicles and have the advantage that they can often enter targeted diseased tissues from the vasculature. Liposomes have excellent potential as nanoscale carriers of imaging agents particularly for multimodal imaging.2,459,460,466 Although radiolabeled liposomes have been used in humans since the 1980s for γ-imaging and PET, the practice has not become standard for a variety of reasons;467 the most important is because it has largely not solved key clinical problems. However, this is changing due to the precision medicine paradigm. An emerging clinical application of liposomal imaging is as a proxy prior to therapy to determine whether liposomal drug formulations will in fact reach the intended site prior to injecting toxic drugs (e.g., liposomal drugs) into the body.468 The paradigm is that the EPR effect is uncertain and highly heterogeneous, making it unpredictable whether a particular patient’s tumor might permit EPR to be used for drug delivery.467 Thus, a liposomal imaging agent of the same nanomaterial size as the drug formulation, but nontoxic and at near-trace quantities, could be injected to ensure efficient uptake at the target site prior to administering a therapeutic liposomal formulation, the delivery of which is a function of individual biology. Iodine-loaded liposomes were injected i.v. into rats bearing breast cancer xenografts in order to perform mammography prior to treatment with liposomal doxorubicin; this allowed prediction of treatment efficacy via imaging.468 Critically, the authors showed very good correlation between liposome extravasation (as evaluated by CT imaging) and therapeutic efficacy with an R2 correlation of 0.838, with P < 0.001; i.e., low tumor leakiness correlated with increased tumor progression despite treatment, and vice versa.468 However, as usual, animal models do not capture the complete story. There is a clinical need to confirm the existence of EPRbased delivery prior to treatment in tumors more representative of human disease. Hansen et al. performed a clinical veterinary study on spontaneous cancers in canine patients in which tracer quantities of 64Cu-labeled 100 nm liposomes were i.v.-injected and imaged with PET (see Figure 29).469 High heterogeneity was observed in which 6 of 7 carcinomas displayed significant EPR effects, but only 1 of 4 sarcomas did at 1 day p.i. This is a critical step toward the successful clinical use of imageable liposomes to boost the efficacy of nanomaterial therapeutics. Nevertheless, this general approach does not account for the fact that most nanomaterials are not 100 nm spherical particles, and smaller or differently shaped nanomaterials may behave differently15proxy nanomaterials matching the size/shape of therapeutic nanomaterials may prove necessary. Still, with the rise in trials for clinical liposomal drug formulations, it is very likely that clinical studies will begin to use trace injections of radiolabeled liposomes to select patients in a given trial most likely to respond to investigational liposomal drugs.467 Indeed, because of the long history of liposome usage, an advantage of choosing them as an imaging platform is that it is relatively straightforward to translate them to human applicationsthis is hinted at by the fact that there are currently 408 clinical trials\nwith “open trial” status in the United States involving liposomes based on clinicaltrials.gov searches. Imaging applications of liposomes most often feature nuclear and/or magnetic contrast for PET/SPECT/γ-scintigraphy and MRI.470−472 For nuclear imaging, one can label liposomes via standard surface chelation/click chemistry, remote loading, membrane labeling, or passive encapsulation (see Figure 30). Reiner and colleagues radiolabeled liposomes with 89Zr (halflife 78.4 h) for tumor imaging.470 Liposomes were constructed via a standard protocol, mixing the phospholipids 1,2- dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2- distearoyl-sn-glycero-3-phosphoethanolamine (DSPE)PEG2000 with cholesterol in a 1.85:0.15:1 molar ratio in chloroform.470 After solubilizing in an aqueous solution and sonicating, 100 nm liposomes were recovered with polydispersity index 0.11 and somewhat negative ζ-potential −21.7 mV. The stability and in vivo efficiency of the 89Zr radiolabeling procedure were then compared by separately labeling via chelation and via click chemistry. Dibenzoazacyclooctyne (DBCO) was included in the liposome reaction mixture (0.4%) for chelation, while for click chemistry DSPEdesferrioxamine (DFO) was included (0.3%); both functionalized liposomes displayed similar physical parameters (size, polydispersity, and ζ-potential) as the bare liposomes. Appending 89Zr to the DBCO-liposomes required overnight incubation with 89Zr-oxalate for chelation (89Zr-Chel; see Figure 31b) or DFO-liposomes (89Zr-Clic) with a 89Zr compound for 4 h for a bioorthogonal chemistry (see Figure 31a, c). Intriguingly, despite the substantial similarity between the physical characteristics of the two 89Zr-liposomal formulations, i.v. injection into xenograft tumor-bearing mice led to considerably divergent biodistribution, time-course, and tumor-uptake characteristics in vivo based on PET imaging and analysis of 89Zr (see Figure 31d, e). These variations likely arose primarily from differences in the circulation half-lives (see Figure 31d), highlighting the importance of optimization of circulation times of nanomaterials and of the particular chemistries chosen for a specific application. Similar chelation strategies, albeit with different chelators and isotopes, are being implemented for liposomal targeting approaches for PET472,473 and SPECT imaging of cancer and\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAY\nheart disease including via remote loading474 (via radionuclide transport through the lipid bilayer, supported here by a lipophilic chelating agent). There also exist alternative forms of liposomes such as nonionic surfactant vesicles often termed “niosomes”. These structures lead to more structural flexibility than typical phospholipid liposomes, yielding highly deformable liposomes.475\nNonliposomal Lipidic Nanomaterials. While liposomes have a lipidic bilayer, micelles have a lipid monolayer, so that their cores are typically hydrophobic as the hydrophilic head interacts with the environment and hydrophobic tails point toward the center. Alternatively, SLNs have a solid lipid core, offering protection against degradation and stability for hydrophobic cargoes. NLCs were developed as a secondgeneration lipidic nanomaterial to overcome some of the shortcomings of SLNsthey are designed to increase loading capacity and mechanical stability (e.g., decreased cargo leakage) through blending lipids of different forms, e.g., solid and liquid, within the nanomaterial.476 We are not aware of a study that directly compares the biodistributions of liposomes to micelles to SLNs to NLCs with similar size, surface chemistry, and reporter molecule. Indeed, the literature is not yet sufficient in imaging many of these nanomaterials to make broad comparative statements on generalized biodistributions for them, although some hints are beginning to emerge particularly for SLNs and NLCs.\nSLNs designed for T1-weighted MRI were loaded with GdDOTA via a water−oil−water double microemulsion strategy.477 Mixing glycerol monocaprate, Span 80 (a nonionic surfactant), and Gd-DOTA in a molar ratio of 4:3:2 under low heat formed an oil phase. Combined with an aqueous phase consisting of water, sodium taurodeoxycholate hydrate (to decrease SLN diameter), and Tween-80 under low heat and stirring in ice water, SLNs containing Gd-DOTA in aqueous pockets were formed (Figure 32a-b). After intracerebroventricular injection, positive contrast (an increase of 726%) in the mouse brain was observed using T1-weighted MRI 55 min p.i. (see Figure 32c) in a proof-of-principle demonstration. Future studies will be needed to demonstrate other advantages of the SLNs, including improved circulation half-life, potential for multimodality imaging or theranostics, targeted delivery, improved stability, and potential for controlled release of imaging and/or therapeutic agent.477\nOn the other hand, NLCs were made imageable by SPECT by appending 99mTc.478 NLCs display a highly disordered lipid matrix that provides large molecular voids in which imaging contrast or drug agents may be stored for high loading and stability. NLCs can be prepared by emulsification of molten lipids followed by recrystallization of solid componentsin one case, a lipid mixture (triglycerides tristearin and miglyol in a 2:1 ratio) in ethanol was melted at 75 °C. A 2-phase system was generated by adding aqueous poloxamer 188. After stirring, ultrasonication of the emulsion generated NLCs. Using N,N′bis(ethoxyethyl)dithiocarbamato sodium salt (DBODC) ligand, NLCs were radiolabeled with 99mTc via a nitride technetium intermediate and purified. SPECT imaging of living rats was performed after i.v. administration of 99mTc-NLCs, displaying uptake in the liver and later the intestine due to fragmentation of the NLCs in the liver.478 However, in a surprising finding, ∼1 h p.i. 99mTc-NLCs localized intrinsically to the principle depot of brown fat tissue in the rat (the corpus adiposum nuchae in the interscapular region). 99mTc-NLCs targeting of brown fat, which is important for heat generation in mammals and has a key role in obesity and metabolic disorders in humans, could be clinically useful for specific imaging and especially therapeutic delivery approaches toward modulating brown fat for helping to control human obesity.478\nWhile typically spherical, liposomes, micelles, SLNs, and NLCs can also be elongated into more sophisticated geometries, for instance, by prudent doping with different lipids or via application of physical stresses such as osmotic pressure.479 Choice of geometry could be particularly useful for improved delivery via passive accumulation in diseases such as cancer or via active delivery since the surface area available for binding is minimal on spheres compared with other geometries such as rods.19 This approach could also extend the use of radiolabeled lipidic nanomaterials as “canaries in the coal mine” for the EPR effect in lipid nanotherapeutic clinical trials to other common nanomaterial geometries.\n2.7.2. Polymeric Nanomaterials. Polymeric nanomaterials, like lipidic nanomaterials, offer a wide range of chemistries, sizes, and features to provide a highly flexible platform capable of uni- or multimodal imaging, therapy, or both. Polymer nanomaterials can be fabricated in highly reproducible and scalable ways with a good safety profile, lending them to strong translational potential. In fact, the first targeted nanomaterial to be injected into humans is a block copolymer nanomaterial comprising poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) that contains docetaxel for chemotherapeutic clinical\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nAZ\ncancer trials (PLGA-b-PEG).480 However, polymeric nanomaterials have not met the same success in imaging as they have in drug delivery. A key reason for this is that some of the biggest contributors to their success in therapy turn out to be imaging shortcomingsfor example, the biodegradability of polymeric nanomaterials is often cited as one of their best features as it enables controlled drug release over an extended period of time and ensures the particle can be quickly cleared afterward. However, in imaging applications, release of contrast in vivo is generally associated with poor particle stability and leads to nonspecific signal.481 Fortunately, with new formulations,\nmaterials, and chemistries including smart nanomaterials, there is reason to believe polymeric nanomaterials for imaging will develop rapidly toward clinical use in the coming years. Polymeric nanomaterials include conventional solid poly-\nmeric or copolymeric nanomaterial blends, dendrimeric nanomaterials, and self-assembled nanomaterials (particularly smart nanomaterials that begin as monomers but can be triggered to self-assemble and nanoaggregate at disease sites in vivo). Traditional polymeric nanomaterials are typically synthesized via one of two routes, physical encapsulation or covalent conjugation (see Figure 33).481 Covalent conjugation\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBA\ntypically begins with monomers conjugated to the contrast molecule(s), after which standard cross-linking approaches such as nanoprecipitation are applied to generate the nanomaterials. While covalent linkages typically lead to better stability so that contrast molecules tend not to undergo burst release, they disadvantageously exhibit modest contrast-loading efficiencies. On the other hand, physical encapsulation (enclosing the contrast material in a polymer matrix) increases loading efficiency but often suffers from burst release, which remains a problem for imaging strategies for which agent release is undesirable (at least until after the nanomaterial performs its function). An example of a covalently conjugated nanomaterial is clinically used Omnipaque (polyiohexol (hexamethylene diisocyanate-mPEG-polylactide)), which cross-links iohexol with hexamethylene diisocyanate and is then nanoprecipitated with mPEG-polylactide to form an iodine-containing polymeric nanomaterial for CT imaging (discussed in section 2.6.2).440 Using CT, this compound displayed a 36-fold increase in contrast in murine tumors by 4 h p.i. Physically Encapsulated Polymeric Nanomaterials. Physically encapsulated polymeric nanomaterials can be generated using a variety of chemical methods including spontaneous emulsification solvent diffusion, electrostatic assembly, double emulsification, and sol−gel emulsion polymerization via precipitation. They can be designed to exploit the physical or biochemical properties of the environment such as pH, temperature, or enzymatic degradation.481 Recently developed lipase-cleavable Gd-based polymeric nanomaterials are an example of the latter.482 These smart Gd nanomaterials were designed to detect acute pancreatitis (inflamed pancreas that can range in severity from moderate discomfort to lifethreatening) via conditional activation by lipase enzymes (the extracellular concentration of which increases when pancreatitis occurs) in the pancreas. In this scheme, insoluble Gd chelates are encapsulated within a fatty acid covering. Rendered inactive by their insolubility within the nanomaterial, the Gd chelates\nmay be activated by enzymatic cleavage of aliphatic side chains, giving rise to T1 MR signal to allow imaging of pancreatitis. In particular, the Gd nanomaterials, comprising Gd, its chelator DTPA (diethylenetriaminepentaacetic acid), and a fatty acid, were synthesized by linking the DTPA-fatty acid with Gdacetate. DTPA-fatty acid (6,9-bis(carboxymethyl)-11,19-dioxo3-(2-oxo-2-((2-(2-(stearoyloxy)ethoxy)ethyl)amino)ethyl)15,18-dioxa-3,6,9,12-tetraazahexatriacontan-1-oic acid) and Gdacetate were mixed in a nearly 1:1 molar ratio with methanol and stirred for 3 h, evaporated, washed with water, and purified with column chromatography with 99% yield.482 In acute pancreatitis, pancreatic acinar cells rupture, releasing large amounts of lipase and other enzymes. The Gd nanomaterial exploits this release: by design, upon enzymatic hydrolysis by lipase the T1-inactive lipophilic nanomaterials released watersoluble Gd-DTPA molecules, thereby turning them on. Thus, upon tail-vein injection of the Gd-based nanomaterials into rats with induced acute pancreatitis, T1-weighted MR images displayed significantly increased contrast in the pancreas from 1 to 36 h p.i. This is one of the relatively few examples of smart MR-based nanomaterials due to the complexity of switching them from off to on, here making clever use of the fact that water molecules must be in close proximity to Gd ions for signal generation. One can encapsulate single or multiple contrast agents within polymeric matrices for fluorescence, photoacoustic, MR, nuclear, and many other types of imaging as recently reviewed.481,483,484 In some cases, the polymer matrix itself may provide contrast, such as the semiconducting polymers imaged with PAI described in section 2.4.5.368 A new generation of hybrid nanomaterials for in vivo imaging, polymer−lipid hybrids, combine key superior features of polymeric and lipidic nanomaterials to create highly stable nanomaterials capable of more efficient delivery in vivo.485 Polymer−lipid hybrids can be generated via the coassembly of a diblock copolymer with a phospholipid. In one case, poly-\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBB\n(ethylene oxide)-block-polybutadiene copolymer (PEO−PBD) was mixed with several phospholipids, including hydrogenated soy phosphatidylcholine (HSPC) and a phospholipid PEG in aqueous solution. Fluorescence contrast was incorporated as part of a conjugated anti-Her-2/neu targeting antibody to which near-infrared fluorophores were linked.486 The nanomaterials were injected into mice bearing Her-2/neu positive tumors and were optically imaged accumulating at the cancer site. Interestingly, the incorporation of the phospholipid HSPC increased targeting efficiency to the tumor; when HSPC was not included, tumor uptake was ∼50% less than when it was included (at a 75:25 ratio of PEO−PBD/HSPC). While it is not completely clear why superior delivery was observed, it is possible that the HSPC reduces the steric hindrance that PEG exerts on antibody binding to target protein by diluting the PEG brush at the nanomaterial surface.486 Because delivery efficiency is such a key issue, the improved delivery from the lipid−polymer is alone sufficient rationale to pursue these new hybrid and similarly engineered nanomaterials for in vivo imaging (and therapeutic) use. Covalently Conjugated Polymeric Nanomaterials. Dendrimeric nanomaterials were initially developed during the early years of nanomedicine in the late 1970s to mid-1980s and have thus grown in concert with the field they helped jumpstart. As implied in the name, dendrimers are highly branched, “dendritic” tree-like nanostructures that are very monodisperse with a 3-dimensional architecture and composition487 typically with a radial symmetry. Their flexibility is a function of the facts that (i) almost any molecule can be appended for delivery of image contrast, drug, or some combination as long as it is of appropriate size (sterically) and (ii) many different molecules can comprise the branches, for instance, the branch molecules displayed in Figure 34 are among the most common.487 Grown\nin concentric layers, or generations, dendrimers are constructed with highly precise sizes and numbers of functional groups. This configuration makes possible a high degree of modularity in fabrication of dendrimers for various imaging/diagnostic applications.488 Poly(amidoamine) (PAMAM) dendrimers were designed to carry gold nanomaterials for CT imaging.489 Starting with generation 2 amine PAMAM dendrimers, CTimageable dendrimers were prepared by solubilization in aqueous solution, heating, and adding HAuCl4 acid and gold salt with a gold salt/dendrimer ratio of 3:1 to grow gold nanomaterials of 5.5 nm on the dendrimers. The gold dendrimers had a final size of 6.5 nm. Folic acid (FA) was conjugated as a tumor-targeting molecule via EDC (1-ethyl-3(3-(dimethylamino)propyl)carbodiimide hydrochloride) coupling. The nanomaterial showed superior CT attenuation characteristics compared with commercially available Omnipaque at the same concentration of attenuating element (gold/ iodine). Upon i.v. injection into xenograft tumor-bearing mice, the gold dendrimers displayed high contrast at the tumor site 1 h postinjection.489 The small size and modular chemistry of dendrimers provided easy access (via EPR) to the tumor in addition to significantly increased uptake at 1 h due to FA targeting compared with untargeted nanomaterials. In recent work, Pang and colleagues exploited the very small sizes of dendrimers to target glioblastoma multiforme, a particularly malicious form of brain cancer.490 Generally, as dendrimers increase in generation and size, more functional groups are available on their surface. Thus, generation 5 PAMAM dendrimers, displaying 128 primary amino groups on each nanoparticle’s surface, were easily able to incorporate both targeting agents and an imaging reporter. The fibrin-binding peptide, CREKA, was appended to the amino groups of PAMAM dendrimers (an average of 11.4 per nanoparticle\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBC\ndetermined via high-performance liquid chromatography (HPLC)) to increase retention of the dendrimers within the brain cancer site. Fluorophores were similarly conjugated, with 1.8 FITC and 1.5 IR783 dyes per nanoparticle on average. Dendrimers were i.v.-injected into mice bearing orthotopic U87MG brain tumors, and both CREKA-conjugated and untargeted dendrimers entered the tumor. However, by 24 h p.i. only CREKA-modified dendrimers (∼7.5 nm diameter) were retained in the tumor, allowing easy fluorescence-based identification of the tumors using macroscopic fluorescence imaging. While translation will almost certainly require application of more deeply penetrative and clinically viable modalities, e.g., MR-imageable molecules like Gd or CTimageable nanomaterials like gold/iodine, the results demonstrate the efficacy of very small dendrimeric materials for entry and retention in brain tumors in living animals.490 Very small nanomaterials such as dendrimers are a natural choice for less leaky tumorsthe typically poor EPR properties that brain tumors display are due to characteristically tiny vascular pores. In Vivo Self-Assembling Polymeric Nanomaterials. In a completely different paradigm from assembling polymeric nanomaterials in the laboratory and then injecting them for delivery to a disease site, researchers are developing clever\nchemistries that enable injection of monomeric substrates that self-assemble and report signal specifically at the disease site. Such a strategy has several key advantages. First, the monomeric form has superior potential to target disease sites because of its very small size (e.g., in cases of less leaky tumors like brain cancer in the previous paragraph). Second, the critical issue of rapid washout at the disease site that small molecules typically suffer generally leads to lack of retention; however, self-assembling in vivo nanomaterials solve this issue by forming nanomaterials that do not washout. Third, the selfassembly is smart such that it only occurs upon activation, for instance, by an enzymatic cleavage designed to trigger selfassembly. Therefore, nanomaterial assembly only occurs when and where an enzyme of choice is expressed. This allows functional imaging, for example, providing a measure of the extent of enzyme expression at a site, e.g., caspase for apoptosis imaging, or even to image a reducing environment as part of reduction−oxidation activity.491 The trigger for self-assembly can be designed to substantially increase the output signal such that the nanomaterial signal is higher than the sum of the individual monomers. This makes it “activatable” and “on” only when functional activity is present at disease sites (due to its presence and retention as a nanomaterial) and potentially silent\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBD\nelsewhere. Fourth, the approach is highly modular, as similar chemistries have been used in published articles for optical (e.g., fluorescence/photoacoustics), nuclear (PET), magnetic (MRI), etc. imaging modalities.371,492,493 Although the monomeric self-assembling nanomaterials are capable of being functionalized for imaging with many modalities, each particular agent is typically unimodal. Fifth, regulatory approval for monomeric agents may be simpler than conventional nanomaterials because the formulation is in monomeric (i.e., essentially small molecule) form when injected. It is notable, however, that regulatory approval is likely to be dependent upon the nanomaterial eventually degrading along with proof that it can not grow too large and become a safety hazard in vivo. The highly modular in vivo self-assembly approach allows creation of nanomaterials imageable by any of several different imaging modalities using a similar base monomer platform. For example, Rao and colleagues developed an in vivo apoptosis sensor by designing a biocompatible caspase-sensitive selfassembled MRI-imageable nanomaterial. The probe can be induced to cyclize by cleavage of a peptide bond by caspase 3 or 7 (which share similar substrate specificity).493 In particular, the molecule consists of 2-cyano-6-hydroxyquinoline (CHQ), a DEVD peptide cleavable by caspase 3/7 at which site cyclization may occur, a disulfide bond reducible through glutathione, and an MR-active elementGd-DOTA chelate.493 The disulfide bond is cleavable by the intracellular reducing environment, such as glutathione at appropriate concentrations (see Figure 35a for the chemical scheme). Caspase 3/7 cleavage of DEVD triggers intramolecular cyclization. Because the resulting macrocyclic form is more rigid and hydrophobic than the precyclized form, it is able to self-assemble with other macrocyclic products based upon hydrophobic interactions and π−π stacking. The resultant Gd-conjugated nanomaterials display increased relaxivity values compared to the uncyclized probe, providing a sort of on switch once the nanomaterials are assembled at the apoptotic cell site. The contrast at the site increases not only because more of the agent is trapped within the targeted cells but because MR signal also increases as the larger nanoparticles (compared with constituent small molecules) tumble more slowly, so more interaction is possible with water, yielding higher signal. The precursor form was injected i.v. into mice bearing tumors that had been treated by drugs that induce apoptosis. A significant MR signal increase in the tumor was observed compared with controls (e.g., untreated tumor, which allows uptake of the precursor, but because apoptosis is fairly minimal does not generate a large signal change) due to the formation of Gd nanomaterials at the tumor site493 (Figure 35b, c). Similar approaches toward imaging apoptosis via in vivo nanoaggregation have also emerged using nuclear and optical imaging modalities.492,494 Nanoaggregate PET imaging was developed using a radioactive 18F monomeric precursor (Figure 36a).492 After i.v. injection, the precursor aggregated into polymeric nanomaterials inside apoptotic cells similar to the MRI probe but provided PET signal at the apoptotic site. The new probe provided superior signal in imaging drug-treated apoptotic tumor cells compared with both standard 18F-FDG and the apoptosis-specific PET probe 18F-ML-10, which has been translated already for imaging apoptosis in humans (Figure 36b, c). In vivo self-assembling nanomaterials may find themselves in a unique niche within nanomaterial imaging in that they are in many ways best adapted for in vivo imaging, in\ncontrast to most adaptable nanomaterials that are primarily directed toward therapeutic delivery.\n2.7.3. Silicon-Based Nanomaterials. Silicon-based nanomaterials, particularly silica and porous silicon, are generally regarded as biocompatible, safe, and ultimately powerful agents for imaging disease in living subjects. Silica nanomaterials are being used in translational nanotechnology for revealing metastatic melanoma in patients with head and neck lesions using fluorescence cameras and nuclear imaging35,435 (see section 2.6.1). Silica nanomaterials are also used in fluorescence imaging, both as a nanomaterial coating and as the core particle itself, because dye doping with silica is relatively straightforward due in part to the flexibility of silica chemistry. Reverse microemulsion is one common method for dye doping, which occurs by forming stable nanodroplets in which dyes are trapped in an aqueous core within an oil solution.495 In these\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBE\ncores, silane hydrolysis occurs and silica nanoparticles form with dyes trapped inside. In other cases, magnetic (e.g., iron oxide) and nuclear materials can be incorporated to make silica nanomaterials imageable with MRI, PET, and CT,496,497 or the silica can be used intrinsically to image with ultrasound.498,499\nSilica nanomaterials are typically fabricated in a core/shell configuration or as mesoporous silica nanoparticles (MSNs), with more exotic arrangements such as silica nanorattles also possible.500 In one embodiment, a mesoporous T1 MRimageable silica nanomaterial was developed in a single-step synthetic process.114 After adding a surfactant (cetyltrimethylammonium bromide (C16TAB)) to distilled water, 25% NH3· H2O and then tetraethoxysilane (TEOS) were stirred in. To incorporate MR contrast, GdCl3·6H2O and later gadolinium hydroxide were added to form gadolinium(III) oxide. The precipitate nanomaterial, 86 nm diameter Gd2O3@MCM-41, displayed 5.7% Gd doping. A key feature of this nanomaterial, established via atomistic modeling, is that it was next-toimpossible for Gd ions to dissociate from the silica surface, making the nanomaterial more likely to be nontoxic than Gdchelates (which can dissociate and release toxic free Gd). The silica nanomaterial, once injected in vivo, thus does not leach Gd and was mostly excreted over time via the hepatobiliary transport mechanism without any observable organ toxicity. These nanoparticles proved to be bright, nontoxic MR vascular mapping agents for at least 2 h.114\nPorous silicon (pSi) can display enormous surface-to-volume ratios due to its highly porous structure. pSi has become a useful nanomaterial for in vivo imaging for many reasons: (i) It is intrinsically imageable via room-temperature photoluminescence in the 600−1000 nm range. (ii) The luminescence lifetime is much longer (order of μs) compared with the nanosecond lifetimes of typical fluorescent molecules that give rise to autofluorescence, enabling time-gated imaging with minimal background.501 (iii) It is highly adaptable, able to capture large volumes of a wide variety of small molecules or very tiny nanoparticles within its pores of highly tunable size for imaging with nearly any imaging modality. (iv) It is biodegradable, breaking down into constituent silicic acid molecules within weeks, and is thus highly biocompatible.502 Unlike many other nanomaterial chemistries we have described, pSi is typically fabricated by top-down approaches such as electrochemical (anodization) or wet-chemical (stain) etching of silicon for precision sizing of pores,502 after which the particles can be nanosized via application of ultrasonic energy. For PET imaging of pSi tumor targeting in mice, Kallinen et al. radiolabeled pSi nanomaterials with 18F either by substituting for surface silyl hydrogen/silyl fluoride or via nucleophilic attack of 18F- on Si−O−Si bridges.503 Others utilize the pores within pSi to encapsulate iron oxides or Gd for T2 or T1 MRI, respectively, for example, to spatially constrain the molecular motion of MR-active Gd molecules and thereby increase their relaxivities and thus signal.504,505 Because of the ability of pSi to imbibe small nanoparticles into its pores, it has also been applied as a multistage system (a sort of “mothership”) in which larger pSi particles are used to transport smaller nanomaterials through the bloodstream for docking to the vasculature at the site of disease, at which point it can release the contained nanomaterials for imaging or therapy.506 The versatility of pSi in its imaging and therapeutic capabilities, its range of possible sizes, and its biocompatibility suggest tremendous clinical opportunity. However, its top-down fabrication process could entail prohibitive costs in its scale-\nup to quantities required in clinical medicine. As with other adaptable nanomaterials, the opportunity also exists for pSi to be exploited as a multimodal imaging agent, an area within pSi that remains largely unexplored.\n2.7.4. Natural Nanomaterials. Natural nanomaterials are those nanomaterials found in nature, created by naturally occurring chemical reactions and biological systems. In this section, we focus on natural nanomaterials produced by living organisms. These natural nanomaterials include cell-derived structures such as exosomes, lipoproteins such as HDL (highdensity lipoprotein) and LDL (low-density lipoprotein), and protein scaffolds such as capsids produced by viruses. They are generally highly functional and biologically designed for a particular purpose. Their native functions and intrinsic biodegradability can be cleverly exploited when they are repurposed as nanomaterial contrast delivery vehicles. HDL, for instance, is a natural choice for imaging regions of atherosclerosis because of the biological relationship between HDL and atherogenesisHDL molecules facilitate cholesterol efflux from cholesterol ester-enriched macrophages within the plaque toward excretion from the body.507 Indeed, HDL has been applied as a natural nanomaterial contrast agent to image atherosclerotic plaques via radiolabeling since 2001.508 Recently, Fayad and colleagues loaded HDL nanomaterials with amphiphilic Gd-chelates to render them MR-imageable and targeted them using a collagen-specific peptide.509 Thus, both intraplaque macrophages and collagen were targeted and thereby functionally imaged using MRI. This approach allows not only imaging of atherosclerotic plaque but also monitoring of the compositional changes in plaques over time: for instance, to monitor the plaque’s response to administered therapeutics. Other recent adaptations have applied HDL/LDL toward generating nanomaterials for diagnosing and treating not solely atherosclerosis but even cancer.510\nExosomes are natural nanoscale vesicles of 30−100 nm released from mammalian cells that serve as cell-to-cell communication vehicles. While they have shown intriguing diagnostic utility for tests of early disease,511,512 they have been increasingly exploited as drug delivery vehicles due to their intrinsic propensity (i) to communicate between cells, (ii) to be internalized by those cells, (iii) typically to not be recognized as foreign nor endocytosed by macrophages, (iv) to be selected from a cellular source that enables stability in the circulation (and can be further prolonged by PEG), and (v) to protect their cargo from degradation, as they do natively.513 Exosomes thus navigate across typical biobarriers, supporting their application as repurposed superior nanomaterial delivery vehicles.514 Despite the emerging interest in exosomal therapeutics, only a few studies have begun to explore exosome nanomaterial-based imaging.515 As understanding of exosome biology and efficiency with their production improve, exosomal imaging applications are likely to intensify rapidly. Many different types of cells can release exosomes, which all display protein homing signals and targeting specificity derived from their cell of origin;516 the design of exosomal nanomaterials for imaging and therapy must thus include consideration of the cell origin to exploit their latent superior delivery specificity. Exosomal nanomaterials can be produced through standard protocols by culturing cells of the desired type and harvesting exosomes via differential centrifugation of the cell media.515 To generate imageable exosomes, contrast can either be preincorporated in the original cells from which exosomes are collected, or once collected the contrast can be introduced\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBF\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBG\nacross the vesicle bilayer membrane. In a recent example of the latter, exosomes were electroporated in order to create the holes necessary to load small iron oxide nanomaterials for MRI contrast.515 While we have discussed the use of iron oxides for T2MR imaging (section 2.3.1.2), which have been translated to human medicine in many forms, exosomal loading confers key advantages such as native homing receptors that are likely to more efficiently traffic the contrast to the desired site. Iron oxide-loaded exosomes were injected into the foot pads of mice in order to easily track their uptake into local popliteal lymph nodes via MRI.515 Because exosomes can exploit special privileges to enter cells such as use of tunneling cellular nanotubes for intercellular transport, as well as their native, inherent biocompatibility, they have great potential for contrast delivery using MR and other diagnostic imaging modalities. Optical strategies such as fluorescence and bioluminescence, for example, have also been used to track exosomal biodistribution and targeting upon injection in vivo.515,517 However, despite their translational promise, considerable research remains to determine whether exosomes can overcome critical challenges such as reliable cargo loading, heterogeneous components, and an incomplete understanding of their native role in normal and disease states (exosomes, for example, may not be inert toward some disease states, so one concern is that they may have unintended biological consequences when applied in diseases like cancer).518\nMany natural nanomaterials useful for in vivo imaging are not produced by mammals or even multicellular organisms. In fact, viruses self-assemble protein-based scaffolds (their shell) that can be used as highly functional biological structures. These capsid configurations can be engineered to reliably display functional groups that can be used for covalently appending image contrast molecules or drugs, or can even natively serve as nucleation sites for deposition of metals or semiconductors.519 A key advantage of capsids is that they are highly monodisperse with extremely well-defined sizes, shapes, and numbers of functional groups that depend precisely on the virus’s genetic code. By removing the genome and leaving only the proteinaceous frame, the structures are rendered empty and safe for injection as imageable nanomaterials. Francis and colleagues used this approach, generating 27 nm diameter approximately spherical MS2 bacteriophage capsids.520 The capsids self-assemble from 180 protein subunits and can be produced in Escherichia coli broth cultures. Each protein subunit was engineered to contain a p-aminophenylalanine mutation facing externally and a cysteine mutation facing internally, providing 180 modifications for each capsid of each type. Because the mutations/functional groups are different, the inside and outside can be loaded with different molecules. For PET imaging, the interior of MS2 capsids were labeled with DOTA and 64Cu (Figure 37a−e). The capsids were PEGylated (on the exterior, with ∼135 PEGs per capsid) in part to help shield the negative ζ-potential of the capsid surface.520 Upon i.v. injection of MS2 capsids into tumor-bearing mice, the capsids circulated for longer than 24 h and the EPR effect allowed untargeted capsid nanomaterials to accumulate in the tumor more than 64Cu alone (see Figure 37f, g). In addition to MS2 for PET imaging, agents were developed for in vivo MRI contrast by functionalizing other self-assembling capsids. These larger spherical nanomaterials, 64 nm Salmonella typhimurium bacteriophage P22 capsids, were exploited as scaffolds for Gd(III)-DTPA chelation.521 Assembled from 415 protein monomers, the P22 capsids interestingly yield highly superior\nT1 relaxivity values upon Gd-conjugation compared to free Gdthey proved superior even compared to a different, smaller (12 nm) Gd-conjugated nanoparticle. The authors attribute the increased efficiency to the larger size of the capsid, leading to considerably slower tumbling rates, resulting in faster T1 relaxation rates. Upon i.v. injection into nude mice, the capsids could be used to image blood vessels in mice at resolutions down to 250 μm (due to the excellent T1 relaxation) as an intravascular contrast agent with a 4.7T MR scanner.521 Because of the safety of the empty protein assemblies, their inherent biocompatibility as biological structures that degrade naturally, their monodispersity, and their modularity as adaptable/multifunctional nanomaterials, capsids are attractive structures to translate into clinical diagnostics and therapeutics."
    }, {
      "heading" : "3. MULTIFUNCTIONAL NANOMATERIALS",
      "text" : "The ease with which nanomaterials can be endowed with multimodal and therapeutic properties is one of their key advantages. Multifunctional nanomaterials perform more than one function, whether in their ability to serve as reporter agents for multiple imaging modalities or to serve as both a therapeutic and image contrast vehicle (for one or more modalities). While small-molecule probes often require complex organic syntheses in which many steps must be modified depending on the new imaging functionality one wishes to add, nanomaterials are often quite modularonly minimal changes to the protocol are required when adding contrast to enable imaging with one or more different modalities. This is most easily and commonly observed when the core nanomaterial provides contrast for a single modality and the coating material (e.g., silica and/or PEG) provides functional groups for appending a wide variety of moieties, which can be molecules that enable imaging with other modalities, site-specific targeting biomolecules, therapeutics, or all three. For example, Josephson, Weissleder, and others have produced a broad body of literature on nanomaterials with an iron oxide core imageable with MRI and a dextran coating that easily links to fluorophores for optical imaging,227,261,522 radioisotopes for nuclear imaging,409,523 and targeting molecules.523,524 These and similar nanomaterials could thus be used for anything from MR imaging of atherosclerotic plaques to sentinel lymph node mapping to agents for monitoring cancer therapeutic regimens.525−527 Other multimodality approaches feature a nanomaterial that intrinsically provides contrast for several imaging modalities: for instance, gold nanomaterials alone can be imaged using PAI, CT, and optical contrast such as OCT. Such nanomaterials are highly efficient, and their intrinsic multimodality generally does not preclude adding further contrast for other desired imaging modalities. The development of multimodal nanomaterials can create synergies that span multiple different physical imaging modalities and therapeutic capabilities (theranostics) that should lead to effective, efficient precision in vivo medicine. The imaging field, in particular molecular imaging, has over the last 5−10 years embraced the multimodal imaging paradigm. Advancements in nanomaterial design and chemistry have been one of the largest drivers of this shift. While nanomaterials developed in the infancy of molecular imaging tended to be applicable to only a single imaging modality, many if not most of the nanomaterials developed recently are often multimodal imaging or theranostic nanomaterials, or combined multimodal theranostics. Indeed, in this Review, a number of the articles already cited have involved multimodal nanoma-\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBH\nterialsmany of the interesting chemistries have arisen from the desire to increase the number of different reporter signals that single imaging agents can produce. However, developing a multimodal nanomaterial, while often a brilliant technical achievement, is not necessarily useful clinically. Critical questions to ask when evaluating a new multimodal imaging nanomaterial include the following: (i) Are the sensitivities of the included imaging modalities sufficiently similar (i.e., different masses of contrast may be necessary for different imaging modalities and thus may not pair welldo the different contrast levels required permit a single nanomaterial dose)? (ii) Does the new nanomaterial make sense in the context and time frame of clinical usage (i.e., would a physician use all the relevant imaging modalities for the same patient in the imaging of their disease)? (iii) What gains are made using a single multimodal nanomaterial compared with injecting multiple different one-off imaging nanomaterials? (iv) Can it fit into the existing clinical workflow? In a recent example of a multimodal nanomaterial that was designed with the clinical workflow in mind and with all contrast designed to be at similar imaging sensitivities, a triple-modality gold nanomaterial-based contrast agent was developed for MRI, PAI, and Raman (SERS). The concept is that one nanomaterial could be used for all of the following in a single injection: delineation and staging of brain cancers preoperatively with MRI, higherresolution imaging with PAI, and detailed intraoperative imaging of tumor margins to ensure the surgeon removes all the difficult-to-discriminate microtumor regions with Raman imaging. With a 60 nm gold core, the nanoparticles were intrinsically PAI-active, and SERS imaging capability was bestowed by incorporating Raman dyes on the gold surface and protecting them with a 30 nm silica layer. MRI imageability was incorporated by modifying the nanomaterial with DOTAGd3+ via a maleimide linkage, yielding ∼80 000 Gd3+ ions per nanoparticle.528 All three modalities were able to detect the nanomaterials with picomolar sensitivity. The three modalities can fit into the pre-existing clinical workflow, which may require MRI for guiding stereotactic surgery and tumor staging, high-resolution tumor localization using PAI, and then, once surgery is nearly finished, tumor margin resection using a Raman-based camera. A single injection of the gold nanomaterial allowed all three imaging modalities to be performed in series in multiple mouse models. Assuming the nanomaterial also enters the tumor and remains at the site for a sufficiently long time in humans, it thus has translational potential.528 Moreover, given that the core Raman imageable nanomaterial is gold, a multimodality imaging framework that includes X-ray CT is likewise configurable using the same structure.446 Because there are many recent reviews describing multimodality imaging of nanomaterials,2,91,461,529 in this section we give a broad overview and highlight several recent instances of exciting new nanomaterials for multimodal in vivo imaging."
    }, {
      "heading" : "3.1. Multimodality Nanomaterials",
      "text" : "Nanomaterials are ideal structures for multimodality imaging. A nanomaterial can intrinsically exhibit contrast for one or more modalities, and the high surface area-to-volume ratio provides tremendous opportunities to adsorb420 or to covalently or noncovalently append contrast molecules to produce highdimensional multimodality structures.530,531 Although multimodality nanomaterials are now quite common due to the ease of appending contrast molecules (e.g., a base of iron oxide for MRI upon which optical or nuclear capabilities can be\nmounted227,523), intrinsically multimodal nanoparticles (i.e., those imageable by multiple modalities without further modification) remain relatively rare. One such example is a Gd2O3 nanomaterial recently developed for imaging by both T1-weighted MRI (via Gd) and CT (due to the high electron density and thus X-ray absorption).532 The unique Gd chemistry enables the intrinsic multimodality that in fact makes possible the MRI/CT dual-imaging strategy. The typical approach would be to append Gd to nanoparticles via chelation; however, this strategy is not feasible for CT contrast because Gd-chelates can be concentrated only up to ∼0.5 M as there is only one Gd atom per Gd-chelate complextoo low for CT. A one-pot synthetic method was used to generate iodine-coated Gd2O3 nanomaterials of ∼2 nm in diameter from GdCl3. Soon after i.v. injection, the nanomaterials were visible based on brightened contrast in the liver, kidneys, and aorta using both T1-weighted MR at 1.5T and CT. Because of their small size, the nanomaterials cleared quickly from the organs, from 15 min (kidneys and aorta) to 90 min (liver). Such minimization of the nanomaterial half-life in the body bodes well for clinical translation. Furthermore, ∼10-fold less Gd2O3 nanoparticles were required to visualize organs in vivo when compared with typical iodine-based CT contrast agents.532 Non-Gd-based MRI/CT nanomaterials were recently fabricated for intrinsically multimodal ultrahigh-field MRI and CT imaging. These NaHoF4 nanomaterials were synthesized and shown to provide strong specific X-ray absorption and MR relaxivity properties, particularly for high-field MR systems such as 7T533 (e.g., see the dysprosium nanomaterials described in section 2.3.1.2). SWNTs were the harbinger of nanotubular materials (section 2.4.1), quasi-one-dimensional structures first introduced by Iijima when he described SWNTs of microns in length and only a few nm in diameter.534 Luckily for the imaging field, the fantastic chemical arrangement making possible these nanotubules turned out not to be completely unique to carbon, and a range of transition metal oxides gave rise to nanotubular configurations under appropriate conditions, such as TiO2.\n535,536 The potential medical impact of these materials is owed to the chemical structure that inherently imparts optical and multimodal imaging potential, as well as shape-based in vivo delivery efficiencies. Leading this (preclinical) revolution are the same structures that started itcarbon nanotubes (both single- and their multiwalled cousins). They display excellent intrinsic multimodality capability, including high inherent optical (fluorescence, Raman, and photoacoustic) and acoustic characteristics (Figures 10, 12, and 19).393,537 Furthermore, by imbibing Gd3+ ion clusters inside SWNTs or loading them into sidewall defects (Figure 38),538,539 the SWNTs are rendered MR imageable and their multimodality is increased by one dimension without occupying any precious real estate on the nanomaterial surface.537,539\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBI\nIn a novel multistep and multimodal approach that flips upside down the paradigm of building up nanomaterials from constituent structures in vivo (self-assembling nanomaterials in section 2.7.2), Zheng and colleagues created ultrasonically imageable microbubbles that are convertible to fluorescently and photoacoustically active porphyrin nanomaterials upon a pulse of low-frequency ultrasound.540 This strategy advantageously allowed larger microscale carriers to reach the tumor vasculature, at which point ultrasonic energy bursts the microbubbles to propel nanomaterials into the tumor interstitium rather than depending upon the EPR effect for delivery in an approach that employs ultrasound as both imaging modality and localized delivery vector. These delivered nanomaterials (porphyrins) could then be further imaged using PAI and fluorescence in a multistep multimodality strategy in tumor-bearing mice. In general, the design of multimodal nanomaterials should preferably take into account the characteristics of the imaging modalities used, and optimally the two modalities will synergistically interact to improve diagnostics. For example, PET and MRI are complementary modalities that can now be performed on a single machine. PET’s high sensitivity and low resolution can be well-compensated by MRI’s high spatial resolution, relatively low sensitivity, and exquisite soft-tissue contrast.1 The benefits of each simultaneously permit decreased PET radiation doses and considerably increase the information collected about the patient. Fortunately, it generally turns out to be fairly simple to incorporate nuclear and magnetic labels (e.g., 64Cu and Gd3+) into nanomaterials simply by virtue of the modularity and flexibility of chelation to surface functional groups. Alternative methods such as adsorption can in some cases perform even better; for instance, in the approach taken by Liu and colleagues described in section 2.6.1,420 Cu2+ ion adsorption to defect sites in iron oxide MoS2 nanosheets yields MRI/PET/PAI trimodality nanomaterials that also minimize free Gd3+. Each separate nanomaterial, iron oxide, radioactive Cu2+, and MoS2, was required to construct the trimodality nanomaterial to permit multimodal imaging. Many other approaches similarly append imageable entities to the surface, such as a Gd−Au nanomaterial with magneto-optical properties (MRI/2-photon luminescence/OCT/reflectance),345 gold nanoparticles bound to microbubbles for an acousto-optical material capable of PAI/ultrasound contrast,541 and 69Ge-iron oxide (via pH-dependent adsorption of Ge ions to iron oxide) dual-modal PET/MR nanomaterials.397 On the other hand, intrinsically multimodal nanomaterials such as the nanotubes described earlier and gold nanomaterials are valuable as their chemistries are relatively simple, are well-described, and provide many options for imaging. Because of the simplicity, it is likely that future clinically used multimodal imaging nanomaterials will be derived from intrinsically multimodal nanomaterials; the large number of nanoparticles needed for human medicine requires cost-effective, scalable chemistries that many multicomponent nanomaterials currently lack. Either improved, highly efficient nanofabrication chemistries will be required or a preference for intrinsic multimodality nanomaterials in clinical imaging is likely to emerge. C dots, the silica nanomaterial in clinical trials for imaging metastatic melanoma described in section 2.6.1, are also a multimodal nanomaterial.435 The silica nanoparticles contain a fluorescent dye, making them optically imageable, with an attached 124I radiolabel for PET. PET imaging provides the physician with information on the presence and location of\nmetastatic lesions, while the fluorescence potentially allows a surgeon to intrasurgically resect all tumor cells at the margins. Notably, PET and fluorescence imaging do not display the same degree of sensitivityfor instance, in some studies PET is an order of magnitude more sensitivethus removing one of the primary benefits of multimodality imaging nanomaterials: the capability to inject one nanomaterial at one time to image with multiple imaging modalities.2 However, by optimizing the ratio of contrast mass per nanoparticle such that the ultimate sensitivities balance, such issues can be overcome."
    }, {
      "heading" : "3.2. Theranostic Nanomaterials",
      "text" : "The field of theranostics represents an ideal vision for how medicine might operate in the future. A theranostic is an agent that merges reporter diagnostic capabilities, typically imaging, with therapeutic capabilities. We have described how modular, multifunctional nanomaterials lend themselves to imaging with many modalities. Likewise, nanomaterial chemistry allows diverse therapeutic functionalities such as (i) simple delivery of a therapeutic/drug payload, (ii) an ability to absorb extrinsic energy and dissipate it as heat to destroy nearby cells, and (iii) delivery of photodynamic or other stimulus-responsive therapeutics. Nevertheless, while the theranostic vision is grand, practical considerations may often preclude its use. For instance, unless the therapeutic cargo is innocuous to healthy cells, theranostics should optimally be applied primarily in conditions in which the disease has already been diagnosed because it is unethical to expose healthy people to unneeded drugs. In patients with known disease, the theranostic agent may be used to (i) stage the disease, (ii) determine whether the disease appears at sites other than the primary location, (iii) evaluate the response of the disease to a previously administered therapeutic regimen, (iv) perform image-guided drug delivery, and/or (v) use imaging to monitor the release of therapeutic from the theranostic agent (or the kinetics of therapy by photothermal or photodynamic strategies).542−544 Note, however, that this paradigm leaves open the potential for use of theranostics on healthy patients with drugs that are only able to specifically act on diseased cells or can be remoteactivated by supervising operators/physicians, such as irradiation for tissue heating or neutron capture. Thus, to protect possibly healthy patients undergoing diagnostic tests from potential unnecessary harm, failsafe mechanisms will need to guard against agents acting on healthy cells. Nanomaterials embody the ideal design form for theranostics, just as with multimodal contrast, due to their highly modular nature. Advanced nanomaterials often display many of the properties that can power the theranostics field, including targetable delivery, sustained and controlled release, improved transport efficiency, “smart” stimulus-responsive agent release, synergistic therapeutic regimens (e.g., multidrug combination therapy or drug plus heating/radiation/other therapeutic), and multimodality diagnostic capacity.545 Illustrative of this paradigm is an organic agent recently developed by Lam and colleagues.546 A single theranostic platform, constructed from porphyrin/cholic acid to create a hybrid polymer and termed “nanoporphyrin”, was demonstrated to perform in vivo multimodal imaging and was capable of delivering diverse therapeutic regimens. The nanoconstruct enabled trimodality in vivo near-infrared (NIR) fluorescence, MRI, and PET imaging while simultaneously being capable of trimodality therapeuticsheat-induced (photothermal), photodynamic (conversion of light to singlet oxygen), and drug release therapies, the latter\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBJ\nincluding smart programmable release properties.546 Such allin-one multifunctional, multimodal agents have immense potential, yet ultimately they must be adapted for clinical need. Chemists and materials scientists are pushing the frontiers of\ntheranostic nanomaterials with respect to both increasing their sophistication and their synthetic simplicity/efficiency. Indeed, the clinical potential of theranostic nanomaterials hinges in large part on their synthetic simplicity and efficiency of material use. Emblematic of this, the Gd2O3 nanomaterial described earlier in the multimodal imaging section (section 3.1) was developed as an efficient multimodal (MRI/CT) agent integrated with a radiation therapy component.532 All the imaging and therapeutic functionalities were based on Gd. 157Gd, at 15.6% of the natural abundance of stable Gd, has the highest thermal neutron-capture cross section. This makes the isotope highly amenable to neutron-capture cancer therapy. While many theranostic nanomaterials require complex syntheses that will likely encounter scale-up issues because of the need to append multiple imaging and therapeutic modules, this intrinsic multimodal/therapeutic Gd2O3 nanomaterial is created using a simple synthetic route.532 After injection, the therapeutic strategy requires the patient to be irradiated with slow neutrons, which are stopped by the Gd at the disease site and converted into high-energy particles that destroy surrounding tissues. While boron is the only material that has thus far been used in patients for neutron capture, theranostics such as Gd2O3 are likely to improve the clinical state-of-the-art in the near future by providing superior capture efficiency and multimodality capability.\nPolymeric materials are extraordinarily malleable and can be molded into nearly any geometry, a particularly advantageous feature for nanomaterial theranostics where size and shape are critical.15,544 A common method of molding polymeric contrast and therapeutic agents via physical encapsulation is soft lithography. Soft lithography, a broad term covering many methods for top-down fabrication of polymeric materials often via molds or stamps, has engendered low-cost, high-throughout generation of polymeric nanomaterials.547,548 PRINT (particle replication in nonwetting templates) is a variation of soft lithography designed to create clinically scalable numbers of identical polymeric nanomaterials comprising one’s choice of polymer or copolymer blends with nearly any (2-dimensional) shape and encapsulating desired imaging agents and/or drugs. Pioneered by the DeSimone group, PRINT affords precise control not only over nanomaterial size/shape (Figure 39) but also over nanomaterial surface chemistry and mechanical modulus.548\nCarbon-based nanomaterials with sp2 bonds, such as nanotubes, buckyballs, and graphene, have found numerous applications in theranostics55,249 (see Figure 40). We have already described their intrinsic multimodality imaging properties (see sections 2.4.1 and 3.1), e.g., optical and acoustic imaging, and the same structural chemistry that produces diverse multimodality imaging features also serves them well for therapeutic purposes. For example, the excellent optical absorption properties that drive their PAI use also enable them to easily thermally ablate disease sites.375,549 Moreover, their unique chemical structure provides a suitable surface for π−π stacking of chemically appropriate aromatic-containing\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBK\ndrug molecules or imaging agents.550 Larger drugs such as siRNA or proteins can also be loaded by functionalization with the solubilizing surface linker molecules (often PEG) due to the nanomater ia l s ’ enormous sur face area - to-volume ratio.249,537,545,550,551\nMany theranostic nanomaterials include optical constituents, particularly fluorescence, for in vivo/ex vivo tracking in tissues, e.g., fluorescence imaging, intravital microscopy, and histology. Recent work has paired multimodal core/shell upconversion nanomaterials with an intrinsic Gd shell for MRI capabilities loaded with photosensitizer molecules (chlorin e6) for photodynamic treatment (Figure 41).118 Fluorescence and MRI both revealed tumor uptake upon i.v. injection into nude mice (Figure 41c−f). In a novel strategy, the therapeutic mechanism was directly linked to the imaging approach: by\ncoupling the upconversion nanomaterial with photosensitizers, it was possible to shift the typically visible-light-triggered photosensitizer excitation to the near-infrared, enabling therapy at significantly deeper tissue penetration. The synergism displayed between the diagnostic and therapeutic aspects of the nanomaterial is an excellent example of shrewdly designed chemistries working in concert to improve theranostic value. Many more examples of the utility of upconversion nanomaterials in theranostics were covered in a recent comprehensive review.271\n3.2.1. Smart Theranostic Nanomaterials. Despite the fact that overall it remains extraordinarily challenging to fabricate all-in-one nanomaterials such as theranostics, the emergence of smart theranostic nanomaterials presages potentially completely new roles for nanomaterials that were\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBL\npreviously unthinkable. For instance, quantitatively measuring the delivery of a drug to a disease site is very challenging. However, it is now possible to image and quantify the delivery of therapeutic molecules released from their carrier nanomaterials.543 A multimodal upconversion/MRI nanomaterial was fabricated to monitor drug release via LRET. NaYF4:Yb/Tm@ NaGdF4 core/hollow mesoporous silica shell particles (Figure 42a−h) assessed the release of encapsulated doxorubicin (Dox) via both fluorescence and T1 MRI. The incorporation of a photomechanical-modified azobenzene on the mesoporous nanomaterial surface permitted near-infrared light-triggered drug release. The release was quantitatively monitored fluorescently in real time using the LRET donor−acceptor pair of the upconversion nanomaterial and the fluorescent drug Dox (Figure 42i, j). Upconversion luminescence increases and LRET decreases as the drug is released, reducing energy transfer events. For MRI, T1 signal quantitatively increased upon release of Dox because the Dox loading decreases the probability of water molecules interacting with Gd3+ ions in the nanomaterial. Therefore, upon inoculation and subsequent near-infrared irradiation of the nanomaterial in both zebrafish and rats, time-dependent release of the drug was visualizable with luminescence (zebrafish) and a 3T clinical MR system\n(rats) (see Figure 42i, k), which has potential for eventual clinical translation due to the necessary deep-tissue penetration. Other smart theranostics make use of other physical stimuli to control therapeutic release, such as pH-, thermal-, or ultrasound-mediated activation.7,552 Despite the level of sophistication of experimental nanotheranostics, clinical theranostic nanomaterials are currently in a nascent stage. However, as key issues of biocompatibility, targeting, and synergism in therapy are resolved, theranostics are expected to become an increasingly important part of the personalized medicine paradigm that is emerging in clinical medicine.544"
    }, {
      "heading" : "4. CLINICAL NANOMATERIALS",
      "text" : "A wide gulf spans preclinical and clinical in vivo imaging of nanomaterials. The plethora of preclinical nanomaterials evidenced in this Review does not presage the relatively minute number of nanomaterials currently used in the clinic or those which are passing through regulatory agencies. Partly, this is the nature of translational medicineit requires considerable funding and considerable motivation. Partly, this is a function of the perceived difficulty in obtaining approval for diagnostic (imaging) agents that are injected at greater than trace levels (as is the case for small-molecule nuclear medicine). Finally,\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBM\nthis is partly attributable to the regulatory state of nanomedicine in general: imaging nanomaterials display parallels with several of the same issues plaguing therapeutic nanomedicines (such as nanocarriers often experiencing a more tortuous regulatory path to the clinic than small molecules or antibodies).553 There are multiple strategies for dealing with the risk in pursuing clinical applications with nanomaterials, including the following: (i) make them fully biodegradable into nontoxic byproducts (e.g., liposomes, micelles, polymeric compounds, etc.);438,553,554 (ii) begin with topical or otherwise local rather than systemic administration of the agent to ease worries of systemic toxicity (e.g., delivery to mucosal tissues such as the colon, vagina, etc., in which the materials could predominantly be washed out and never truly enter the body/ bloodstream);335,403 (iii) direct their application toward therapeutic response (which ensures that patients already\nhave a disease and requires a (improved) mechanism for predicting their response to conventional or experimental therapeutics; increased risk of side effects may also be tolerable in such populations if the nanomaterial is sufficiently efficacious); and (iv) direct their utility toward diagnostics for disease states that tend to be terminal if the diagnosis can provide earlier, actionable information for the physicians. However, even with the benefit of one or more of these strategies, considerable risk remains. There must be clear rationale to proceed to the clinic with\nnanomaterials over traditional small-molecule imaging agents, whether efficacy, cost, or other advantage. A number of preclinical studies have demonstrated superior efficacy of nanomaterials over similar small-molecule imaging agents. For example, polymeric nanomaterials outcompeted their monomeric counterparts on circulation half-life (about an order of\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBN\nT ab le\n3. C om\npa ri so n be tw ee n th e C lin\nic al\nA ct iv it y of\nSe ve ra l Sm\nal l-M\nol ec ul e an d N an om\nat er ia l Im\nag in g A ge nt s fo r Im\nag in g D is ea se a\nsm al l m ol ec ul e/ na no - m at er ia l\nim ag in g m oda lit y\ndi se as e\npu rp os e\nse ns iti vi ty (a bi lit y to av oi d fa ls e ne ga tiv es )\nsp ec ifi ci ty (a bi lit y to av oi d fa ls e po si tiv es )\not he r cl in ic al m ea su re s (D\nA ,\nPP V ,N\nPV )\nm os t cl in ic al ly re le va nt\ndi ff er en ce\nre as on\nfo r di ff er en ce\n(h yp ot he si ze d)\nre f\nM an ga fo di pi r (G d ch el at e)\nM R I (T\nl, G R E)\nhe pa tic\nca nc er\n(p rim\nar ily\nhe pa - to ce llu la r ca rc ino m a, H C C )\nde te ct io n/ ch ar ac te riz at io n\n63 %\nN A\nD A (f oc al le - si on s) 74 % ; D A (d is tin - gu is hi ng\nH C C\nvs no nH C C )b 92 %\nH C C re ad in gs\nw er e si gn ifi ca nt ly m or e cl ea r\nus in g th e Fe ru m ox id es\nna no m at er ia ls (n on -\nH C C le si on s sh ow\ned si m ila r se ns iti vi ty\nbe tw ee n th e tw o) ,e sp ec ia lly\nfo r sm\nal l H C C ;\nco nv er se ly ,t he\nac cu ra cy\nfo r di st in gu is hi ng be tw ee n he pa to ce lu la r an d no nh ep at oc el lu la r or ig in s w as si gn ifi ca nt ly be tt er us in g M an - ga fo di pi r\nG d is an\nex tr ac el lu la r sp ac e ag en tw\nith ut ili ty\nin fi lli ng\nup su ch\nsp ac e, w hi ch\nis us ef ul fo r\nfo ca ll iv er\nan d hy pe rv as cu la r le si on s, w hi le iro n ox id e na no m at er ia ls ar e tis su esp ec ifi c fo r he pa to cy te s an d th e m on on uc le ar ph ag oc yt e sy st em ,a nd th ey pr ov id e a lo ng er sc an w in do w ; au th or s no te th at iro n ox id e co ul d be us ed fo r T l-w ei gh te d im ag es al so ,w hi ch co ul d ai d di ag no si s, bu t w as no t do ne in th is st ud y\n56 4\nFe ru m ox id es\n(s up er -\npa ra m ag ne tic\niro n\nox id e)\nM R I (T\n2, FS\nE) he pa tic\nca nc er\n(p rim\nar ily\nhe pa - to ce llu la r ca rc ino m a, H C C )\nde te ct io n/ ch ar ac te riz at io n\nb 82 %\nN A\nD A (f oc al le - si on s) b 86 % ; D A (d is tin - gu is hi ng\nH C C vs no nH C C ) 79 %\nM ag ne vi st (g ad op en - ta te di m eg lu m in e)\nM R I (T\nl, T FE\n) fo ca l liv er\nle si on s\ndi ag no si s/ ch ar ac te riz at io n\n79 %\n85 %\nD A 83 % ; PP V 68 % ;N\nPV 91 %\nsu pe rio\nr sp ec ifi ci ty\nan d PP\nV re su lt in\na st ro ng\nre co m m en da tio\nn to\nus e iro\nn ox id e na no m a-\nte ria ls to\ndi ag no st ic al ly ch ar ac te riz e fo ca l liv er\nle si on s pa rt ic ul ar ly w he n G d im ag es\nar e\nun ce rt ai n\nth e w ay\nin w hi ch\niro n ox id e na no m at er ia ls\nho m og en eo us ly di st rib\nut e in\nth e liv er\nw he n no\ndi se as e is pr es en ti s an\nim po rt an t\nfe at ur e fo r its\nex ce lle nt\nfa ls e po si tiv e ra te s,\nw he re as\nG d ca n le ad\nto su sp ic io n of\nm al ig na nc y w he re\nno ne\nex is ts\n15 1\nR es ov is t\nM R I (T\n2, T SE\n) fo ca l liv er\nle si on s\ndi ag no si s/ ch ar ac te riz at io n\nc 7 4%\nb 99 %\nD A c 9 2%\n; PP\nV b 96 % ;\nN PV\nc 9 0%\n18 FFD\nG PE\nT /C\nT co lo re ct al ad en oca rc in om\na id en tifi ca to n of m et as ta si s po st - ch em ot he ra py\n52 %\n96 − 98\n% N A\nhi gh\nse ns iti vi ty\nby iro\nn ox id e na no m at er ia ls to\nde te ct m et as ta si s in\nth e w ho le po pu la tio\nn an d\npe r se gm\nen t (s ur gi ca l; fo llo w -u p pa tie nt s)\nsi gn ifi ca nt ly ou tp er fo rm\ned PE\nT -C T w ith\nFD G\niro n ox id e na no m at er ia ls w ith\nM R I di sp la y\nst ro ng er\ntis su e ch ar ac te riz at io n ca pa bi l-\niti es ;a ls o, FD\nG -P ET\ndi sp la ys\nlo w er sp at ia l\nre so lu tio\nn, w hi ch\nm ay\nhu rt di sc rim\nin at io n\nof sm\nal l le si on s\n56 6\nEn do re m\nM R I (T\n2- w ei gh te d G R E)\nco lo re ct al ad en oca rc in om\na id en tifi ca tio\nn of\nm et as ta si s\nb 92 %\nc 9 5−\n96 %\nN A\n18 FFD\nG PE\nT m et as ta tic\nm el a-\nno m a\ndi ag no si s/ st ag in g/ tr ea tm en t m an - ag em en t\nN A\nN A\nN A\nin th is sm\nal l pi lo t st ud y w ith\nlo w do se s (N\n= 5\npa tie nt s) ,n\no si gn ifi ca nt\ncl in ic al ta ke aw\nay s\nw er e po ss ib le ; w hi le tu m or\nta rg et in g w as\nno t\nth e st at ed\ngo al in\nfa vo r of\nge ne ra l ch ar ac te r-\niz at io n,\npr el im in ar y ev id en ce\nsu gg es te d th at\nFD G\nsi gn al at\nth e tu m or\nsi te\nm ay\nha ve\nbe en\nhi gh er\nth an\nC do t PE\nT si gn al ; ho w ev er ,o\nnl y\nPE T w as\npe rf or m ed ,a nd\nFD G\nca nn ot be vi su al iz ed in tr as ur gi ca lly as C do ts ca n us in g its m ul tim od al fl uo re sc en ce pr op er tie s\nC do ts w er e ta rg et ed\nto bl oo d ve ss el s ba se d\non pe pt id e bi nd in g to\nva sc ul ar\nin te gr in s,\nw hi le FD\nG is ta rg et ed\nba se d on\nin cr ea se d\nce ll m et ab ol is m\n43 5\nC do ts (1\n24 IcR G D y-\nPE G -C do t)\nPE T -C T /fl uor es ce nc e\nm et as ta tic\nm el a-\nno m a\ndi ag no si s/ st ag in g/ tr ea tm en t m an - ag em en t\nN A\nN A\nN A\nb In di ca te s si gn ifi ca nt\ndi ff er en ce .c In di ca te s no t si gn ifi ca nt .a A bb re vi at io ns : D A = di ag no st ic ac cu ra cy ; PP\nV = po si tiv e pr ed ic tiv e va lu e; N PV\n= ne ga tiv e pr ed ic tiv e va lu e; T FE\n= tu rb o fi el d ec ho ; T SE = tu rb o sp in ec ho ; G R E = gr ad ie nt -r ec al le d ec ho ; FS E = fa st sp in ec ho ; N A = no t av ai la bl e.\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBO\nmagnitude longer for the nanoparticles) and increased the probability of binding to target in murine and rat models413 (see section 2.6.1, chelated nanomaterials subsection). In MRI applications, Gd-based nanomaterials allowed 10-fold less Gd to be used than the clinically used small-molecule agent Magnevist (and may thus be safer) primarily due to improved tumor accumulation and retention of the nanoparticle.107 There are a variety of other reasons nanomaterials may eventually outperform small molecules in imaging, such as physical amplification of reporter signal,320 spatial constriction,505 and intelligent responses to stimuli525 (see section 3). However, these newer-generation nanomaterials have not yet reached the clinical imaging trial stage. Due to the paucity of nanomaterials in the clinic, few comparison studies have been performed between nanomaterials and small molecules aside from iron oxide nanomaterials versus small molecules using clinical MRI. Indeed, the literature is relatively rich in clinical studies performed to compare nanomaterials (iron oxides) with gadolinium chelates specifically for imaging focal liver lesions.555−564 To help appreciate the state-of-the-art in contrast-based clinical imaging, we selected and compared several nanomaterial/small-molecule pairs that were used for identical patient indications (Table 3). The agents are assessed as a function of their key differences in clinical value; nanomaterials prove heterogeneous in their benefits, displaying both advantageous and disadvantageous qualities for imaging compared with their small-molecule counterparts (Table 3). Iron oxide nanomaterials often represent a superior choice to small-molecule 18F-FDG PETCT or small-molecule gadolinium chelates in liver imaging oncology applications, for instance, to identify and characterize liver metastasis or focal liver lesions.565,566 On the other hand, nanomaterials can be disadvantageous for certain diagnostic applications if, for example: (i) they are required to extravasate (due to the heterogeneity of EPR in cancer); (ii) early timepoints are desirable; or (iii) in the specific case of hepatic MR imaging, the ability to explore hypervascularity in liver lesions appears to be reduced for nanomaterialsall three areas in which small molecules often excel.113,151,559 It is possible that a single i.v. injection of both iron oxide and small-molecule gadolinium agents may be optimal to reap the combined advantages of both early extracellular liver imaging (Gd) and delayed intracellular hepatobiliary imaging (nanomaterial).151\nIron oxides have also been found to be superior to small gadolinium agents for brain cancer applications,189,567 such as for improved tumor margin delineation over a longer time period.567 In one study, Gahramanov et al. compared ferumoxytol (iron oxide) to a small-molecule gadolinium agent for identification of progression versus pseudoprogression in patients with glioblastoma multiforme.189 The nanomaterial improves discrimination because it does not extravasate (based on size) during contrast-based image acquisition and thus does not require leakage correction, which substantially simplifies the modeling necessary to make the progression/pseudoprogression judgment. Similarly, carbon nanomaterials have been used as optical agents that can detect lymph node metastasis (which is a key prognostic indicator and most predictive for survival) in colorectal cancer based on their sizein particular, their ability to enter lymph vessels but not blood vessels (small molecules enter both).84 In yet other applications, iron oxide nanomaterials were observed to be superior to their small-molecule counterparts to accurately detect liver metastasis (compared with iodine-based iohexol in\nCT and ultrasonic microbubbles, especially for smaller tumor foci)568 and to detect sentinel lymph nodes for biopsy as part of breast cancer treatment planning (showing significantly higher nodal retrieval compared with small-molecule 99mTc SPECT and a blue dye).569,570\nNotably, comparisons between iron oxide nanomaterials and small molecules have been more limited in recent years primarily due to the considerably limited markets in which iron oxides are now available for imaging, mainly in Japan (aside from off-label nanomaterial imaging studies185,189,571). Clinical studies are also branching out from cancer imaging, with visualization of other diseases becoming increasingly common, including type-I diabetes and atherosclerosis.571,572 Taken together, clearly when one chooses a nanomaterial for a clinical application, it is critical to evaluate it on its merits for that particular application, as there are typically a complex set of trade-offs between nanoimaging agents and small molecules. As is particularly transparent from this section, while several nanomaterials are entering or in the clinic for imaging applications, the vast majority of the excitement over imageable nanomaterials stems from their promise and demonstrated potency in preclinical imaging and characterization. To stir the same levels of enthusiasm about nanomaterials in the clinical realm as has recently developed in preclinical and basic research, the agents will need to not only display the high signal and other physical/biological properties demonstrated by many research groups70,91,283,573 but also to change clinical outcomes. This much higher bar for success arises mainly out of the difference in culture between basic/preclinical and translational/clinical research; while the basic side is focused more on the physical parameters, in vivo contrast, and ultimate potential of a new nanomaterial, clinical work concentrates on diagnostic accuracy (e.g., false positive/false negative rate; see section 2.6.1, subsection on imaging screens), clinical actionability, cost savings, and survival benefits as a direct consequence of the imaging scan.433 To optimize the chance of clinical success, nanomaterials (just as any imaging agent) must be paired intelligently with their clinical application. Although it is difficult to accurately gauge, an impression of the literature in the field reveals that many nanomaterial imaging agents are likely directed into preclinical disease models (if the agents make it even that far toward medical application574) based more on ease of access, familiarity, and cost rather than on the basis of a diligent assessment of the clinical landscape with substantial physician input to match specific nanomaterial benefits/disadvantages with clinical needs and process. To improve clinical successes, narrowing the gap between basic/ preclinical research and translational/clinical research is necessary. To accomplish this directive, options include the following: (i) to better organize clinical needs and key parameters into databases that researchers can easily search and/or (ii) when embarking upon preclinical studies with a new agent, researchers should be strongly encouraged to consult with clinicians, perhaps even as a precondition to publication in some journals."
    }, {
      "heading" : "5. CONCLUSIONS AND OUTLOOK",
      "text" : "The past few years have seen enormous strides made in the in vivo imaging of nanomaterials, impacting the spectrum of human disease. We have shown how nanomaterials often display considerable advantages over small-molecule imaging agents and fill a critical niche between small-molecule and larger imaging agents. In fact, novel nanomaterials have driven\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBP\nunprecedented imaging sensitivity, penetration depth, and multimodality capacity that were scarcely imagined over a decade ago. Because of this, they have also raised the expectations for a field that has seen its share of hype. A key to fulfilling these expectations is a balance between nanomaterial safety concerns, synthetic simplicity/efficient scale-up, innovation, and suitable match to clinical needs that makes possible markedly superior imaging properties such as delivery, sensitivity, and efficiency. If the nanomaterials field realizes these goals, the field’s and the public’s lofty expectations of nanomedical diagnostics will be achieved. Nanomaterials often offer features that would be impossible or nearly so for small-molecule agents.413 Nanomaterials, for instance, have been used to constrain the diffusion of molecules such as Gd, increasing signal contrast.575 They can also be designed to increase signal at an appropriate site,413 to unlock high-dimensional multimodality and theranostic applications and synergistic benefits thereof,1,544 decrease toxicity (e.g., by minimizing the probability of toxic Gd dissociation compared with chelate dissociation114), increase spatial resolutions (e.g., by improving T1 relaxivities, thereby leading to improved MRI resolution521), unlock the ability to use some imaging modalities (e.g., MPI and magneto-motive methods require magnetic nanomaterials to obtain images164,167), and permit the use for the first time of contrast in other imaging modalities (e.g., ultrasound contrast cannot be generated by small molecules, rather, to enable application as an ultrasonic contrast agent, larger structures such as nano- to micromaterials are required384,385). The pace of all new nanomaterials moving into clinical trials remains relatively gradual but is clearly accelerating for therapeutic nanomaterials.576 The safety standards for diagnostic nanomaterials used for in vivo imaging are justifiably higher than for therapeutic nanomaterials because of the potential for chronic harm to completely healthy patients due to diagnostic tests. Despite this higher bar, increasingly diverse nanomaterials for in vivo imaging are appearing in clinical trials and provide a glimpse into their potential to identify and localize disease early.113,435,473,577 As increasingly sophisticated and smart imaging nanomaterials enter clinical trials, including multimodal and theranostic nanomaterials, it will become clear to clinicians why the imaging field is so enthusiastic about their potential to transform medicine. Once nanomaterials are fit into clinicians’ existing workflow and provide key benefits over other options such as the ability to detect otherwise imperceptible disease, they are likely to become essential medical tools. It is important for scientists and clinicians alike to choose the most appropriate nanomaterial to pair with a suitable imaging modality to optimize the diagnostic information collected.113,432 Understanding the basis of the nanomaterial signal through the physicochemical properties as described in this Review supports this pursuit. For instance, appreciating that upconversion nanomaterials will produce minimal autofluorescence based on their anti-Stokes emission properties may lead to their selection in some instances, depending on the toxicity tolerance for lanthanides in vivo; likewise, simply recognizing that iron oxide nanomaterials could be used for multimodal MRI, MPI, and MMUS could lead to synergistic multipurpose imaging. Moreover, new nanomaterials can not only support clinical imaging but can elucidate physiologic structures with unprecedented precision to make possible new biological discoveries through in vivo preclinical imaging.\nNanomaterials are changing the face of what is possible in imaging by fostering superior sensitivity, depths, spatial resolutions, and contrast. In this rapidly transforming diagnostic landscape, it is important for clinicians to keep abreast of the latest nanomaterials clinically available to make the best decisions possible for patient health. Indeed, ever-smaller disease sites will be imageable with ever-more-accurate diagnoses and prognoses, and the detection of ever-earlier molecular hints of disease will be made possible by the shrewd use of in vivo imaging nanomaterials. Nevertheless, as this Review demonstrates, despite the stunning recent advances in the use of nanomaterials in vivo, much future work remains to achieve these grand goals.\nASSOCIATED CONTENT Special Issue Paper\nThis paper is an additional review for Chem. Rev. 2015, 115, issue 19, “Nanoparticles in Medicine”.\nAUTHOR INFORMATION Corresponding Authors\n*brsmith@stanford.edu. *sgambhir@stanford.edu. Notes\nThe authors declare no competing financial interest.\nBiographies\nDr. Bryan Ronain Smith is an Instructor in the Department of Radiology and the Molecular Imaging Program at Stanford (MIPS) at the Stanford University School of Medicine. He was awarded his B.S. in Physics, Mathematics, and Biomedical Engineering from Tufts University. He completed his Ph.D. at The Ohio State University in Biomedical Engineering as an NSF IGERT Predoctoral Fellow. At Stanford, Dr. Smith has been selected as a Stanford Molecular Imaging Scholar and Stanford Dean’s Fellow. His lab centers on the imaging of living subjects, particularly with nanomaterials, toward the development of nanoenabled precision medicine.\nDr. Sanjiv Sam Gambhir is the Virginia & D.K. Ludwig Professor of Cancer Research and the Chair of Radiology at Stanford University School of Medicine. He also heads up the Canary Center at Stanford for Cancer Early Detection and directs the Molecular Imaging Program at Stanford (MIPS). He received his M.D. and Ph.D. from the UCLA Medical Scientist Training Program. He has over 575 publications in the field and over 40 patents pending or granted. An internationally recognized researcher in molecular imaging with over $90 Million of NIH funding as the Principal Investigator, his lab has focused on interrogating fundamental molecular events in living subjects. He has developed and clinically translated several multimodality molecular imaging strategies. He was elected to the Institute of Medicine/National Academy of Medicine in 2008 and the American Association for the Advancement of Science in 2014."
    }, {
      "heading" : "ACKNOWLEDGMENTS",
      "text" : "We gratefully acknowledge the support of Dr. Seung-Min Park in developing Figure 1 and the TOC graphic, and we are grateful to the many colleagues who read and commented on the article, including Drs. Ophir Vermesh, Avnesh Thakor, Jos Campbell, Tim Witney, Michelle James, and Seung-Min Park. B.R.S. was supported by a K99/R00 award (K99 CA160764). S.S.G. was supported by a Center for Cancer Nanotechnology\nDOI: 10.1021/acs.chemrev.6b00073 Chem. Rev. XXXX, XXX, XXX−XXX\nBQ\nExcellence−Translation (CCNE-T) Grant (National Cancer Institute U54 CA119367)."
    } ],
    "references" : [ {
      "title" : "Nanoparticles for Multimodal in Vivo Imaging in Nanomedicine",
      "author" : [ "J. Key", "J. Leary" ],
      "venue" : "Int. J. Nanomed. 2014,",
      "citeRegEx" : "Key and Leary,? \\Q2014\\E",
      "shortCiteRegEx" : "Key and Leary",
      "year" : 2014
    }, {
      "title" : "Multimodality Imaging Probes: Design and Challenges",
      "author" : [ "A. Louie" ],
      "venue" : "Chem. Rev. 2010,",
      "citeRegEx" : "Louie,? \\Q2010\\E",
      "shortCiteRegEx" : "Louie",
      "year" : 2010
    }, {
      "title" : "Imaging Macrophages with Nanoparticles",
      "author" : [ "R. Weissleder", "M. Nahrendorf", "M.J. Pittet" ],
      "venue" : "Nat. Mater. 2014,",
      "citeRegEx" : "Weissleder et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Weissleder et al\\.",
      "year" : 2014
    }, {
      "title" : "Delivering Nanomedicine to Solid Tumors",
      "author" : [ "R.K. Jain", "T. Stylianopoulos" ],
      "venue" : "Nat. Rev. Clin. Oncol. 2010,",
      "citeRegEx" : "Jain and Stylianopoulos,? \\Q2010\\E",
      "shortCiteRegEx" : "Jain and Stylianopoulos",
      "year" : 2010
    }, {
      "title" : "Why Integrin as a Primary Target for Imaging and Therapy",
      "author" : [ "G. Niu", "X. Chen" ],
      "venue" : "Theranostics 2011,",
      "citeRegEx" : "Niu and Chen,? \\Q2011\\E",
      "shortCiteRegEx" : "Niu and Chen",
      "year" : 2011
    }, {
      "title" : "Pilot Study of FPPRGD2 for Imaging α(v)β(3) Integrin–How Integral Are Integrins",
      "author" : [ "P.L. Choyke" ],
      "venue" : "Radiology 2011,",
      "citeRegEx" : "Choyke,? \\Q2011\\E",
      "shortCiteRegEx" : "Choyke",
      "year" : 2011
    }, {
      "title" : "Nanoparticle Therapeutics for Prostate Cancer Treatment",
      "author" : [ "V. Sanna", "M. Sechi" ],
      "venue" : "Nanomedicine 2012,",
      "citeRegEx" : "Sanna and Sechi,? \\Q2012\\E",
      "shortCiteRegEx" : "Sanna and Sechi",
      "year" : 2012
    }, {
      "title" : "Design Considerations for Tumour-Targeted Nanoparticles",
      "author" : [ "J.V. Frangioni" ],
      "venue" : "Nat. Nanotechnol. 2010,",
      "citeRegEx" : "Frangioni,? \\Q2010\\E",
      "shortCiteRegEx" : "Frangioni",
      "year" : 2010
    }, {
      "title" : "A Multi-Center Study of Using Carbon Nanoparticles to Track Lymph Node Metastasis in T1−2 Colorectal Cancer",
      "author" : [ "L. Cai", "G. Xiang", "Z Deng" ],
      "venue" : "Surg. Endosc. 2014,",
      "citeRegEx" : "Cai et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Cai et al\\.",
      "year" : 2014
    }, {
      "title" : "Renal Clearance of Quantum Dots",
      "author" : [ "B. Ipe", "M.G. Bawendi", "J.V. Frangioni" ],
      "venue" : "Nat. Biotechnol",
      "citeRegEx" : "Ipe et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Ipe et al\\.",
      "year" : 2007
    }, {
      "title" : "Chemical Design of Biocompatible Iron Oxide Nanoparticles for Medical Applications",
      "author" : [ "D. Ling", "T. Hyeon" ],
      "venue" : "Small 2013,",
      "citeRegEx" : "Ling and Hyeon,? \\Q2013\\E",
      "shortCiteRegEx" : "Ling and Hyeon",
      "year" : 2013
    }, {
      "title" : "Compact Zwitterion-Coated Iron Oxide Nanoparticles for Biological Applications",
      "author" : [ "M.G. Bawendi" ],
      "venue" : "Nano Lett. 2012,",
      "citeRegEx" : "Bawendi,? \\Q2012\\E",
      "shortCiteRegEx" : "Bawendi",
      "year" : 2012
    }, {
      "title" : "Magnetic Particle Imaging (MPI) for NMR and MRI Researchers",
      "author" : [ "B. Zheng", "S.M. Conolly" ],
      "venue" : "J. Magn. Reson",
      "citeRegEx" : "K. et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "K. et al\\.",
      "year" : 2013
    }, {
      "title" : "Nanoparticles for Imaging: Top or Flop",
      "author" : [ "F. Kiessling", "M.E. Mertens", "J. Grimm", "T. Lammers" ],
      "venue" : "Radiology 2014,",
      "citeRegEx" : "Kiessling et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Kiessling et al\\.",
      "year" : 2014
    }, {
      "title" : "Inorganic Nanoparticles for MRI Contrast Agents",
      "author" : [ "H.B. Na", "I.C. Song", "T. Hyeon" ],
      "venue" : "Adv. Mater. 2009,",
      "citeRegEx" : "Na et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Na et al\\.",
      "year" : 2009
    }, {
      "title" : "T1 and T2 Dual-Mode MRI Contrast Agent for Enhancing Accuracy by Engineered Nanomaterials",
      "author" : [ "K.I. Park", "J. Cheon" ],
      "venue" : "ACS Nano 2014,",
      "citeRegEx" : "Park and Cheon,? \\Q2014\\E",
      "shortCiteRegEx" : "Park and Cheon",
      "year" : 2014
    }, {
      "title" : "Lanthanide-Based Nanocrystals as Dual-Modal Probes for SPECT and X-Ray CT Imaging",
      "author" : [ "W. Feng", "F. Li" ],
      "venue" : "Biomaterials 2014,",
      "citeRegEx" : "Feng and Li,? \\Q2014\\E",
      "shortCiteRegEx" : "Feng and Li",
      "year" : 2014
    }, {
      "title" : "Synthesis of Long T1 Silicon Nanoparticles for Hyperpolarized 29Si Magnetic Resonance Imaging",
      "author" : [ "Kauzlarich", "S. M" ],
      "venue" : "ACS Nano 2013,",
      "citeRegEx" : "M. and M.,? \\Q2013\\E",
      "shortCiteRegEx" : "M. and M.",
      "year" : 2013
    }, {
      "title" : "In Vivo Magnetic Resonance Imaging of Hyperpolarized Silicon Particles",
      "author" : [ "C.M. Marcus" ],
      "venue" : "Nat. Nanotechnol. 2013,",
      "citeRegEx" : "Marcus,? \\Q2013\\E",
      "shortCiteRegEx" : "Marcus",
      "year" : 2013
    }, {
      "title" : "In Vivo Magnetic Resonance Imaging of Hyperpolarized Silicon Particles",
      "author" : [ "C.M. Marcus" ],
      "venue" : "Nat. Nanotechnol. 2013,",
      "citeRegEx" : "Marcus,? \\Q2013\\E",
      "shortCiteRegEx" : "Marcus",
      "year" : 2013
    }, {
      "title" : "Red Blood Cells as Carriers in Magnetic Particle Imaging",
      "author" : [ "M. Magnani" ],
      "venue" : "Biomed. Tech. 2013,",
      "citeRegEx" : "Magnani,? \\Q2013\\E",
      "shortCiteRegEx" : "Magnani",
      "year" : 2013
    }, {
      "title" : "MRI Meets MPI: A Bimodal MPI-MRI Tomograph",
      "author" : [ "P. M", "F. Fidler", "V.C. Behr" ],
      "venue" : "IEEE Trans. Med. Imaging 2014,",
      "citeRegEx" : "M. et al\\.,? \\Q1959\\E",
      "shortCiteRegEx" : "M. et al\\.",
      "year" : 1959
    }, {
      "title" : "Reveals Pumping System to Penetrate Solid Tumors",
      "author" : [ "C. Jia", "S.-W. Huang", "M. O’Donnell", "X. Gao" ],
      "venue" : "Nat. Med. 2014,",
      "citeRegEx" : "Y. et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Y. et al\\.",
      "year" : 2010
    }, {
      "title" : "Imaging of Her2-Targeted Magnetic Nanoparticles for Breast Cancer Detection: Comparison of SQUID-Detected Magnetic Relaxometry and MRI",
      "author" : [ "J.E. Trujillo", "H.J. Hathaway", "D.L. Fegan", "T.C. Monson", "T.E. Stevens", "D.L. Huber" ],
      "venue" : "Contrast Media Mol. Imaging 2012,",
      "citeRegEx" : "Trujillo et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Trujillo et al\\.",
      "year" : 2012
    }, {
      "title" : "Nanoparticle-Enhanced Electrical Impedance Detection and Its Potential Significance in Image Tomography",
      "author" : [ "R. Liu", "C. Jin", "F. Song", "J. Liu" ],
      "venue" : "Int. J. Nanomed. 2013,",
      "citeRegEx" : "Liu et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Liu et al\\.",
      "year" : 2013
    }, {
      "title" : "Tomography during Major Open Upper Abdominal Surgery: A Pilot-Study",
      "author" : [ "J. Karsten", "C. Grusnick", "H. Paarmann", "M. Heringlake", "H. Heinze" ],
      "venue" : "BMC Anesthesiol. 2014,",
      "citeRegEx" : "Karsten et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Karsten et al\\.",
      "year" : 2014
    }, {
      "title" : "Surgery Patients",
      "author" : [ "T. I", "W.C. Jeong", "A. McEwan", "H.M. Park", "H.J. Kim", "O.I. Kwon", "E.J. Woo" ],
      "venue" : "Acta Anaesthesiol. Scand",
      "citeRegEx" : "I. et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "I. et al\\.",
      "year" : 2015
    }, {
      "title" : "A Comparison of Imaging Techniques to Monitor Tumor Growth and Cancer Progression in Living Animals",
      "author" : [ "A.-L. Puaux", "L.C. Ong", "Y. Jin", "I. Teh", "M. Hong", "P.K.H. Chow", "X. Golay", "J.-P. Abastado" ],
      "venue" : "Int. J. Mol. Imaging",
      "citeRegEx" : "Puaux et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Puaux et al\\.",
      "year" : 2011
    }, {
      "title" : "Nanoscopy in a Living Mouse Brain",
      "author" : [ "S. Berning", "K.I. Willig", "H. Steffens", "P. Dibaj", "S.W. Hell" ],
      "venue" : "Science",
      "citeRegEx" : "Berning et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Berning et al\\.",
      "year" : 2012
    }, {
      "title" : "Fluorescent Magnetic Nanoparticles for Magnetically Enhanced Cancer Imaging and Targeting in Living Subjects",
      "author" : [ "R.J. Wilson", "B.R. Smith", "J. Mullenix", "C. Earhart", "D. Akin", "S. Guccione", "S.X. Wang", "S.S. Gambhir" ],
      "venue" : "Mutant C. Elegans. Nat. Commun. 2014,",
      "citeRegEx" : "A. et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "A. et al\\.",
      "year" : 2012
    }, {
      "title" : "A Nanoparticle Size Series for in Vivo Fluorescence Imaging",
      "author" : [ "A.B. Greytak", "N. Insin", "D.G. Nocera", "D. Fukumura", "R. K Jain" ],
      "venue" : "Angew. Chem., Int. Ed. 2010,",
      "citeRegEx" : "Greytak et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Greytak et al\\.",
      "year" : 2010
    }, {
      "title" : "Nanocrystal Targeting in Vivo",
      "author" : [ "E. Ruoslahti" ],
      "venue" : "Proc. Natl. Acad. Sci. U. S. A. 2002,",
      "citeRegEx" : "Ruoslahti,? \\Q2002\\E",
      "shortCiteRegEx" : "Ruoslahti",
      "year" : 2002
    }, {
      "title" : "Noninvasive Imaging of Quantum Dots in Mice",
      "author" : [ "A.S. Waggoner" ],
      "venue" : "Bioconjugate Chem. 2004,",
      "citeRegEx" : "Waggoner,? \\Q2004\\E",
      "shortCiteRegEx" : "Waggoner",
      "year" : 2004
    }, {
      "title" : "Design of New Quantum Dot Materials for Deep Tissue Infrared Imaging",
      "author" : [ "Pons" ],
      "venue" : "Adv. Drug Delivery Rev. 2013,",
      "citeRegEx" : "B. and T.,? \\Q2013\\E",
      "shortCiteRegEx" : "B. and T.",
      "year" : 2013
    }, {
      "title" : "Graphene Quantum Dots",
      "author" : [ "M. Bacon", "S.J. Bradley", "T. Nann" ],
      "venue" : "Part. Part. Syst. Charact. 2014,",
      "citeRegEx" : "Bacon et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Bacon et al\\.",
      "year" : 2014
    }, {
      "title" : "Competitive Performance of Carbon “Quantum",
      "author" : [ "Y. Liu", "Y.-P. Sun" ],
      "venue" : "Dots in Optical Bioimaging. Theranostics 2012,",
      "citeRegEx" : "Liu and Sun,? \\Q2012\\E",
      "shortCiteRegEx" : "Liu and Sun",
      "year" : 2012
    }, {
      "title" : "Carbon Nanotubes for Enhanced Biopharmaceutical Delivery",
      "author" : [ "H. Rallapalli", "B.R. Smith" ],
      "venue" : "Rev. Cell Biol. Mol. Med. 2016,",
      "citeRegEx" : "Rallapalli and Smith,? \\Q2016\\E",
      "shortCiteRegEx" : "Rallapalli and Smith",
      "year" : 2016
    }, {
      "title" : "The in Vitro and in Vivo Toxicity of Graphene Quantum Dots",
      "author" : [ "S. Fan", "Z. Zhang" ],
      "venue" : "Biomaterials 2014,",
      "citeRegEx" : "Fan and Zhang,? \\Q2014\\E",
      "shortCiteRegEx" : "Fan and Zhang",
      "year" : 2014
    }, {
      "title" : "In Vivo Compatibility of Graphene Oxide with Differing Oxidation States",
      "author" : [ "R. Langer" ],
      "venue" : "ACS Nano 2015,",
      "citeRegEx" : "Langer,? \\Q2015\\E",
      "shortCiteRegEx" : "Langer",
      "year" : 2015
    }, {
      "title" : "Fluorescence Origin of Nanodiamonds",
      "author" : [ "J. Xiao", "P. Liu", "L. Li", "G.W. Yang" ],
      "venue" : "J. Phys. Chem. C 2015,",
      "citeRegEx" : "Xiao et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Xiao et al\\.",
      "year" : 2015
    }, {
      "title" : "An Overview of Nanoparticles Commonly Used in Fluorescent Bioimaging",
      "author" : [ "O.S. Wolfbeis" ],
      "venue" : "Chem. Soc. Rev. 2015,",
      "citeRegEx" : "Wolfbeis,? \\Q2015\\E",
      "shortCiteRegEx" : "Wolfbeis",
      "year" : 2015
    }, {
      "title" : "Hypoxia and Cancer",
      "author" : [ "M.C. Brahimi-Horn", "J. Chiche", "J. Pouysseǵur" ],
      "venue" : "J. Mol. Med. (Heidelberg,",
      "citeRegEx" : "Brahimi.Horn et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Brahimi.Horn et al\\.",
      "year" : 2007
    }, {
      "title" : "How Can We Overcome Tumor Hypoxia in Radiation Therapy",
      "author" : [ "H. Harada" ],
      "venue" : "J. Radiat. Res. 2011,",
      "citeRegEx" : "Harada,? \\Q2011\\E",
      "shortCiteRegEx" : "Harada",
      "year" : 2011
    }, {
      "title" : "Imaging of Leukocyte Trafficking in Blood Vessels and Tissues",
      "author" : [ "H. In Vivo" ],
      "venue" : "Curr. Opin. Immunol",
      "citeRegEx" : "Vivo,? \\Q2004\\E",
      "shortCiteRegEx" : "Vivo",
      "year" : 2004
    }, {
      "title" : "Dendritic Cells and Cancer Immunotherapy",
      "author" : [ "K.J. Radford", "K.M. Tullett", "M.H. Lahoud" ],
      "venue" : "Curr. Opin. Immunol. 2014,",
      "citeRegEx" : "Radford et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Radford et al\\.",
      "year" : 2014
    }, {
      "title" : "Immunotherapeutic Approaches for Alzheimer’s Disease",
      "author" : [ "T. Wisniewski", "F. Goñi" ],
      "venue" : "Neuron 2015,",
      "citeRegEx" : "Wisniewski and Goñi,? \\Q2015\\E",
      "shortCiteRegEx" : "Wisniewski and Goñi",
      "year" : 2015
    }, {
      "title" : "Optical Imaging of Cerenkov Light Generation from Positron-Emitting Radiotracers",
      "author" : [ "S. R", "Silva", "M. D" ],
      "venue" : "Phys. Med. Biol. 2009,",
      "citeRegEx" : "R. and D.,? \\Q2009\\E",
      "shortCiteRegEx" : "R. and D.",
      "year" : 2009
    }, {
      "title" : "Optical Coherence Tomography− 15 Years in Cardiology",
      "author" : [ "T. Yonetsu", "B.E. Bouma", "K. Kato", "J.G. Fujimoto", "I.-K. Jang" ],
      "venue" : "Circ. J. 2013,",
      "citeRegEx" : "Yonetsu et al\\.,? \\Q1940\\E",
      "shortCiteRegEx" : "Yonetsu et al\\.",
      "year" : 1940
    }, {
      "title" : "Optical Coherence Tomography",
      "author" : [ "A.G. Podoleanu" ],
      "venue" : "J. Microsc. 2012,",
      "citeRegEx" : "Podoleanu,? \\Q2012\\E",
      "shortCiteRegEx" : "Podoleanu",
      "year" : 2012
    }, {
      "title" : "Concave Cubic Gold Nanocrystals with High-Index Facets",
      "author" : [ "C.A. Mirkin" ],
      "venue" : "J. Am. Chem. Soc. 2010,",
      "citeRegEx" : "Mirkin,? \\Q2010\\E",
      "shortCiteRegEx" : "Mirkin",
      "year" : 2010
    }, {
      "title" : "Biological Synthesis of Triangular Gold Nanoprisms",
      "author" : [ "M. Sastry" ],
      "venue" : "Nat. Mater. 2004,",
      "citeRegEx" : "Sastry,? \\Q2004\\E",
      "shortCiteRegEx" : "Sastry",
      "year" : 2004
    }, {
      "title" : "Smart Drug Delivery Systems: Back to the Future vs",
      "author" : [ "T. Lammers" ],
      "venue" : "Clinical Reality. Int. J. Pharm. 2013,",
      "citeRegEx" : "Lammers,? \\Q2013\\E",
      "shortCiteRegEx" : "Lammers",
      "year" : 2013
    }, {
      "title" : "Biogenic Gas Nanostructures as Ultrasonic Molecular Reporters",
      "author" : [ "D.V. Schaffer", "S.M. Conolly" ],
      "venue" : "Nat. Nanotechnol. 2014,",
      "citeRegEx" : "S. et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "S. et al\\.",
      "year" : 2014
    }, {
      "title" : "The Advantages of Nanoparticles for PET",
      "author" : [ "M.J. Welch", "C.J. Hawker", "K.L. Wooley" ],
      "venue" : "J. Nucl. Med. 2009,",
      "citeRegEx" : "Welch et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Welch et al\\.",
      "year" : 2009
    }, {
      "title" : "Metal Ion Binding and Heat-Induced Radiolabeling of Iron Oxide Nanoparticles",
      "author" : [ "P. Chelate-Free" ],
      "venue" : "Chem. Sci. 2015,",
      "citeRegEx" : "Chelate.Free,? \\Q2015\\E",
      "shortCiteRegEx" : "Chelate.Free",
      "year" : 2015
    }, {
      "title" : "PET versus : Strengths, Limitations and Challenges",
      "author" : [ "A. Rahmim", "H. Zaidi" ],
      "venue" : "Nucl. Med. Commun. 2008,",
      "citeRegEx" : "Rahmim and Zaidi,? \\Q2008\\E",
      "shortCiteRegEx" : "Rahmim and Zaidi",
      "year" : 2008
    }, {
      "title" : "Advantages and Disadvantages of PET and SPECT in a Busy Clinical Practice",
      "author" : [ "T.M. Bateman" ],
      "venue" : "J. Nucl. Cardiol",
      "citeRegEx" : "Bateman,? \\Q2012\\E",
      "shortCiteRegEx" : "Bateman",
      "year" : 2012
    }, {
      "title" : "Imaging and Cancer: A Review",
      "author" : [ "L. Fass" ],
      "venue" : "Mol. Oncol. 2008,",
      "citeRegEx" : "Fass,? \\Q2008\\E",
      "shortCiteRegEx" : "Fass",
      "year" : 2008
    }, {
      "title" : "Can Imaging Help Improve the Survival of Cancer Patients",
      "author" : [ "K. Miles" ],
      "venue" : "Cancer Imaging 2011,",
      "citeRegEx" : "Miles,? \\Q2011\\E",
      "shortCiteRegEx" : "Miles",
      "year" : 2011
    }, {
      "title" : "Screening for Oesophageal Cancer",
      "author" : [ "P. Lao-Sirieix", "R.C. Fitzgerald" ],
      "venue" : "Nat. Rev. Clin. Oncol. 2012,",
      "citeRegEx" : "Lao.Sirieix and Fitzgerald,? \\Q2012\\E",
      "shortCiteRegEx" : "Lao.Sirieix and Fitzgerald",
      "year" : 2012
    }, {
      "title" : "Targeted Gold Nanoparticles Enable Molecular CT Imaging of Cancer: An in Vivo Study",
      "author" : [ "R. Popovtzer" ],
      "venue" : "Int. J. Nanomed. 2011,",
      "citeRegEx" : "Popovtzer,? \\Q2011\\E",
      "shortCiteRegEx" : "Popovtzer",
      "year" : 2011
    }, {
      "title" : "Nanooncology: The Future of Cancer Diagnosis and Therapy",
      "author" : [ "A.S. Thakor", "S.S. Gambhir" ],
      "venue" : "Ca-Cancer J. Clin. 2013,",
      "citeRegEx" : "Thakor and Gambhir,? \\Q2013\\E",
      "shortCiteRegEx" : "Thakor and Gambhir",
      "year" : 2013
    }, {
      "title" : "Nano-Sized CT Contrast Agents",
      "author" : [ "N. Lee", "S.H. Choi", "T. Hyeon" ],
      "venue" : "Adv. Mater. 2013,",
      "citeRegEx" : "Lee et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Lee et al\\.",
      "year" : 2013
    }, {
      "title" : "Optimization of K-Edge Imaging with Spectral CT",
      "author" : [ "P. He", "B. Wei", "W. Cong", "G. Wang" ],
      "venue" : "Med. Phys. 2012,",
      "citeRegEx" : "He et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "He et al\\.",
      "year" : 2012
    }, {
      "title" : "Non-Lamellar Lipid Liquid Crystalline Structures at Interfaces",
      "author" : [ "F. Tiberg", "T. Nylander" ],
      "venue" : "Adv. Colloid Interface Sci. 2015,",
      "citeRegEx" : "Tiberg and Nylander,? \\Q2015\\E",
      "shortCiteRegEx" : "Tiberg and Nylander",
      "year" : 2015
    }, {
      "title" : "Multifunctional Nanocarriers",
      "author" : [ "V.P. Torchilin" ],
      "venue" : "Adv. Drug Delivery Rev. 2012,",
      "citeRegEx" : "Torchilin,? \\Q2012\\E",
      "shortCiteRegEx" : "Torchilin",
      "year" : 2012
    }, {
      "title" : "A Critical Review of Lipid-Based Nanoparticles for Taxane Delivery",
      "author" : [ "L. Feng", "R.J. Mumper" ],
      "venue" : "Cancer Lett. 2013,",
      "citeRegEx" : "Feng and Mumper,? \\Q2013\\E",
      "shortCiteRegEx" : "Feng and Mumper",
      "year" : 2013
    }, {
      "title" : "Nonionic Surfactant Vesicular Systems for Effective Drug Deliveryan Overview",
      "author" : [ "G.P. Kumar", "P. Rajeshwarrao" ],
      "venue" : "Acta Pharm. Sin. B 2011,",
      "citeRegEx" : "Kumar and Rajeshwarrao,? \\Q2011\\E",
      "shortCiteRegEx" : "Kumar and Rajeshwarrao",
      "year" : 2011
    }, {
      "title" : "Biodistribution of Nanostructured Lipid Carriers: A Tomographic Study",
      "author" : [ ],
      "venue" : "Eur. J. Pharm. Biopharm. 2015,",
      "citeRegEx" : "C,? \\Q2015\\E",
      "shortCiteRegEx" : "C",
      "year" : 2015
    }, {
      "title" : "Polymeric Vesicles: From Drug Carriers to Nanoreactors and Artificial Organelles",
      "author" : [ "W. Meier" ],
      "venue" : "Acc. Chem. Res. 2011,",
      "citeRegEx" : "Meier,? \\Q2011\\E",
      "shortCiteRegEx" : "Meier",
      "year" : 2011
    }, {
      "title" : "Dendrimer-Based Molecular Imaging Contrast Agents",
      "author" : [ "Z. Qiao", "X. Shi" ],
      "venue" : "Prog. Polym. Sci. 2015,",
      "citeRegEx" : "Qiao and Shi,? \\Q2015\\E",
      "shortCiteRegEx" : "Qiao and Shi",
      "year" : 2015
    }, {
      "title" : "Nanoparticles as Image Enhancing Agents for Ultrasonography",
      "author" : [ "X. Pan", "T.J. Rosol" ],
      "venue" : "Phys. Med. Biol. 2006,",
      "citeRegEx" : "Pan and Rosol,? \\Q2006\\E",
      "shortCiteRegEx" : "Pan and Rosol",
      "year" : 2006
    }, {
      "title" : "Gated Luminescence Imaging of Silicon Nanoparticles",
      "author" : [ "J. M" ],
      "venue" : "ACS Nano 2015,",
      "citeRegEx" : "M.,? \\Q2015\\E",
      "shortCiteRegEx" : "M.",
      "year" : 2015
    }, {
      "title" : "A Biological Perspective of Particulate Nanoporous Silicon",
      "author" : [ "S.C. Lee", "M. Ferrari" ],
      "venue" : "Mater. Technol. 2004,",
      "citeRegEx" : "M. et al\\.,? \\Q2004\\E",
      "shortCiteRegEx" : "M. et al\\.",
      "year" : 2004
    }, {
      "title" : "Exosomes from Human Saliva as a Source of microRNA Biomarkers",
      "author" : [ "R. A", "G.G. Illei", "I. Alevizos" ],
      "venue" : "Oral Dis. 2010,",
      "citeRegEx" : "A. et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "A. et al\\.",
      "year" : 2010
    }, {
      "title" : "Targeted Nanoagents for the Detection of Cancers",
      "author" : [ "R. Weissleder" ],
      "venue" : "Mol. Oncol. 2010,",
      "citeRegEx" : "Weissleder,? \\Q2010\\E",
      "shortCiteRegEx" : "Weissleder",
      "year" : 2010
    }, {
      "title" : "Helical Microtubules of Graphitic Carbon",
      "author" : [ "S. Iijima" ],
      "venue" : "Nature",
      "citeRegEx" : "Iijima,? \\Q1991\\E",
      "shortCiteRegEx" : "Iijima",
      "year" : 1991
    }, {
      "title" : "Theranostic Nanoparticles for Future Personalized Medicine",
      "author" : [ "I.C. Kwon" ],
      "venue" : "J. Controlled Release 2014,",
      "citeRegEx" : "Kwon,? \\Q2014\\E",
      "shortCiteRegEx" : "Kwon",
      "year" : 2014
    }, {
      "title" : "Stimuli-Responsive Nanocarriers for Drug Delivery",
      "author" : [ "S. Mura", "J. Nicolas", "P. Couvreur" ],
      "venue" : "Nat. Mater. 2013,",
      "citeRegEx" : "Mura et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Mura et al\\.",
      "year" : 2013
    }, {
      "title" : "Cancer Nanomedicines: So Many Papers and so Few Drugs! Adv",
      "author" : [ "V.J. Venditto", "F.C. Szoka" ],
      "venue" : "Drug Delivery Rev. 2013,",
      "citeRegEx" : "Venditto and Szoka,? \\Q2013\\E",
      "shortCiteRegEx" : "Venditto and Szoka",
      "year" : 2013
    }, {
      "title" : "Clinical Translation of Nanomedicine",
      "author" : [ "Y. Min", "J.M. Caster", "M.J. Eblan", "A.Z. Wang" ],
      "venue" : "Chem. Rev. 2015,",
      "citeRegEx" : "Min et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Min et al\\.",
      "year" : 2015
    }, {
      "title" : "Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin",
      "author" : [ "L.W. Seymour" ],
      "venue" : "J. Clin. Oncol. 2002,",
      "citeRegEx" : "Seymour,? \\Q2002\\E",
      "shortCiteRegEx" : "Seymour",
      "year" : 2002
    } ],
    "referenceMentions" : [ ],
    "year" : 2017,
    "abstractText" : "In vivo imaging, which enables us to peer deeply within living subjects, is producing tremendous opportunities both for clinical diagnostics and as a research tool. Contrast material is often required to clearly visualize the functional architecture of physiological structures. Recent advances in nanomaterials are becoming pivotal to generate the high-resolution, high-contrast images needed for accurate, precision diagnostics. Nanomaterials are playing major roles in imaging by delivering large imaging payloads, yielding improved sensitivity, multiplexing capacity, and modularity of design. Indeed, for several imaging modalities, nanomaterials are now not simply ancillary contrast entities, but are instead the original and sole source of image signal that make possible the modality’s existence. We address the physicochemical makeup/ design of nanomaterials through the lens of the physical properties that produce contrast signal for the cognate imaging modalitywe stratify nanomaterials on the basis of their (i) magnetic, (ii) optical, (iii) acoustic, and/or (iv) nuclear properties. We evaluate them for their ability to provide relevant information under preclinical and clinical circumstances, their in vivo safety profiles (which are being incorporated into their chemical design), their modularity in being fused to create multimodal nanomaterials (spanning multiple different physical imaging modalities and therapeutic/theranostic capabilities), their key properties, and critically their likelihood to be clinically translated.",
    "creator" : "Arbortext Advanced Print Publisher 10.0.1465/W Unicode"
  }
}